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ABSTRACT 
 
P68 RNA helicase (p68), as a DEAD family protein, is a typical RNA helicase protein. P68 
functions in many other biological processes, which include the regulations of the gene 
transcription, cell proliferation and cell differentiation. In our group, Y593 phosphorylated p68 
was found to have a function in the epithelial mesynchymal transition, which is an important 
process for cancer metastasis. In the present study, we found that p68 is a nucleocytoplasmic 
shuttling protein. The protein carries two functional nuclear exporting signal sequences and two 
nuclear localization signal sequences.  Calmodulin, a calcium sensor protein, is well known to 
play roles in cell migration by regulating the activities of its target proteins at the leading edge. 
Calmodulin interacts with p68 at the IQ motif of p68. However, the biological function of this 
interaction is not known. In this study, we found that the p68/calmodulin protein complex 
functions as a microtubule motor in migrating cells. The shuttling function of p68 along with the 
motor function of p68/calmodulin causes the leading edge distribution of calmodulin in 
migrating cells. Disruption the interaction between p68 and calmodulin inhibits cancer cell 
metastasis in an established mouse model. On the other hand, Y593-Y595 double phosphorylated 
p68 were found to interact with PKM2, an important tumor isoform of pyruvate kinase. The 
 shuttling function of p68 is reasoned to promote the dimer formation of PKM2 and transport the 
PKM2 to the cell nucleus. The nuclear PKM2 was found to function as a protein kinase to 
promote cell proliferation. In specific, the nuclear PKM2 phosphorylates and activates Stat3, an 
important transcription factor functions in cell proliferation. Overall, p68 is found to have 
functions in both cell migration and cell proliferation, and these two functions depend on the 
nucleocytoplasmic shuttling activity and the post-translational modification of p68. 
 
INDEX WORDS: P68 RNA helicase, Calmodulin, PKM2, Nucleocytoplasmic shuttling, Cell 
migration, Cell proliferation 
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CHAPTER 1 
INTRODUCTION 
1.1 Cell migration and cancer metastasis 
1.1.1 Cell migration 
Cell migration refers to the translocation of cell from one site to another site. It has 
functions in regular biological processes including wound healing, embryonic development and 
immune response; cell migration is also involved in different disease processes such as tumor 
formation, cancer metastasis, mental retardation and vascular disease. There are two major 
schemes for the cell migration (Bretscher 1996): First, extension of the cell in the front by 
polymerization of the actin filaments at the leading edge (polarized actin cycle); Second, 
extension of the cell surface by exocytosis at the leading edge (polarized endocytic cycle). In the 
polarized actin cycle scheme, the actin filament ahead of the nucleus is constantly depolymerized 
to provide actin monomers; the actin monomers diffuse to the front of the cell and polymerize 
there, which pushes the leading edge forward. In the polarized endocytic cycle, a lipid flow in 
the plasma membrane is generated when endocytosis occurs at the front of the cell surface. The 
cell is pushed forward when the lipid flow pushes on substratum-attached feet. 
1.1.1.1 Molecular mechanism of process of cell migration 
In general, the process of cell migration is considered to involve several steps: 
polarization, protrusion and adhesion, translocation of the cell body and retraction of the rear 
(Bretscher 1996). 
Polarization in the process of cell migration refers to the molecular and functional 
differences between the front and back in cells (Ridley, Schwartz et al. 2003). The cell can 
polarize with or without the extracellular asymmetric stimulation (Wedlich-Soldner and Li 2003). 
Polarization may be caused by adhesion to the substratum or the formation of lateral contacts 
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with other cells. A polarized influx of extracellular signal may determine the asymmetric 
recruitment or activation of signaling proteins in the cell. The consequence of this influx will 
create morphological and functional asymmetry. The gradients of stimuli, including 
chemoattractants, induce the polarized signals and generate a protrusion at the front of cell which 
faces to the highest concentration of the gradient (Iglesias and Devreotes 2008). Monolayer 
scratch assay can also generate cell polarization towards the scratch area (Goulimari, Kitzing et 
al. 2005). The composition of the plasma membrane may reflect the functional polarization in 
some cases. Interestingly, cells can be induced into polarization even when the chemoattractants 
are loaded in a non-polarized and homogeneous manner (called chemokinesis) (Verkhovsky, 
Svitkina et al. 1999). The front area may be generated first in the polarizing process; while the 
rear area may be created before the front area has been established. Chemoattractants generate 
the asymmetry by activating some specific receptors, such as G-protein coupled receptor (GPCR) 
(Cotton and Claing 2009; Swaney, Huang et al. 2010), which is considered to be evenly 
distributed on the cell membrane in the resting cells. The small difference in gradient between 
the front and the rear regions of the cell leads to the asymmetical activation of the receptor. This 
small gradient difference can be amplified by activation of receptor, as the receptor will recruit 
and activate the signaling adaptors and their downstream targets. The cells will then be polarized, 
and protrusion can be achieved after the polarization. 
Protrusion usually involves the polymerization and depolymerization of the actin. The 
growth of the actin filaments pushes the leading edge to move forward. The extension of cellular 
membranes is also involved in the protrusion process. The leading edge protrusion faces the 
direction of movement in most cells. Protrusions usually respond to chemoattractants. When 
there is no directional extracellular stimulation, cells may probe and explore the surrounding 
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environment by forming the protrusion. Several cellular processes are required to form the 
protrusions. The dynamic polymerization of the actin pushes the membrane forward. The 
trafficking and the fusion of membrane-containing vesicles support the membrane expansion. At 
the same time, the protrusion needs to adhere to the basement to prevent the membrane moving 
backward. Cell body translocation is driven by the contraction of the actomyosin cytoskeleton in 
a harmonized way. The detailed mechanism is not well understood. 
In order to retract the rear part of the cell, contraction of the actin filaments and 
disassembly of the adhesion at the rear edge are required. There are several mechanisms to 
promote adhesion disassembly. In brief, the contraction of actomyosin generates the force 
against the adhesion to disassemble adhesions (Chrzanowska-Wodnicka and Burridge 1996); 
microtubules play an important role in the disassembly of the adhesion (Kaverina, Krylyshkina et 
al. 1999); the endocytosis of integrins also facilitates the dissociation of the adhesion (Gomes, 
Jani et al. 2005); and the cleavage of the focal adhesion proteins helps in the retraction of the rear 
(Chan, Bennin et al. 2010). All these mechanisms facilitate the retraction of the rear part of the 
cell. 
1.1.1.2 Major signaling pathways that regulate cell migration 
Cells migrate in a specific direction in response to different stimuli, such as growth 
factors, chemokines or ECM molecules. The cell surface receptors are engaged by these factors. 
The receptors will initiate a series of cellular events. Briefly, G protein coupled receptors and 
receptor tyrosine kinases are activated, while GEFs are stimulated to activate CDC42. The lipid 
kinases are in activated form, and the activated Rac is then recruited. Along with the activation 
of Rac and/or Cdc42 in the local region, other regulators, including WASP/WAVE family 
proteins and Arp2/3 complex, are stimulated to branch actin filament at the leading edge (Cory 
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and Ridley 2002) (Ridley, Schwartz et al. 2003). A protrusion in the direction of migration is 
formed. The growth of the actin filament is regulated by the proteins that sever the existing 
filaments, cap the growing filaments, and control the availability of the monomeric actins.  
Activation of Rac and Cdc42 at specific area will decrease the activity of Rho and enhance the 
activity of PI3K, which then lead to the production of PIP3 at the leading edge (Devreotes and 
Janetopoulos 2003). The reorientation of the MTOC facing  the leading edge that leads to the 
growth of microtubules and transport vesicles to the leading edge is also mediated by Cdc42 
(Etienne-Manneville and Hall 2003). Adhesion proteins including integrins are activated by 
PI3Ks, PKCs, and Rap. Those adhesion proteins stabilize the cell protrusion by connecting the 
actin filaments to the leading edge structure. The adhesion molecules recruit additional integrins 
and form adhesions by signaling to Rac. The activity of Rac, Cdc42, and PI3K is reinforced by 
recruitment of these additional integrins. Sensitization of the receptors at the leading edge during 
the cell polarization favors the continuous movement in the same direction. The cycle of cell 
migration is completed when the adhesions are disassembled and the rear is retracted (Ridley, 
Schwartz et al. 2003).  FAK, ERK, Src, and the protease calpain are important molecules to 
signal the disassembly of adhesions (Alahari, Reddig et al. 2002; Brahmbhatt and Klemke 2003). 
Microtubule dynamics play an additional role in disassembling of the adhesions. Rho kinase, 
with low activity at the leading edge and high activity at the rear, plays an important role in 
retraction at rear side of cells in a myosin dependent manner (Ridley, Schwartz et al. 2003). 
1.1.1.3 Ca
2+
/calmodulin in cell migration 
Ca
2+
/calmodulin is an important factor in regulating cell migration. Regulation of cell 
migration by Ca
2+
/calmodulin is demonstrated in many signaling pathways in multiple processes. 
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Importantly, Ca
2+
/calmodulin is known to regulate many molecules that participate in the major 
signaling pathways of cell migration.  
G protein coupled receptors (referred to as GPCR) are transmembrane receptors that 
sense the migration signals through the extracellular domain and subsequently activate 
intracellular domain to activate G proteins. G protein coupled receptor kinases (refers to GRKs) 
phosphorylate the GPCR at the specific site to regulate the activity of GPCR. Calmodulin is 
found to regulate the activity of a number of GRKs, such as GRK5, in a Ca
2+
-dependent manner 
(Pronin, Satpaev et al. 1997). 
IQGAP1 is a RasGAP-related protein that functions as a scaffold protein and plays a role 
in cell migration. IQGAP1 is known to interact with the cytoskeleton, and bind to actin, Rho 
family members, and E-cadherin. Interestingly, binding of calmodulin to IQGAP1 regulates its 
association with Cdc42 and actin (Ho, Joyal et al. 1999). On the other hand, calmodulin regulates 
the binding of E-cadherin to IQGAP and consequently affects the cell-cell adhesion (Li, Kim et 
al. 1999). 
The Arp2/3 complex controls the rate of actin polymerization to induce membrane 
protrusion, which is important in cell migration. Caldesmon, presented in the membrane ruffles, 
slows down the Arp2/3-induced actin polymerization. Interestingly, Ca
2+
/calmodulin reverses 
this inhibitory effect (Yamakita, Oosawa et al. 2003). 
PI3-kinase has multiple functions in cell migration as the activation of PI3-kinase has 
been linked to actin rearrangement, tubulin binding, and membrane ruffling (Ridley 1994; 
Wennstrom, Hawkins et al. 1994; Kapeller, Toker et al. 1995; Martin, Haruta et al. 1996). 
Importantly, calmodulin is found to be able to acitivate PI3-kinase (Joyal, Burks et al. 1997). 
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All those examples illustrate that Ca
2+
/calmodulin is an important regulator in the process 
of cell migration. Since many regulating events by Ca
2+
/calmodulin occur at the leading edge, 
translocation of calmodulin to the leading edge is very important. 
1.1.2 Cancer metastasis 
Cancer metastasis is an event about the spreading of cancer cells to the nearby/distant 
site(s) that are not immediately adjacent to the primary tumor site. Cancer cells may spread by 
invasion through blood vessels and/or lymph vessels. The cancer cells may also spread by 
penetration into the body cavity or the places surrounding the organs. The process of metastasis 
includes local invasion, intravasation, transport, extravasation, formation of micrometastases, 
and colonization (Steeg 2006). The initiation process for metastasis is the cancer cell invasion. 
During the invasion step, the adherence junctions between cells, and between cell and the 
extracellular matrix (ECM), undergo dramatic changes. These changes allow cancer cells to 
detach from the primary tumor. The cells gain the capability of migration through the tissues. 
Integrins are important transmembrane proteins that mediate the adhesion between tumor cells 
and ECM (Friedl and Wolf 2003); while cadherins are important proteins for the cell-cell 
adhesion. Inside the cell, the cadherins can signal to catenins and actin cytoskeleton in order to 
regulate the movement of the cell (Cavallaro and Christofori 2004). The movement of most 
tumor cells during invasion is dynamic. The tumor cells adhere to the ECM at the leading edge 
of the cells.  At the trailing edge, tumor cells detach from the ECM. Thus, the cell will move 
forward. Growth factor and chemokines can stimulate tumor cell migration. 
During the process of intravasation, the tumor cells invade through the basal membrane 
and get into the lymphatic or blood vessels. When the tumor cells get into the blood stream, the 
tumor cells must survive and avoid immune attack. The factors that affect the survival of the 
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tumor cells are: velocity-induced shear forces, lack of a substratum, and the existence of immune 
cells (Steeg 2006). In order to extravasate from the blood circulation, the tumor cells need to be 
arrested at the specific area in the circulatory system. The tumor cells may be arrested by 
nonspecifically binding to the coagulation factors, thereby the cells may be restricted in the 
capillary beds because of the size of the cells. In certain cases, tumor cells may specifically 
adhere to the surface of endothelial cells (Weiss, Grundmann et al. 1986). When the endothelial 
retraction is induced, tumor cells attach to the subendothelial ECM and the capillary is reformed 
after the tumor cells extravasate from the blood circulation. 
When the tumor cells get into the new distant organ by invasion through the vessel wall, 
they form micrometastases at the beginning, and they may grow progressively to form 
macrometastases. This process is termed metastatic colonization. This process involves the 
interaction between tumor cells and the surrounding cells in this distant organ. However, the 
colonization efficiency is very low. During the process of cancer metastasis, only 2.5% of cancer 
cells that survived in blood circulation extravasate to form micrometastasis. And only 1% of the 
micrometastasis can grow to form macroscopic metastasis, as some of the metastasized cells may 
get into the dormant situation (Luzzi, MacDonald et al. 1998). 
1.1.3 The relationship between cell migration and cancer metastasis 
Cell migration is considered as the first step of the cancer metastasis (Steeg 2006), as the 
tumor cells need to invade (migration) through the surrounding tissue at the primary site to 
spread the cells to the distant organ. Successful invasion (including migration) is required for the 
tumor cells metastasize to the distant organ. Theoretically, cancer metastasis can be stopped if 
the cell migration is inhibited.  
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However, the process of cancer metastasis is more complicated than the process of cell 
migration. Many microenvironmental factors (including surrounding non-cancer cells) are 
involved in promoting metastasis. These factors are constantly changed when the cancer cells 
spread to the different locations. Instead, the study of the cell migration is often performed using 
the simplified in vitro system. We only consider one factor or several combined factors in 
studying the mechanism of the cell migration.  Therefore, animal model for cancer metastasis is 
often applied to further test the mechanism that has been illustrated in in vitro system. 
1.1.4 Clinical significance and model of colon cancer metastasis  
The second leading cause of death in the U.S. is cancer (Death: Preliminary data for 2009 
from National Vital Statistic Reports). About 90% of cancer patient death is due to metastasis. 
Therefore, elucidation of the molecular mechanism that regulates the migratory activity of cancer 
cells is very important. 
Colon cancer is the second leading cause among all cancer types in the United States 
(from National Cancer Institute at the National Institutes of Health). Over half of the colon 
cancer patients develop metastasis. Around 50% of patients suffer from liver metastasis, and 
around 15% of the patients produce lung metastasis (Chambers, Groom et al. 2002). 
There are very few models of colon cancer metastasis except the locally invasive models, 
even though there are many genetic mouse models of benign adenoma. Unlike in humans, there 
are no genetic mouse models which can spontaneously form tumors in the intestines, become 
invasive and metastasize to the other organs. Since most of the colon cancer mortality is due to 
the cancer metastasis, it is very important to study the colon cancer metastasis. The 
transplantation (xenograft) models are therefore becoming the suitable model to study the colon 
cancer metastasis at the current stage (Taketo and Edelmann 2009). The xenograft models of the 
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colon cancer used to study the colon cancer metastasis include intrarectal implantation of the 
colon cancer cells (Tsutsumi, Kuwano et al. 2001), orthotopic implantation of the tumor tissue 
(Sun, Sasson et al. 1999) or tumor cells (Cespedes, Espina et al. 2007), and subcutaneous 
implantation of tumor cells. However, every model has its own benefits and shortcomings. For 
intrarectal implantation, the tumor cells can only metastasize to the nearby lymph nodes but not 
to the distant organs. For orthotopic implantation of the human tumor tissue or tumor cells, even 
though the cancer cells metastasize to the distant organ, the procedure is quite complicated (may 
not be suitable for the experiment with many mice). Meanwhile, research shows that injection of 
SW620 cells at the orthotopic site (intracaecal) does not generate liver metastasis as examined by 
gross inspection and histological examination 10 weeks after tumor cell injection. The growth of 
SW620 tumors at the orthotopic sites appears much slower than that at the subcutaneous site 
(Hewitt, McMarlin et al. 2000). On the other hand, the procedure is quite simple for the 
subcutaneous implantation of the colon cancer cells. Even though the distant organ metastasis of 
the tumor is not directly observed (not macrometastasis), trace amount of the tumor cells 
metastasis to the spleen has been successfully detected by RT-PCR technique (micrometastasis).  
There are other systems that have been generated to study the colon cancer metastasis. 
For example, colon cancer cells are injected into the blood circulation through tail vein (Cambien, 
Karimdjee et al. 2009) or cardiac ventricle (Ma, Rong et al. 2008). Those methods are good 
systems to study extravasation and colonization. However, those methods skipped the invasion 
and intravasation steps of cancer metastasis. They are not good systems if the target molecules 
play major roles in the invasion step of cancer metastasis. 
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1.2 Cell proliferation  
1.2.1 Cell proliferation and tumor growth 
Cell proliferation refers to the increase in the cell number by cell division. The function 
of cell proliferation is to maintain the cell amount to a certain level. The cell proliferation rate is 
determined by cell division rate (cell cycle) and cell apoptosis rate. Cell proliferation proceeds 
through the following steps: first, growth factors bind to the receptors on the cell surface; second, 
the receptors are linked to the signaling molecules and convey the message into the nucleus; 
third, transcription factors bind to DNA to turn on/off the corresponding genes; fourth, the above 
events will lead to the cell division. Any changes in step during cell proliferation will lead to the 
change of the cell proliferation rate. The induction of tumor is the consequence of the cell 
proliferation being out of control. In tumors, factors that involve signaling pathways of cell 
proliferation are altered due to accumulation of genetic and epigenetic alterations. The alterations 
of signaling factors lead to the alteration of cell cycle and apoptosis. As a consequence, cell 
proliferation is altered (Evan and Vousden 2001).  
1.2.2 Major signaling pathway in cell proliferation 
The cell proliferation process is complicated. It involves multiple signaling pathways and 
interconnects with other biological processes including apoptosis (Sears and Nevins 2002). One 
central player in the cell proliferation is the retinoblastoma tumor suppressor protein (Rb). In this 
pathway, the D-type G1 cyclins and the associated kinases (Cdk4 and Cdk6) initiate the 
phosphorylation of Rb and Rb family proteins (p130 and p170) to inactivate their binding to E2F 
transcription factors (E2F1, E2F2, and E2F3a). This event leads to the accumulation of E2F 
member proteins and activation of the transcription of a number of genes. Transcriptions of those 
genes are required for cell cycle progression and DNA replication. Meanwhile, phosphorylation 
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of Rb and p130 can disrupt its interaction with other E2F member proteins (E2F3b, E2F4, and 
E2F5), which play a role in the repression of transcription of the S phase genes (Sears and 
Nevins 2002). Rb can be further phosphorylated and inactivated by the E2F target genes cyclin E 
and the associated kinase Cdk2, which will lead to continual inactivation of Rb. On the other 
hand, small protein inhibitors CKIs (including p21, p27 and p16) negatively regulate the activity 
of the G1 Cdks. All these proteins participate in the Rb/E2F pathway that plays a central role in 
regulating cell proliferation. 
 Myc proteins are demonstrated to play an essential role in normal cell function. Several 
target genes for Myc have been identified. Expression of these genes promote cell proliferation 
(Dang 1999). Myc can directly activate the transcription of cyclin D1 and D2, Cdk4 (cyclin D 
partner), and Cdc25A (phosphatase in removing negative regulatory phosphates from the Cdks). 
These transcription activities activate the G1 cyclin-dependent kinase. In the Myc induced cell 
proliferation, the activity of cyclin E/Cdk2 is induced when Myc is expressed (Beier, Burgin et al. 
2000). Myc expression leads to the down regulation of p27 CKI as well as the sequestration of 
p27 (Rudolph, Saffrich et al. 1996; Bouchard, Thieke et al. 1999). Interestingly, Myc directly 
contributes to the activation of E2F proteins (E2F1, E2F2 and E2F3), which can induce G1 to S 
phase transition (Leone, DeGregori et al. 1997; Sears, Leone et al. 1999; Adams, Sears et al. 
2000). 
 The Ras proto-oncogene has a critical function in cell growth. The function of Ras in cell 
growth is mediated by Ras effector molecules. The Raf/MEK/ERK kinase cascade is one of the 
Ras effector that is primarily involved in signaling from plasma membrane to nucleus (Seger and 
Krebs 1995). The Ral GTPase signaling pathway, another Ras effector pathway, is involved in 
G1 to S phase progression (Gille and Downward 1999; Marshall 1999). The third Ras effector 
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signaling pathway, the PI3-K/AKT pathway, is mainly involved in cell survival signaling 
(Kennedy, Wagner et al. 1997). All these three Ras effector pathways are activated by Ras-GTP 
and are involved in initiating cyclin D1 gene transcription and activating cyclin D1/Cdk4 kinase 
(Robles, Rodriguez-Puebla et al. 1998). These three Ras effector pathways act cooperatively in 
cell proliferation. 
1.3 Tumor metabolism and metabolism adjustment 
1.3.1 Tumor metabolism 
The metabolism in cancer cells is not the same as that in normal cells (Merida and Avila-
Flores 2006). Normal cells utilize the oxidative phosphorylation to generate energy, and 
glycolysis in normal cells is tightly regulated as the glycolysis is inhibited in the presence of 
oxygen. Cancer cells prefer to metabolize glucose by glycolysis to produce energy even in the 
presence of sufficient oxygen (Warburg 1956; Kondoh, Lleonart et al. 2007).  
Interestingly, the efficiency of producing ATP by the glycolysis process is much lower 
than that by the oxidative phosphorylation.  In the glycolysis, one molecule of glucose generates 
two molecules of pyruvate and two molecules of ATP. Pyruvate, as the product of glycolysis, has 
different fates in mammalian cells. Pyruvate can be catalyzed into lactate by lactate 
dehydrogenase when the oxygen level is low. This process is called anaerobic glycolysis. 
Pyruvate can also be converted into acetyl coenzyme A by the pyruvate dehydrogenase complex 
when the oxygen level is high. In the citric acid cycle, acetyl coenzyme A is used to generate 
electrons in the mitochondria. The electrons create an electron gradient which leads to the 
generation of a pH gradient across the inner mitochondrial membrane. The pH gradient can lead 
to the generation of ATP by ATP synthase. This process is named as aerobic oxidative 
phosphorylation. One acetyl CoA molecule can produce two molecules of NADH, one molecule 
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of FADH2, and eight molecules of electrons in the citric acid cycle. By the oxidative 
phosphorylation process, one molecule of glucose can be completely degraded into H2O and CO2 
and produce 38 molecules of ATP. Clearly, the generation of ATP is more efficient by the 
oxidative phosphorylation than by the glycolysis. 
1.3.2 Metabolism adjustment in tumor 
Why cancer cells prefer glycolysis instead of oxidative phosphorylation to generate ATP 
is not well understood. Interestingly, there are a lot of phosphointermediates generated in the 
glycolysis. The phosphointermediates can be used by the cancer cell to synthesize 
macromolecules including lipids, proteins, and nucleic acids, which may facilitate the tumor 
growth. This may be the most important reason for the switch of the metabolism pathways in 
cancer cells. On the other hand, the switch to the glycolysis may avoid the apoptosis of the 
cancer cells as activation of the oxidative phosphorylation may promote cancer cell apoptosis 
(Bonnet, Archer et al. 2007). Finally, employing the glycolysis pathway may support cancer-
specific signaling. Since specific metabolite (such as lactate) from glycolysis might be 
concentrated in the tumor cells and allow the tumor cells to engage in metabolite-mediated 
autocrine and paracrine signaling  that does not occur in the normal tissues. 
There are two possible ways to alter the metabolism in cancer cells. First, the tumor 
microenvironment drives changes in metabolism. As the tumor expands, the local blood supply 
is limited. This can lead to hypoxia and stabilize the hypoxia-inducible transcription factor (HIF). 
The activation of HIF leads to the overexpression of glycolytic enzymes as well as glucose 
transporters. Nearly all glycolysis enzymes, including hexokinase, phosphofructokinase, aldolase, 
pyruvate kinase and lactate dehydrogenase, are upregulated by activation of HIF-1(Semenza 
2007). More energy can be provided to cancer cells as the overexpression of those glycolytic 
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enzymes increase the rate of glycolysis. Meanwhile, activation of HIF stimulates angiogenesis as 
HIF induces VEGF expression from cancer cells. Second, several important oncogenes and 
tumor suppressor genes are known to regulate glycolysis in cancer cells and induce the shift to 
the glycolysis. Those genes include AKT, c-Myc, AMPK, Ras and p53. Akt is a serine/threonine 
kinase and is amplified in different cancers. Akt regulates glycolysis through several 
mechanisms, such as upregulation of glucose transporter to increase glucose uptake (Plas, 
Talapatra et al. 2001), stimulation of the hexokinase activity to convert glucose to glucose-6-
phosphate (Rathmell, Fox et al. 2003), and regulation of phosphofructokinase activity to control 
glycolysis rate (Deprez, Vertommen et al. 1997). C-Myc is a nuclear oncoprotein which is 
constantly active in many malignant tumors (Elliott, Ge et al. 2000). C-Myc regulates 
transcription of many glycolysis-related genes, including glucose transporters, hexokinase, 
phosphofructokinase and pyruvate kinase (Gordan, Bertout et al. 2007). AMP-activated protein 
kinase (AMPK), is a master regulator for controlling energy metabolism. AMPK is reported to 
regulate glucose consumption by controlling the transcription of glucose transporter and 
translocation of this transporter to the cell surface (Russell, Bergeron et al. 1999). P53 is an 
important tumor suppressor. P53 is inactivated in more than half of cancers (Hainaut and 
Hollstein 2000). Activation of p53 causes the downregulation of transcription of several 
glycolytic enzyms, such as phosphoglycerate mutase and glucose transporters (Schwartzenberg-
Bar-Yoseph, Armoni et al. 2004). 
1.4 Nuclear import and nuclear export 
Eukaryotic cells have nuclear envelope that creates two distinct cellular compartments in 
the cells. Even though these two separated compartments have unique functions by themselves, 
their functions are interconnected.  In order for the nuclear and cytoplasmic processes to act in 
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concert, communication between the nucleus and the cytoplasm by exchange of proteins and 
other molecules are needed. The nuclear import refers to the process by which specific molecules 
move into the nucleus, and the nuclear export refers to the process by which specific molecules 
come out from the nucleus. The nuclear pore complexes (NPC), which is a large protein complex 
that crosses the nuclear envelope, is the place that allows the exchange components to get in/out 
of the nucleus (Alber, Dokudovskaya et al. 2007). Nucleoporins are the major proteins that make 
up the nuclear pore complex (NPC). About half of the nucleoporins have a typical alpha solenoid 
or beta-propeller fold structure. The other half is a group of very flexible proteins due to its 
native unfolded characteristic. The components of the NPC allow the pore to be dilated to around 
26 nanometers wide from 9 nanometers at the opening status. 
1.4.1 Nuclear localization signal (NLS) 
NLS is a short stretch of amino acids that mediates the transportation of proteins into the 
nucleus. Typically, NLS consists of one or more short sequences of positively charged lysines or 
arginines. Some NLSs are glycine-rich with few positive charged residues (Bonifaci, Moroianu 
et al. 1997). The NLSs can be divided into classical NLSs and non-classical NLSs. Classical 
NLSs can be divided into two types: monopartite and bipartite (Boulikas 1994). Typically, the 
monopartite motif has a cluster of basic residues preceded by a helix-breaking residue. The 
bipartite motif has two clusters of basic residues with 9-12 non-charged residues in between. 
Classical NLSs can be recognized by importin-α. Interestingly, most of the non-classical NLSs 
can be recognized by importin-β (considered as import mediate).  Studies show that quite a lot of 
NLS motifs bind to DNA (Cokol, Nair et al. 2000). 
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1.4.2 Nuclear exportation signal (NES) 
NESs have a very important function in regulating the subcellular location of proteins. 
Subcellular translocation of proteins affects the transcription and other nuclear processes. The 
well known NESs are leucine-rich sequence motifs. The first NESs were identified in 1995 in the 
human immunodeficiency virus type 1(HIV-1) Rev protein (Fischer, Huber et al. 1995) and 
cAMP-dependent protein kinase inhibitor (PKI) (Wen, Meinkoth et al. 1995). NESs are now 
extended to the motifs that contains multiple hydrophobic amino acids residues including L, V, I, 
and M. CRM1 has been illustrated to be the export receptor for proteins containing the leucine 
rich NESs. The transport mediated by CRM1 can be effectively inhibited by the fungicide 
leptomycin B (LMB) (Fornerod, Ohno et al. 1997), as LMB can covalently bind to a cysteine 
residue in CRM1 (Kudo, Matsumori et al. 1999). RanGTP and proteins with leucine-rich NESs 
are considered to bind cooperatively to CRM1 and form a ternary CRM1-RanGTP-NES complex 
(la Cour, Kiemer et al. 2004). This complex can be diffused to the cytoplasm, where GTP is 
hydrolysed and the NES-cargo protein is released. CRM1-RanGDP will diffuse back to the 
nucleus and be reused. CRM1 mediated export is a tightly regulated process, as not all NES 
substrates can be exported constitutively from the nucleus. The NES-dependent export is 
regulated by several mechanisms: masking/unmasking of NESs (Craig, Zhang et al. 2002), 
phosphorylation (Brunet, Kanai et al. 2002), and forming a disulfide bond (Kuge, Arita et al. 
2001).  
1.4.3 The process of nucleocytoplasmic shuttling 
Nucleocytoplasmic shuttling refers to the transport of water-soluble molecules across the 
nuclear envelope by a back and forth manner. The transported water-soluble molecules include 
RNA, ribosomes, proteins, carbohydrates, and signal molecules. Some of them are transported in 
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a one-way manner, such as RNA moves from the nucleus to the cytoplasm (Rodriguez, 
Dargemont et al. 2004). Others can be transported out and into the nucleus. Many proteins 
(Rehberg, Lischka et al. 2002; Lahaye, Lespinasse et al. 2010) have been reported to shuttling 
between the nucleus and the cytoplasm. Although small molecules (<30 kDa) cross the NPC by 
simple diffusion, large molecules may need to carry a specific signal sequence (NLS and/or NES) 
with the help of the nucleoporins to get through the nuclear envelope.  
Ras-related nuclear protein (Ran) is a small 25 kDa protein that is known to be 
transported into and out of the cell nucleus during interphase (Moore and Blobel 1994; Dasso 
and Pu 1998). Ran is a GTP binding protein. Ran exists in the cell in GDP-bound and GTP-
bound forms. With the action of RCC1 (RanGEF, Ran Guanine nucleotide Exchange Factor), 
RanGDP can be converted to RanGTP. The GTPase activity of Ran can be activated by 
interaction with Ran GTPase activating protein (RanGAP). The conversion of RanGTP to 
RanGDP is through the activation of the Ran GTPase. Since RCC1 is located inside of the 
nucleus and RanGAP is bound to the cytoplasmic side of the nuclear pore complex, the ratio of 
RanGTP to RanGDP is high inside the nucleus and low outside the nucleus. Meanwhile, the 
protein concentration of Ran is higher in the nucleus than that in the cytoplasm. The nucleo-
cytoplasmic gradient of RanGTP powers the import cycle. Ran interacts with karyopherins (act 
as importin or exportin) and changes their ability to bind or release cargo molecules, therefore 
facilitates the transport of proteins across the NPC. When the cargo proteins carry NLS(s), the 
proteins bind to importin and are transported into the nucleus. In the nucleus, RanGTP binds to 
the importin and the imported cargo protein are released. Importin will then be diffused back to 
the cytoplasm and used for another cycle. When the cargo proteins carry NES(s), the proteins 
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bind to the exportin together with RanGTP. When GTP is hydrolyzed to GDP outside of the 
nucleus, the exported cargos are released.  
1.4.4  The function of nucleocytoplasmic shuttling of proteins 
 After the demonstration of nucleolin as the first nucleocytoplasmic shuttling protein in 
1989 (Borer, Lehner et al. 1989), many different nucleocytoplasmic shuttling proteins have been 
identified. They are many RNA binding proteins (Nakielny and Dreyfuss 1999; Shyu and 
Wilkinson 2000), cell cycle regulators (Yang and Kornbluth 1999), transcription factors 
(Cartwright and Helin 2000), transport receptors and adaptors (Gorlich and Kutay 1999; 
Nakielny and Dreyfuss 1999), and steroid hormone receptors (Hache, Tse et al. 1999). The 
nucleocytoplasmic shuttling proteins can translocate between the cytoplasm and the nucleus. 
Therefore, shuttling proteins can be factors for conveying information between nucleus and 
cytoplasm in the cells. The nucleocytoplasmic shuttling proteins have multiple functions 
depending on the nature of the proteins. Studies have shown that nucleocytoplasmic shuttling 
protein have a function in signal transduction because of their cellular location (Gama-Carvalho 
and Carmo-Fonseca 2001). The translocation of proteins can regulate the cell cycle progression 
and proliferation (Kau and Silver 2003). Shuttling proteins may also have a function in coupling 
nuclear and cytoplasmic mRNA metabolism. Misregulation of the subcellular location was 
shown to be involved in cancers (Takai, Tan et al. 2005). 
1.5 p68 RNA helicase (p68) 
1.5.1 General function of p68 as a member of DEAD-box protein  
The DEAD box family proteins have a core segment of eight conserved motifs including 
a Asp(D)-Glu(E)-Ala(A)-Asp(D) box (Linder, Lasko et al. 1989). The DEAD box proteins share 
similar functions of RNA-dependent ATPase activity, and many of them exhibit RNA helicase 
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activity. According to the previous studies, the DEAD box proteins play many important roles in 
RNA metabolism, including ribosome biogenesis, pre-mRNA splicing, and translation (Fuller-
Pace 1994; de la Cruz, Kressler et al. 1999). 
DEAD box proteins play important roles in a wide range of cellular processes through 
interaction with specific RNA molecules. Interestingly, several DEAD box proteins, such as 
rck/p54 and DDX1, have been implicated in both growth regulation and tumor development 
(Godbout and Squire 1993; Akao, Marukawa et al. 1995; Nakagawa, Morikawa et al. 1999). P68 
is a member of the DEAD box family of RNA helicases, its ATPase and RNA helicase are 
demonstrated (Hirling, Scheffner et al. 1989; Iggo and Lane 1989). P68 was originally identified 
through a cross reaction with an antibody for simian virus 40 (SV40) large T antigen (Lane and 
Hoeffler 1980). The amino acid sequence of p68 RNA helicase core has a striking homology to 
the other RNA helicase of DEAD box proteins, such as vasa, eIF-4A, Dhhlp, and UAP56. The 
definition of p68 as a DEAD box family protein is due to its homology sequence to eIF-4A (Ford, 
Anton et al. 1988). P68 is highly conserved through evolution. The mouse and human p68 are 
98% identical (Lemaire and Heinlein 1993), and the sequence of IQ motif at the C-terminal of 
p68 is exactly same in both mouse and human.  
As a member of DEAD box family, p68 binds to both double- and single-stranded RNA. 
The binding of p68 to RNA stimulates its ATPase activity. The released energy can be used to 
unwind RNA duplexes in both directions (Huang and Liu 2002; Lee 2002). The function of p68 
is mainly involved in RNA metabolism, such as pre-mRNA and pre-rRNA processing, 
alternative splicing, and mRNA decay. Importantly, p68 plays a role in cell proliferation. 
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1.5.2 Biological function of p68  
Even though most functions of p68 are related to RNA, new functions of p68 have been 
uncovered in recent years. Expression of p68 is regulated by cell growth and development, which 
strongly indicate that p68 may play a role in cell proliferation (Lane and Hoeffler 1980; 
Stevenson, Hamilton et al. 1998). Interestingly, p68 is found to be essential for the development. 
Specifically, DDX5 knockout embryos die at day 11.5(Fukuda, Yamagata et al. 2007). On the 
other hand, p68 has functions in organ maturation during development. P68 is overexpressed in 
the differentiated adipocyte and skeletal muscle cells (Kitamura, Nishizuka et al. 2001; Caretti, 
Schiltz et al. 2006).  
Recently, p68 is found to regulate gene transcription. This transcription function of p68 is 
found often linked with p72. P68 and p72 are homologous and can form homo- or hetero-dimer 
(Janknecht 2010). P68 interacts with RNA polymerase II, and the ubiquitous transcriptional 
cofactors including CBP, p300 and PCAF (Rossow and Janknecht 2003). CBP, p300 and PCAF 
are acetyltransferase that can acetylate lysine residues of histone tail to activate the gene 
transcription (Yang, Ogryzko et al. 1996; Janknecht 2002; Lee and Workman 2007). 
Interestingly, p68 also binds to histone deacetylase (HDAC) that can repress the gene 
transcription (Wilson, Bates et al. 2004). Thus, p68 can act as transcription co-activator or 
repressor depending on the associated protein contents. P68 is known to function as 
transcriptional co-activator for transcription factors. Interestingly, the RNA helicase activity of 
p68 is not required for the transcriptional co-activator function. For example, the RNA helicase 
of p68 is not required when it functions as a coactivator for p53 tumor suppressor (Bates, Nicol 
et al. 2005), Runx2 (Jensen, Niu et al. 2008) and MyoD (Caretti, Schiltz et al. 2006). RNA 
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helicase activity, however, is required for p68 to function as the transcription cofactor for cyclin 
D1 and c-myc (Yang, Lin et al. 2007). 
1.5.3   Posttranslational modification of p68 
Posttranslational modification is the chemical modifications after a protein has been 
translated. The posttranslational modifications can change the structure, activity, and stability of 
a protein. P68 was found to be phosphorylated by PKC in vitro. However, the phosphorylation 
site has not been confirmed. It is proposed that the serine/threonine within IQ motif may harbor 
the phosphorylation site. Phosphorylation of p68 by PKC inhibits the ATPase activity (Buelt, 
Glidden et al. 1994). Meanwhile, binding to single-stranded RNA by the C-terminal region of 
p68 is inhibited (Yang, Yang et al. 2004). P68 is also phosphorylated at Y593 by c-Abl upon the 
stimulation of PDGF in colon cancer cells. The phosphorylation of p68 at Y593 is required for 
its interaction with beta-catenin. This interaction can translocate beta-catenin from the cytoplasm 
to the nucleus to induce the epithelial-mesenchymal transition (Yang, Lin et al. 2006; Lin and 
Arlinghaus 2008). Interestingly, double phosphorylation of p68 at Y593 and Y595 leads to 
resistance to the trail-induced apoptosis of T98G glioblastoma cells (Yang, Lin et al. 2007). In 
addition, p68 is phosphorylated by p38 MAP kinase (Yang, Lin et al. 2005). The 
phosphorylation site(s) and its biological function are currently unknown. 
P68 is also highly poly-ubiquitylated in colon cancers. In principle, ubiquitylation of p68 
should lead to degradation of p68 (Causevic, Hislop et al. 2001). Whether ubiquitylation of p68 
has other function and which lysine residue(s) is ubiquitylated are open questions. 
The lysine residue (K53) at the N-terminus of p68 is demonstrated to be sumoylated 
(Mooney, Grande et al. 2010). The sumoylation of p68 can stabilize the protein. It increases the 
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interaction between p68 and HDAC1 and affects the potential of p68 as a transcription co-
activator (Jacobs, Nicol et al. 2007). 
1.5.4   P68 and cancer 
It is well known that p68 has important functions in cell proliferation and survival 
(Kahlina, Goren et al. 2004; Yang, Lin et al. 2007). The expression level of p68 is correlated 
with the growth status of cells. P68 exhibits tissue specific expression (Stevenson, Hamilton et al. 
1998). P68 is suggested to be a proto-oncogene, as ectopic expression in fibroblast cells 
(NIH3T3 and NC3H10) can induce the tumor formation in nude mice (Wei and Hu 2001). 
Overexpression of p68 in cells leads to the resistance to the cancer therapy (Cohen, Geva-
Zatorsky et al. 2008). 
The protein level of p68 is upregulated in colorectal tumors (Causevic, Hislop et al. 2001; 
Shin, Rossow et al. 2007). Immunohistochemical analyses show that the expression of p68 is 
increased with the progression of the tumor from hyperplastic polyps to adenomas and 
adenocarcinomas (Shin, Rossow et al. 2007). Interestingly, the aberrant activation of beta-
catenin is associated with colon carcinogenesis (Segditsas and Tomlinson 2006). P68 can bind to 
beta-catenin and activate beta-catenin dependent gene transcriptions including cyclin D1 and c-
myc (Yang, Lin et al. 2007). The upregulation of p68 may lead to and/or target the activated 
beta-catenin to promote gene transcriptions, which results in colorectal tumorigenesis. 
P68 is reported to be over expressed in the breast tumor as well (Mooney, Grande et al. 
2010). Around 70% of the breast tumors are ERα positive (Yager and Davidson 2006). P68 is 
transcription coactivator of ERα (Endoh, Maruyama et al. 1999). Overexpression of p68 may 
activate the ERα dependent gene transcriptions, and subsequently lead to the induction of the 
breast tumor. P68 is upregulated in prostate tumor (Clark, Coulson et al. 2008). Formation of the 
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prostate tumor may be resulting from activating androgen receptor dependent gene transcription 
by p68 (Clark, Coulson et al. 2008). 
1.5.5 Cytoplasmic p68 and cancer  
P68 is consistently overexpressed in colorectal cancer cells when compared with the 
corresponding normal cells. The mRNA level of p68 has no significant difference between tumor 
and normal cells (Causevic, Hislop et al. 2001). Therefore, posttranslational modifications such 
as sumoylation, may stabilize p68 and consequently lead to the upregulation of p68 in the tumor 
cells (Mooney, Grande et al. 2010). On the other hand, overexpression/ubiquitylation of p68 is 
observed in both pre-invasive and invasive lesions (Causevic, Hislop et al. 2001), indicating that 
p68 or the ubiquitylation levels may connect to the tumor growth but not relevant to the invasion 
of tumor cells. 
P68 was first demonstrated to be localized in the nucleus by using antibodies against 
SV40 large T antigen that cross-reacts p68 (Iggo and Lane 1989; Iggo, Jamieson et al. 1991; 
Nicol, Causevic et al. 2000). Later on, p68 is also found in the cytoplasm using the antibodies 
raised against the C-terminal of p68. Specifically, p68 is found in the cytoplasm of ovarian and 
breast cancer cells (Rossow and Janknecht 2003). In fact, the results of colon cancer tissue 
staining shows that p68 exist in the cytoplasm of the colon cancer cells in 2001 using the 
antibodies against p68 (Causevic, Hislop et al. 2001). Interestingly, analysis of HCT-116 and 
SW620 colon cancer cells reveals that p68 is present in the cytoplasm and the cell nucleus, 
whereas normal CCD-841-CoN colon cells display exclusive nuclear localization pattern (Shin, 
Rossow et al. 2007). All these observations suggest that cytoplasmic p68 may have important 
functions in cancer development and progression. 
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Y593 phosphorylated p68 is proposed to translocate to the cytoplasm. The cytoplasmic 
p68 dissociated Axin by binding to beta-catenin. The beta-catenin will therefore translocate to 
the nucleus to act on the expression of a number of mesenchymal promoting genes. This process 
leads to the epithelial mesenchymal transition (EMT) of the tumor cells (Yang, Lin et al. 2006). 
EMT is one critical step for cancer cell metastasis.  
1.6  Calmodulin  
1.6.1 Calmodulin is a conserved Ca
2+
 sensor protein 
Calmodulin is a small protein with the molecular weight of around 16 kDa. Calmodulin is 
an acidic protein. It has four EF-hand motifs, and Ca
2+
 is bound by those EF-hand motifs. 
Calmodulin consists of two symmetrical domains connected by a long α-helix. Two Ca2+ ions 
bind to each domain. The long helix involves the interaction of calmodulin with many proteins 
(Motohashi 1991). 
Calmodulin is expressed in all eukaryotic cells and is highly conserved among different 
species.  Calmodulin is a typical Ca
2+
 sensor, as the conformation of calmodulin will change in 
the presence of Ca
2+
 (Ikura 1996). Specifically, the structure of calmodulin can be changed from 
random coil (without Ca
2+
) to a dumbbell shape structure (with Ca
2+
). Calmodulin is able to 
respond to an intracellular Ca
2+
 concentration change. The range of intracellular Ca
2+
 
concentrations is 10
-7
M to 10
-6
M in most cells. The affinity of calmodulin for Ca
2+
 falls in the 
range of 5x10
-7
M to 5x10
-6
M, which matches well with the range of intracellular Ca
2+
 
concentration.  
The total amount of calmodulin (10
-6
M to 10
-5
M) in cells constitutes over 0.1% of the 
total proteins. The expression level of calmodulin can be upregulated in rapidly growing cells 
and the cells under differentiation. 
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1.6.2 Calmodulin binding proteins 
Calmodulin itself has no intrinsic enzymatic activity, while it has the capability to 
regulate biological activities of many cellular proteins as well as transmembrane proteins. 
Calmodulin binding proteins can be classified into at least six groups based on their model of 
regulation in the presence of absence of Ca
2+
. In group I, the effectors bind to calmodulin 
irreversiblly in a Ca
2+
 independent manner. However, the effector/calmodulin complex may be 
activated in the presence of Ca
2+
. In group II, the effectors bind to calmodulin in the absence of 
Ca
2+
, but dissociate in the presence of Ca
2+
. In group III, the effectors form low affinity and 
inactive complexes with calmodulin at low concentration of Ca
2+
; while at high concentration of 
Ca
2+
, these effectors engage in a high-affinity and active complex with calmodulin. In group IV, 
the effectors bind to calmodulin in the presence of Ca
2+
, and calmodulin inhibits their function. 
In group V, effectors are activated by Ca
2+
-calmodulin, which is a more conventional behavior. 
In group VI, effectors bind to Ca
2+
-calmodulin. The formed complex will be further regulated by 
another calmodulin-regulated kinase (Chin and Means 2000). 
P68 is known to interact with calmodulin. Interestingly, two groups showed that the 
interaction between p68 and calmodulin is Ca
2+
 dependent, and another showed that this 
interaction is Ca
2+
 independent. However, the functional relevance of the interaction is unknown. 
In vitro experiments showed that the RNA-dependent ATPase of p68 was regulated by the 
binding to calmodulin. 
1.6.3  Calmodulin translocation in the cells 
The concentration and location of calmodulin appear to play important roles in regulating 
its biological activity. The local concentration of calmodulin may have significant influence as 
various calmodulin targeting proteins are regulated by different concentration of free calmodulin 
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(10
-12
~10
-16
M) (Chin and Means 2000). Interestingly, the majority of calmodulin is observed to 
be freely diffusible, as shown in the experiment with serum-deprived Swiss 3T3 fibroblasts.  
Calmodulin is immobilized under the stimulation of serum (Gough and Taylor 1993). Most 
calmodulin is Ca
2+
 bound in unstimulated smooth-muscle cells. This information indicates that 
calmodulin is not always freely diffusible inside the cells. Mechanism that regulates the 
calmodulin translocation may exist. Understanding the mechanism by which the calmodulin 
translocates in the cells is important, as translocation of the calmodulin appears to be required for 
many of its biological functions. 
Interestingly, calmodulin is observed to be redistributed from the cytosol to the nucleus in 
response to a rise of Ca
2+
 in cells (Luby-Phelps, Hori et al. 1995). The movement of calmodulin 
to the nucleus is also observed in the neuron cells under the stimulation (Deisseroth, Heist et al. 
1998). In hormone-treated pancreatic acinar cells, calmodulin is accumulated slowly in the 
nucleus (Craske, Takeo et al. 1999). Due to the small size of the calmodulin (16.8 kDa), 
calmodulin has a similar pattern of accumulation in the nucleus with 20 kDa fluorescein-dextran. 
It is speculated that accumulation of calmodulin in the nucleus is the result of the passive 
diffusion of calmodulin into the nucleus (Liao, Paschal et al. 1999). However, whether all the 
calmodulin nucleus translocation depends on the passive diffusion is not conclusive. 
Interestingly, Richard Thorogate and co-workers found that the majority of calmodulin nuclear 
entry occurs by the facilitated mechanism in both Ca
2+
 dependent and Ca
2+
 independent manners 
(Thorogate and Torok 2004). Since calmodulin has important function in the cytosol, the nuclear 
calmodulin needs to be redistributed to the cytoplasm and to a specific area. However, the 
mechanism governing this redistribution is unclear. The diffusion as well as the redistribution of 
calmodulin may be slowed down by many other factors in the cells including macromolecular 
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crowding and cytoskeleton. The elevated Ca
2+
 can also slow down the diffusion of calmodulin in 
the presence of calmodulin kinase II (Kim, Heinze et al. 2004). Therefore, redistribution of 
calmodulin by active mode seems very likely.  
1.7 PKM2 
1.7.1 PKM2 and tumor 
Cancer cells employ glycolysis to generate energy and phosphointermediates which is 
different from the normal tissue. Glycolysis is a metabolic pathway that converts glucose into 
pyruvate and ATP. Glycolysis involves ten reactions. There are three regulation points in the 
pathway: hexokinase, phosphofructokinase, and pyruvate kinase. Pyruvate kinase (PK) is the 
third rate-limiting enzyme in glycolysis. The transfer of phosphoryl group from 
phosphoenolpyruvate (PEP) to ADP to produce pyruvate and ATP is catalyzed by pyruvate 
kinase.  There are four isoforms of pyruvate kinases (L type, R type, M1 type, and M2 type) in 
mammalian cells. PKM2 is one isoform of pyruvate kinase which is expressed in highly 
proliferating tissues including fetal tissue and tumor tissues. During tumorigenesis, M2 type of 
pyruvate kinase is expressed while other tissue specific form of PK is completely down-
regulated (van Berkel, de Jonge et al. 1974; Miwa, Nakashima et al. 1975; Etiemble and Boivin 
1976; Marie, Kahn et al. 1976). The expression of M2 type of pyruvate kinase can change the 
glycolysis rate to produce more phosphoryl intermediates for cell growth. 
PKM2 has three structural forms: monomer, dimer, and tetramer. Each monomer of 
PKM2 has four domains: A domain, B domain, C domain and N domain. Two monomers bind to 
each other at the A domain interface to form a dimeric structure. Two dimers form a tetramer 
through binding at the A domain and C domain interface (Dombrauckas, Santarsiero et al. 2005). 
A domain is the core structure of the monomer. The active site of PKM2 is located in the cleft 
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constructed by A domain and B domain. The FBP binding site for PKM2 is positioned at the C-
domain. Lysine 433 at the C-domain is important for the binding of FBP to PKM2, and this site 
is important for PKM2 binding to the tyrosine phosphorylated peptides (Christofk, Vander 
Heiden et al. 2008; Spoden, Morandell et al. 2009). Tetrameric PKM2 has a higher affinity for its 
glycolysis substrate PEP than dimeric PKM2 does. 
Interestingly, there are more dimeric PKM2 in cells during tumorigenesis. The existence 
of high portion of dimeric PKM2 is reasoned to be beneficial for cell growth and proliferation. 
This is because the low affinity of dimeric PKM2 to PEP decreases the glycolysis rate, and more 
phosphor intermediates is then produed. The phosphor intermediates can be used to synthesize 
lipids, amino acids and some other macromolecules which are essential for cell proliferation. 
Studies show that pp60V-src kinase and HPV-16E7 proteins directly interact with PKM2, 
and help the conversion of dimeric form from tetrameric form (Zwerschke, Mazurek et al. 1999). 
However, how the tetrameric PKM2 converts to dimeric PKM2 is not well studied.  Interestingly, 
PKM2 is a phosphor tyrosine binding protein, and the binding of these peptides can decrease its 
enzymatic activity (Christofk, Vander Heiden et al. 2008).  
1.7.2 Localization of PKM2 
As a pyruvate kinase, PKM2 is dominantly located in the cytoplasm. Interestingly, PKM2 
is also found in the nucleus under certain situations. Under the stimulation of interleukin 3 (IL-3), 
more PKM2 localizes to the nucleus to regulate cell proliferation in hematopoietic cell, Ba/F3 
(Hoshino, Hirst et al. 2007). PKM2 interacts with several nuclear proteins, such as Oct-4 and 
PIAS3 (Lee, Kim et al. 2008). Sumoylation changes protein properties including transcription, 
nuclear-cytosolic localization as well as protein stability. The overexpression of PIAS3 increases 
the sumoylation of PKM2, which leads to the accumulation of nuclear PKM2 (Spoden, 
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Morandell et al. 2009). Somatosatin, a neuropeptide hormone and its anti-cancer analogues, TT-
232, interact with pyruvate kinase in COS-7 cells. The interaction induces the nuclear 
accumulation of PKM2 from the cytoplasm to trigger cell apoptosis (Stetak, Veress et al. 2007). 
Moreover, UV and H2O2 cause PKM2 nuclear accumulation independent of its kinase activity to 
induce cell apoptosis (Stetak, Veress et al. 2007). Even though the nuclear location of PKM2 has 
been observed, the putative function of nuclear PKM2 is a paradox. Furthermore, the mechanism 
in regulating the translocation of PKM2 to the nucleus is not known. 
1.8 Microtubule Motor 
1.8.1 General information about microtubule and microtubule motor  
 Microtubule is one important part of cytoskeleton. The structure of microtubule is 
dynamic in the cells. Microtubules grow from the microtubule-organizing center (MTOC) 
towards the plasma membrane. Microtubules at the MTOC are the minus end where 
microtubules are more stably tethered. The end of microtubule which faces to the plasma 
membrane is the plus end where microtubule can grow dynamically (Valiron, Caudron et al. 
2001). Two major well known microtubule motors have been found, kinesins and dyneins. 
Kinesin super family contains up to 45 members (Miki, Okada et al. 2005). Most kinesin 
members move toward the plus end of microtubule. Different kinesins have variations in the 
accessory subunits and cargo binding domain which lead to the specific transportation of 
individual cargos. Dynein is the major motor that moves toward the minus end of the 
microtubule. 
 Conventional kinesin (kinesin-1) has two heavy chains and two light chains. Each heavy 
chain has an ATP-binding motor domain (globular structure) at the N-terminus. The motor heads 
move kinesin along the microtubule. The stalk domains of two heavy chains interact to form a 
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coiled coil structure. The stalk domain connects the globular head and the tail. The two light 
chains bind at the tail regions of the two heavy chains. C-terminal domain of kinesin light chains 
carry several tetratrico peptide repeats which are involved in the binding of cargos (Dietrich, 
Sindelar et al. 2008). 
1.8.2 The function of microtubule motor and motor as an antitumor target 
Microtubule motor proteins are a class of molecular motors that can move along the 
surface of the microtubules. They utilize the energy that is generated by the hydrolysis of ATP 
(Schnitzer and Block 1997). The general functions of the motors are active transport of the 
associated protein(s) and vesicles (may include mitochondria and Golgi bodies) in the cytoplasm 
(Vale 2003). They also have functions in the formation of spindle apparatus and separation of the 
chromosomes during mitosis/meiosis. The microtubule motors also have functions in anchoring 
the microtubule to the actin filaments, which stabilize/destabilize the microtubule structures, and 
bundling of the microtubules (Gatlin and Bloom 2010). 
The formation of tumor is due to the uncontrolled proliferation of the tumor cells. 
Therefore, the process of mitosis is an important target to prevent cell proliferation (Janssen and 
Medema 2011). There are a variety of anti-mitotic drugs that are successfully used in the clinic. 
Most approved antimitotic drugs target the spindle microtubules. These drugs lead to mitotic 
arrest and apoptosis by interfering with spindle dynamics. However, these drugs have side 
effects including neurotoxicity. In the recent years, the mitotic kinesins or mitotic motors have 
drawn attention. Since the mitotic kinesins have their specific function during mitosis, those 
proteins are becoming the alternative mitotic drug targets (Mayer, Kapoor et al. 1999). Because 
of the specific function of the mitotic kinesins in mitosis, the side effect profile will be improved 
if the drugs specifically target these proteins. On the other hand, the resistance to the microtubule 
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targeting drugs may be overcame by applying the kinesin inhibitors (Huszar, Theoclitou et al. 
2009). 
1.8.3 The functions of microtubule motors in cell migration 
Cell migration is a multistep process that has important functions in normal physiological 
processes such as embryonic morphogenesis, tissue repair and regeneration. Cell migration also 
plays important roles in pathogenic conditions, including cancer, arthritis, and mental retardation 
(Ridley, Schwartz et al. 2003).  
The popular model for cell migration is the formation and rearrangement of actin 
filaments at the leading edge, which induce the protrusion. Microtubule is also proposed to 
function in vesicle transport to provide membrane and proteins at the leading edge to promote 
the protrusion of the cells. The microtubule growth into the leading edge which leads to the 
transport of the molecules to the leading edge is important in initiating/maintaining the 
protrusion (Ridley, Schwartz et al. 2003).    
There are three groups of cytoskeleton associated motors: myosins, kinesins, and dyneins. 
The major function of these proteins is the transport of macromolecular complexes and 
membranous vesicles inside the cells. Interestingly, multiple motors have been suggested to have 
functions in cell migration. Myosins, such as myosin II, play a role in the migration of fibroblasts 
and neurons (Krendel and Mooseker 2005). Interestingly, myosin II is suggested to push the 
nucleus forward from behind in migrating cells. Cytoplasmic dynein is also indicated plays a role 
in directed cell movement. Both myosin II and dynein are proved to have function in soma 
translocation in migrating cells (Vallee, Seale et al. 2009). Surprisingly, the extension of the 
leading edge is not affected when dynein HC is knocked down. This indicates that other 
microtubule motors may be involved in the extension of the leading edge. 
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Cell migration can be divided into 4 steps: polarization, protrusion, traction, and 
retraction. Before the formation of the lamellipodium at the front area, the cell must be polarized. 
This means some of the molecules must be unevenly distributed, and this may need the 
facilitation of the microtubule motor to distribute the molecules to the front area. How the motor 
senses the difference of the front area and tail area is not well understood. 
1.9  Aims of the dissertation 
P68 is previously found to be predominantly located in the nucleus. Many functional 
studies of p68 are focused in the nucleus. Due to its homology with other RNA helicases, many 
functions of p68 related to RNA metabolism have been discovered. P68 was found to exist in the 
cytoplasm of the cancer cells (Causevic, Hislop et al. 2001). A number of research laboratories 
also found the existence of p68 in the cytoplasm of cultured colon cancer cells as well as colon 
cancer tissues (Jacobs, Nicol et al. 2007).  The previous studies in our lab indicate that Y593 
phosphorylated p68 can be exported to the cytoplasm and carry beta-catenin back to the nucleus 
(Yang, Lin et al. 2006). However, it is not known why and how p68 is translocated to the 
cytoplasm. Therefore, the first aim of this study is to identify whether p68 is a 
nucleocytoplasmic shuttling protein. 
Even though several groups have found the existence of p68 in the cytoplasm, the 
biological function of p68 in the cytoplasm is unknown. Meanwhile, what is the regulating 
mechanism behind the export of p68 to the cytoplasm is not known. Our laboratory revealed that 
the cytoplasmic tyrosine phosphorylated p68 can translocate cytoplasmic beta-catenin into the 
nucleus under the stimulation of PDGF (Yang, Lin et al. 2006). Interestingly, high level of p68 
are found in the cytoplasm of the highly metastatic tumor cells but not in the normal cells (Shin, 
Rossow et al. 2007), which indicate the potential role of cytoplasmic p68 in colon cancer 
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motility. Therefore, we used the cultured colon cancer cells as a study system to try to elucidate 
the function of cytoplasmic p68 in cell migration. 
P68 interacts with calmodulin in the presence of calcium (Buelt, Glidden et al. 1994). 
However, the biological function of this interaction in the cell is unknown. Previous study has 
successfully illustrate the function of two interacting proteins by fusing ubiquitin to the C-
terminal of the target protein (Lee, Wang et al. 2005). We adopted the similar system to 
investigate the function role of the interaction by fusing calmodulin to the C-terminal of p68. 
Interestingly, expression of this fusion protein promotes the cell migration. Specifically, p68-
calmodulin fusion protein is located in the cytoplasm and in the regions of the leading edge. 
Along with the previous observations that p68 is up-regulated in the highly metastatic cells, we 
speculated that the interaction between p68 and calmodulin may have function in cell 
migration, and the binding between p68 and calmodulin may have an important function 
in the cytoplasmic translocation of p68 and calmodulin.  
Calmodulin has important functions in cell migration.  The function of calmodulin in cell 
migration is mainly regulated by binding the target proteins in cells at specific region. The active 
redistribution of calmodulin is important as calmodulin is not always freely diffusible. The 
nuclear translocation of calmodulin by binding to other proteins is quite well known. How the 
calmodulin is redistributed to the cytosol, however, is unknown. Since p68 is a 
nucleocytoplasmic shuttling protein, and p68-calmodulin fusion protein is located to the 
cytoplasm, we speculated that the interaction between p68 and calmodulin may facilitate 
the cytoplasmic translocation of calmodulin. 
PKM2 plays important roles in tumor progression as PKM2 is the isoform of pyruvate 
kinase expressed in cancer cells. PKM2 binds to the tyrosine phosphorylated peptide. Our study 
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demonstrated that the Y593/595 double phosphorylated peptide from p68 binds PKM2. Since 
Y593 phosphorylated p68 is able to translocate to the cytoplasm and carry its associated beta-
catenin back to the nucleus, we hypothesized that PKM2 might be transported to the nucleus 
by associating with Y593/595 phosphorylated p68. The nuclear PKM2 is dominantly in 
dimeric structure. The nuclear accumulation of PKM2 was found to alter the cancer cell growth 
by promoting the growth or by inducing apoptosis. Therefore, the function of dimeric PKM2 
on the tumor growth was tested in this study. 
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CHAPTER 2  
GENERAL MATERIALS AND METHODS 
2.1 Nucleic acids related techniques 
2.1.1 Mini preparation for DNA 
QIAprep® Spin Miniprep Kits (QIAGEN, Cat. No. 27106) was used to purify the 
plasmid from E. coli. Simply, 2-3 ml of overnight cultured E.coli in LB medium was centrifuged 
and the pellet was collected. The pellet cells were then suspended in 250 µl of Buffer P1. 250 µl 
of Buffer P2 was added and the mixture was inverted for 6 times till the mixture become clear. 
350 µl of Buffer N3 was then added and the mixture was inverted for 6 times till the solution 
became cloudy. The mixture was then centrifuged for 10 minutes at 13,000rpm. The supernatant 
was collected and the QIAprep spin column was used and was centrifuged for 1 minute. The 
flow-through was discarded. The QIAprep spin column was washed by adding 0.5 Buffer PB and 
centrifuge for 1 minute. The flow-through is discarded. The column was further washed by 
adding 0.75ml of Buffer PE and was centrifuged for 1 minute. The flow-through was discarded, 
and the column was centrifuged for additional one minute. The column was then moved to a new 
microcentrifuge tube. 30 µl of water was used to elute DNA by standing for 1 minute and 
centrifuging for 1 minute at 13,000 rpm.  The eluted DNA was confirmed by either running gel 
electrophoresis and/or sending for DNA sequencing. 
2.1.2 Midi preparation for DNA 
Bacteria carrying DNA plasmid were cultured in 1ml of LB medium supplemented with 
antibiotics (50ng/ml Kanamycin or Ampicillin). Then, the bacteria culture was transferred into 
150ml warm LB medium and cultured overnight at 37°C to amplify bacteria together with 
plasmid DNA. On the second day, the bacteria were collected by centrifuging at 6,000rpm for 8 
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minutes. 3ml of resuspension buffer was used to suspend the cell pellet, and 3 ml of lysate buffer 
was used to lysis the bacteria. The lysate was neutralized by adding 3 ml of neutralization buffer 
and inverting the mixture. Then, the solution was centrifuged at 15,000 for 25 minutes and the 
supernatant was carefully collected into a 50 ml conical tube. 10 ml of DNA purification resin 
provided with the kit was added to the same tube and mixed gently. The mixture was loaded to a 
mini preparation column and the vacuum equipment was applied to remove supernatant. The 
resin beads bounded with DNA plasmids were washed with washing buffer twice (10ml each 
time) by using the vacuum equipment. 300 µl of pre-warmed ddH2O (~70°C) was added into the 
dehydrated resin. Then, DNA plasmid was eluted from the column by centrifuging at 13,200 rpm 
for 1 minute. The plasmid DNA may be further purified with phenol/Chloroform/Ethanol 
method and the concentration of the DNA was measured with spectrometry at OD260nm. 
2.1.3 Agarose gel electrophoresis and gel extraction of DNA 
A double stranded DNA binding dye, Ethidium Bromide, can be used to visualize 
plasmid DNA or DNA fragments under a UV transilluminator. 1% agarose gel was prepared by 
adding 1g of agarose into 100ml of TAE buffer. The mixture was heated with microwave to 
completely dissolve agarose. The solution was cooled down to 50-60°C with a water bath before 
adding 6 µl of ethidium Bromide into it. The solution was then poured into a gel casting 
apparatus. Well inserts was set up to make suitable well. 8~10 µl of DNA ladder was loaded into 
one well to indicate the molecular weight of DNA fragments. The gel ran at constant voltage of 
120V until the DNA/DNA fragment was separated and visualized under the UV transilluminator. 
2.1.4 Quantification of DNA or RNA 
The concentration of nucleic acids was measured in a spectrophotometer (UV-1700 
spectrophotometer, Shimadzu Co.) at OD260nm. The DNA concentration was determined by the 
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formula: DNA concentration (µg/ml)=(OD260nm)X(diluted factor)X(50 µg DNA/ml)/(1 
OD260nm unit). The purity of DNA was determined by the ratio of the absorbance of 
OD260nm/OD280nm. The purity of DNA was acceptable when the ration is between 1.8 and 2.0. 
2.1.5 Polymerase chain reaction (PCR) method 
PCR method was applied to amplify a target sequence from DNA including plasmid 
DNA. PCR method also can be used to mutate specific nucleic acids of a plasmid vector. In 
general, 0.5 µg of template DNA was mixed with 1mM of dNTP, 0.5 µg of both forward and 
reverse primers, and 1-2 unit of Pfu polymerase in 1X reaction buffer. The reaction mixture was 
denatured at 95°C for 2 minutes and then was followed by 25-35 cycles: 95°C denaturation for 
30 seconds, 57-62°C annealing for 45 seconds, 72°C elongation for 45seconds (the elongation 
time can be adjusted based on the length of the target sequence). An additional elongation step at 
72°C for 10 minutes was performed to stabilize the double strands. The PCR product was 
examined by agarose gel electrophoresis. 
2.1.6 Restriction enzyme digestion and plasmids construction 
CDNA of target gene needs to be constructed into the vector in order to exogenously 
introduce proteins into the cells. The plasmid needs to be chosen based on the purpose of the 
research. The sequences of the vectors are available from the companies. The primers 
incorporating the digestion site(s) used for cloning the target gene would be very carefully 
designed. The restriction enzymes have optimum conditions therefore the right buffer reaction 
system is critical to make the digestion successful. The restriction digestion could be carried by 
using one restriction enzyme one time or by using two restriction enzymes one time.  In general, 
in the final digestion system, 1 µg of the plasmid DNA or 30 µl of PCR product and 1 µl of the 
specific enzyme was used. The mixtures were then incubated at the recommended temperature 
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for 2hours or even longer. Agorose gel electrophoresis was used to separate the digested PCR 
product or digested vector. T4 DNA ligase was applied to ligase the digested DNA into the 
digested vector. The 3’-OH of one nucleic acid and 5’ phosphate of the other nucleic acid can be 
joined by T4 DNA ligase. The recommended ration of the DNA to plasmid vector was around 
3:1. The ligation process was performed in 1X ligation buffer with 1-2 µl of T4 DNA ligase. The 
mixture was incubated at 4°C overnight or at room temperature for 30 minutes. The ligation 
product containing the ligased vector was transformed into competent bacteria on the second day.  
2.1.7 Site-directed mutation method 
QuikChange II XL site-directed mutagenesis kit (stratagene) was used to perform a site-
directed mutation. The primer for the mutation can be designed on-line (The Quikchange primer 
design program). 0.5 µg of primers was applied to PCR reaction mixture. 2 µl of DpnI enzyme 
(20U) was added to the reaction system to digest the parental plasmid vector. The digestion 
reaction was performed at 37°C water bath for 2 hours. The mutated plasmid vectors were 
transformed into XL-1 Blue competent cells after the DNA was purified. The transformed XL1-
Blue cells were coated on the agar plate containing an appropriate antibiotic overnight at 37°C. 
On the second day, several colonies were picked and were cultured in 2ml of LB medium 
overnight at 37°C. DNA plasmid was isolated by mini-prep from the bacteria. DNA sequence 
technique at the core facility of GSU was used to identify the mutated DNA sequences. 
2.1.8 Ethanol purification of DNA 
Ethanol purification was performed to remove salt or protein in DNA samples. At first, 
DNA solution was added and mixed well with 1/10 volume of 3M sodium acetate. The mixture 
was then added and wixed well with 2 volumes of ice-old 100% ethanol. The mixture was 
centrifuged at full speed for 10 minutes at 4°C to pellet DNA. The supernatant was removed and 
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the DNA was washed with ice-cold 70% ethonal twice and centrifuge at 4°C for 5 minutes. The 
supernatant was removed and then the DNA pellet was dried by air at room temperature until the 
pellet becomes transparent. The concentration of the DNA was determined at OD260nm in 
spectrophotometer after the DNA pellet was dissolved in ddH2O.  
2.1.9 RNA extraction from tissue  
Whole spleens from mice were collected and submerged into 1.5ml of the RNAlater 
RNA stabilization reagent (QIAGEN, Cat. 76104). The tumor was cut into small pieces (0.5 
cmX0.5cmX0.5cm) and was consequently put into the same amount of the reagent. The samples 
were kept at 4°C for overnight and were then moved to -20°C (for less than 4 weeks). 1/3 of the 
spleen was collected, and the total mRNA was isolated by the mini-plus kit (including the 
shredder column). In detail, the spleen tissue (~30mg) was homogenized in Buffer RLT which 
had been added with B-mercaptoethonal. The tissue lysates were then added into the 
QIAshredder spin column (QIAGEN, Cat. 79654). Then the lysate were centrifuged for 3 
minutes at the maximum speed. The supernatant was transferred into a gDNA Eliminator spin 
column and centrifuged for 30s at 10,000rpm. The flow-through in the tube was added with 1 
volume of 70% ethanol and mixed by pipetting. The mixture was transferred to an RNeasy spin 
column and centrifuged for 30s at 10,000rpm. The flow-through was discarded. 700 µl of Buffer 
RW1 was added into the RNeasy spin column and the flow-through was discarded after 
centrifuging. 500 µl of Buffer RPE was added into the column. The flow-through was discarded 
after centrifuging. And this step was repeated once. The trace amount of Buffer RPE was 
removed by centrifuging the column in a new tube for 1 minute at the full speed. The total RNA 
was eluted into the collection tube from the column by adding 30-50 µl of H2O into the column 
and centrifuging the column for 1 minute.  
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2.1.10 Reverse transcription PCR 
The generation of cDNA from mRNA can be performed by reverse Transcription PCR. 1 
µg of total RNA extract and 1 µl of oligo dt15 was mixed in a final volume of 5 µl by adding 
RNase-free H2O. The mixture was incubated at 25°C for 5 minutes. The mixture was then 
incubated at 70°C for 5 minutes. After that, the mixture was incubated on ice for 5 minutes. 
Among each reaction, 1 µl of reverse transcriptase, 1 µl of RNase inhibitor, 4 µl of MgCl2 
(25mM) and 4 µl of 5X reaction buffer were added together and mixed thoroughly. The mixture 
was incubated at 25°C for 5 minutes, 45°C for 1hour and 70°C for 15 minutes. The final RT-
PCR products were then stored at -80°C. 
2.2 Bacterial Techniques 
2.2.1 JM109 competent cell preparation 
5 µl of JM109 was added into 50ml of pre-warmed, antibiotic free LB medium. The 
culture solution was put in incubator for 1 hour (optional). The solution was then shaken for 2 
hours till the absorbance at 600nm reaches 0.5-1. The amplified bacteria were transferred to 2 
centrifuge tubes and the solutions were centrifuged at 3000-5000rpm for 8 minutes at 4°C. The 
supernatant was discarded and the pellet cells were re-suspended in 20ml of ice cold, sterile 
50mM CaCl2. The cell suspension was incubated on ice for 20 minutes. Then the cell suspension 
was centrifuged again at 3000-5000rpm for 8 minutes at 4°C. The supernatant was discarded and 
the pellet cell was re-suspended in 4ml of ice cold, sterile 50mM CaCl2 and 15% glycerol. Then 
100 µl of the aliquots in eppendorf tube were stored at -80°C. 
2.2.2 Bacterial culture and storage 
The E.coli strains, such as JM109, XL1-blue, BL-21 were used for plasmid DNA 
construction, amplification or recombinant protein expression. E.Coli strain was inoculated in 
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autoclaved Luria Broth (LB) medium containing 1% bacto-tryptone w/v, 0.5% bacto-yeast-
extract w/v and 1% NaCl w/v. 50 µg /ml of Ampicillin or Kanamycin was added into LB 
medium for antibiotic resistant strains selection. The bacteria were cultured in shakers (culture 
medium) or incubators (agar plates) at 37°C. Agar plates were prepared in LB medium with the 
addition of 1.5% Agar prior to autoclaving. 50 µg /ml of Ampicillin/Kanamycin was added in 
when the autoclaved LB medium containing agar was cooled down to around 50°C. The 
transformed bacteria was added with sterile 30% glycerol w/v and preserved at -80°C in order to 
store the bacteria for long term. 
2.2.3 Transformation 
For DNA plasmid amplification, E.coli JM109 can be used to transform the plasmid into 
it. The bacteria together with the plasmid can be amplified by this way. JM109 competent cells 
with 100 µl of the volume were thawed on ice. 1 µg of plasmid DNA was added into the tube 
and incubated with JM109 competent cells for 30 minutes on ice. Heat shock was applied to the 
mixture at 42°C for 90 seconds. The mixture was chilled on ice for additional 2 minutes and 200 
µl of the pre-warmed LB were added into the tube. Then the tube was incubated at 37°C in a 
shaker with 220rmp for 1 hour. The bacteria solution were then spread onto the agar plates 
containing appropriate antibiotics and incubated at 37°C overnight. On the second day, colonies 
were picked with sterile plastic sticks separately from the agar plates and dipped into 2ml of LB 
medium containing antibiotics for single colony amplification. The mini-culture was then used 
for large scale amplification (100ml-150ml) of the plasmid. 
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2.3 Protein and peptide Techniques 
2.3.1 HA-p68 protein expression and purification 
pHM6-p68 vector (or HA-p68-calmodulin expression vector) was transiently expressed 
in HEK cells for two days. The cells were collected and the whole cell lysate was used to purify 
HA-p68 proteins. The cells were suspended in 1XPBS (with protease inhibitor cocktails) and 
were sonificated to break the cells. The supernatant was collected. 20 µl of the poly anti-HA 
antibodies were added into the supernatant, which were collected from one dish. And the mixture 
was incubated for 3 hours to overrnight at 4°C.  The washed G-agarose was added into the 
mixture solution and incubated for additional 2 hours.  The G-agarose was collected and washed 
for 5 times, and the G-agarose were additionally washed by washing buffer (20mM Tris-HCl, 
0.5M NaCl, pH7.5) for ~20 volumes of the G-agarose to remove the proteins which were 
associated with p68. The HA-p68 proteins on G-agarose was released by incubating with the 
elution buffer (20mM Tris-HCl, 0.1M NaCl, 0.1mM EDTA, pH7.5) containing 1mg/ml of HA-
peptide (Sigma) for 15 minutes at 37°C. The HA peptide was removed by dialysis and HA-p68 
protein was concentrated by centrifuging of the solution in Amicon Ultra Centrifugal Filter 
Devices (Millipore, Cat No. UFC800308). 
2.3.2 Recombinant p68-calmodulin fusion protein expression and purification  
His-p68-calmodulin fusion protein encoding DNA fragment was constructed into pET30a 
bacteria expression vector. BL-21 bacteria were transformed with pET30a-p68-calmodulin 
vector and were cultured in LB medium containing 50ng/ml Kanamycin. Single clone of the 
transformed BL-21 was cultured in 50ml of LB, and the culture was transferred into 1L pre-
warmed LB medium and shook at 220 rpm at 37°C until OD600nm of the culture mixture 
reached between 0.4 and 0.6. Isopropyl-B-D-thiogalactoside (IPTG) was added to LB medium to 
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a final concentration at 1mM to induce recombinant protein expression. 4 hours later, bacteria 
were collected with centrifuging at 5,000rpm at 4°C for 10 minutes. Bacteria pellet were washed 
with ice cold PBS twice and lysed in lysis buffer containing 1mg/ml lysozome. The bacteria 
lysate was sonicated for 1 minute on ice and centrifuged at 17,000rpm for 20 minutes. The 
expression of recombinant His-p68-calmodulin was examined in SDS-PAGE gel. Most 
recombinant His-p68-calmodulin protein was expressed in inclusion bodies. The pellet was 
washed with washing buffer (0.5M Urea and 50mM phosphorylate buffer, pH 7.4). The inclusion 
body was lysated at room temperature for 1 hour and was centrifuged at 16,000rpm for 30 
minutes. The supernatant was collected and diluted dropwise with 50 mM phosphorylated buffer 
till Urea was diluted to 0.5 M. Recombinant His-p68-calmodulin protein was purified with 
HiTrap column using Akta purifier 100 FPLC system. Recombinant His-p68-calmodulin protein 
was gradient eluted with 0.5M imidazole. The eluted protein was collected and dialyzed in buffer 
(50mM Tris, pH 7.5, 0.1 M KCl, and 20% glycerol). His-p68-calmodulin protein solution was 
added with 25mM DTT and consequently dialyzed in the refolding buffer (50mM Tris, pH 8.0, 
0.1M KCl, 20% glycerol, 0.1M EDTA, 1mM DTT). 
2.3.3 Protein quantification 
Biorad protein assay was used to determine the concentration of soluble proteins. The 
standard curve was generated based on a serial of different concentration of Bovine serum 
Albumin (BSA) from 0 to 0.01 µg / µl. The standard curve was generated according to the 
absorption values of BSA. 1-2 µl of sample solution was added into ddH2O till the final volume 
800 µl. 200 µl of BioRad dye solution was added. The OD was obtained in a spectrophotometer 
at a wavelength of 595nm. The protein concentration was calculated according to the absorption 
values. The equation for the standard curve was used. 
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2.3.4 Sodium dodecyl sulfate polyacryalmide gel electrophoresis (SDS-PAGE) 
SDS-PAGE gel was applied to separate denatured proteins according to their molecular 
weight. The electrophoresis apparatus was assembled according to the manufacture’s instructions. 
SDS-PAGE gel consists of separating gel and stacking gel. Separating gel (375mM Tris-HCl, 
0.1% SDS, and pH 8.8) was prepared as the following method. The mixture was prepared in a 
100ml glass beaker and poured into two glass plates. Around 500 µl of isopropanol was added on 
the top of separating gel to get rid of air bubbles. In rough, it took 45 minutes for separating gels 
to be polymerized. After the separating gel was polymerized, isopropanol was rinsed away by 
ddH2O gently. 4%stacking gel mixture (125mM Tris-HCl, 0.1% SDS, and pH 6.8) was prepared 
and poured on the top of the separating gel when there is no ddH2O. An appropriate comb was 
inserted into the stacking gel to generate wells before the stacking gel is polymerized. The 
prepared SDS-PAGE gels were kept in 1X SDS-PAGE running buffer (25mM Tris, 250mM 
Glycine, 0.1% SDS, and pH 8.3) at 4°C for few days. Protein samples were mixed with 5X 
loading buffer (50mM Tris-HCl at pH 6.8, 2% SDS, 10% glycerol, 1% beta-Mercaptoethonal, 
0.02% Bromophenol Blue and 12.5mM EDTA) and boiled at 95°C for 8 minutes. The boil-
denatured protein samples were then loaded into the well. Both the inner chamber and the outer 
chamber was filled with SDS-PAGE running buffer before the protein samples were loaded. The 
gel was run at 60V until the dye just reached the separating gel and then the voltage was 
switched to 120V until the blue dye running out of the gel. 
2.3.5 Coomassie blue staining 
Coomassie blue stain was used to visualize the high amount of proteins (>1 µg) on SDS-
PAGE gel. The gel was washed with ddH2O for few minutes. Then, the gel was stained with 
Coomassie blue solution (0.1% Coomassive Brilliant Blue, 20% Methanol, and 10% Acetic Acid) 
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for 30 minutes. The gel was destained with the destaing buffer (40% Methanol and 10% Acetic 
Acid) to remove extra Coomassie blue dyes which did not bind to the proteins. 
2.3.6 ATPase assay 
A direct colorimetric assay was used to measure the ATPase activities through measuring 
the released inorganic phosphate during ATP hydrolysis. The method is based on the change in 
absorbance (A623 nm) of malachite green-molybdenum complex with or without inorganic 
phosphate.  In general, ATPase assay was carried out in 50 µl reaction volumes, containing 20 
mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM MgCl2, 5 mM DTT, ~1–2 µg of appropriate RNA, 
40 units of RNasin, 4 mM NTP, and 10 µl of helicase. The ATPase reactions were incubated at 
37 °C for 30 minutes. After incubation, 1 ml of malachite green-molybdenum reagent was added 
to the reaction mixture, and reactions were further incubated at room temperature for exactly 5 
minutes. The absorption (A) at 630 nm was then measured. The concentrations of inorganic 
phosphate were determined by matching the A630 nm in a standard curve of A630 nm versus 
known phosphate concentrations. In order to generate a Standard curve of Pi, 1-0.1mM of 
Na2HPO4.7H2O was used. If the proteins were purified before testing the ATPase activity, 
RNasin is not required. Reagent for phosphorus determination: 1) ammonium molybdate: 28.6g 
of ammonium molybdate was dissolved in 500 ml of 6N HCl. 2)Polyvinyl alcohol: 11.6g of 
polyvinyl alcohol was dissolved in 500 ml of boiling water. 3) Malachite green: 0.812g of 
malachite green was dissolved in 1000 ml of deionized water.4) Mixed reagent: 2x 3)+ 1x 1)+ 1x 
2)+ 2x deionized water (prepared on the day of use, room temperature for 30 minutes until it 
turned golden yellow.) 
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2.3.7 Motor assay 
The protein HA-p68-calmodulin, HA-p68, or His-p68-calmodulin (10 μl) was loaded into 
a glass slide. The slide was then blocked with the blocking buffer. For the slide loaded with HA-
p68, 10 μl of calmodulin with 0.5 mM of Ca2+ was added into the slide and was incubated for 
10 minutes. The slide was consequently washed with the wash buffer added with Ca2+ in order 
to remove the unbound proteins. The pre-prepared Rodamine labeled microtubules were then 
loaded into the slide. The same wash buffer containing Ca2+ was used to remove unbound 
microtubules. The movement of microtubules was then recorded by the confocal microscope 
after the wash buffer was replaced with the buffer containing ATP. 
2.3.8 Microtubule pellet down assay 
The commercial microtubule was reconstituted in the warm PM buffer (15 mM Pipes pH 
7.0, 1 mM MgCl2) which were added with taxol as instructed by the vendor. The microtubules 
were ready to use after 15-minute of incubation at room temperature. The proposal protein(s) 
was incubated with the reconstituted microtubules under specific conditions. The microtubules 
with the associated proteins were separated from the incubation solution by centrifugation at 
100,000g for 30 minutes. The precipitated microtubules were re-suspended in 50 µl of 2 x SDS 
PAGE loading buffer and were heated at 85 °C for 10 minutes and were subsequently analyzed 
by western blot. 
2.3.9 Peptide purification 
The crude peptide was dissolved into ddH2O to a final concentration around 1mg/100 µl. 
HPLC equipment (Agilent Technologies 1200 series) was used. C-18 reverse phase semi-prepare 
column (10mmx25cm, ultrasphere) was used. The buffer A was 0.1% TFA in H2O. The buffer B 
was 0.1% TFA in Acetone Nitrial (ACN). 3ml/minute of the flow rate was used.  
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The pump was set as follows: 
Flow: 3.0ml/minute      A: 95% H2O 
Stop time: 60 minutes  B: 5% CAN  Max: 400Bar 
Table 1 The setup for HPLC pump 
  Time (minute) %B Flow 
1 0 0 3.0 
2 3 5.0 3.0 
3 17 40.0 3.0 
4 18 40.0 3.0 
5 19 95.0 3.0 
6 25 0 3.0 
7 30 0 3.0 
8 31 0 0 
9 60 0 0 
 The peptide fraction was collected during 14.6-15.2 minutes. The peptide was then dehydrated. 
The weight of the dehydrated peptide was measured. The fraction of the peptide was confirmed 
by running MS.   
2.4 Mammalian cell techniques 
2.4.1 Mammalian cell culture and storage 
Cell lines including LN686, M4C1, SW480, SW620, WM115, WM266, T98G, U87MG, 
H146 and H460 were purchased from ATCC. The culturing methods of the cells follow the 
vendor’s instructions provided by ATCC. In order to freeze cells, the confluences of the cells 
were maintained around 60-70%, T75 flasks may be used to amplify the cells. The cells were 
released from the flask by trypsinization, and cell numbers were counted by using 
hemocytometer. Cells were harvested by centrifuging at 800 rpm for 5 minute. The supernatants 
were removed and cell pellets were resuspended in freezing medium (10% v/v DMSO, 90% of 
culture medium contained 10% of FBS). The reusupended cells were aliquoted into freezing 
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vials (5 x 10
6
 cells/vial). The vials were stored in a freezing container at -80C overnight. The 
next day, the freezing vials were transferred to a liquid nitrogen reservoir for long storage.  
2.4.2 Transient transfection method 
In order to exogenous express a specific protein, mammalian cells can be transiently 
transfected the protein encoding plasmids by adding with Fugene-HD reagent (Roche).  The 
instruction of manufacture which was provided by the Roche was followed. Mammalian cells 
were seeded in corresponding medium in 6-well plates. The trasfection were performed on the 
second day, and 70-90% confluence of the cell density was preferred. The mixture of plasmids 
DNA and Fugene-HD was prepared in polystyrene transfection tubes. 2 µg of plasmid DNA was 
added into 100 µl of Opti-MEM medium and mixed thoroughly. Then, 5 µl of Fugen-HD reagent 
was added into the tube and mixed with plasmid DNA thoroughly. The mixtures were incubated 
for 20 minutes at room temperature. During the time, the wells in the plates were washed with 
fresh normal medium twice and fed back with 1ml corresponding medium. Then, 100 µl of the 
transfection mixture was added to each well gradually. Then the solutions in the plates were 
mixed well by rocking back and forth for several times. The cells were then cultured in an 
incubator with/without 5 % CO2 at 37 °C for additional 48-72 hours before harvesting. For 
immuno-staining experiments, the transfected cells were reseeded in chambers 24 hours later.  
2.4.3 Stable cell line establishing 
SW480 cells or SW620 cells were seeded into the tissue culture dishes with around 50% 
confluency. The cells were transiently transfected with eGFP/eGFP-IQ/eGFP-MA/HA-
PKM2/HA-399E respectively. The medium was replaced on the next day, and cells were 
reseeded into the new dishes with around 10% confluency. The selective medium (containing 
0.4mg/ml of G418) was applied when the cells have adhered to the dishes. The selective medium 
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was replaced every two days till the clones have been formed. For the eGFP expression cells, 
fluorescent microscope was applied to examine the stable expression of the GFP proteins. 24 
clones for each construction were picked up by using the autoclaved discs. Each clone was 
cultured in each well of the 24-well plate. The clones of cells were gently pipetted to disassociate 
the cells. After the cells had adhered to the bottom of the plates, the discs were removed and the 
selective medium (0.2mg/ml of G418) was replaced as previously. The fluorescent microscope 
and western blot were used to confirm the stable expression of the proteins after the cells has 
been amplified.  
2.4.4 RNA interference 
The expression level of endogenous protein can be down regulated by RNA interference 
technique. 30-50 % confluence of cells was seeded to into a 6-well plate in corresponding culture 
medium one day before the performance of knockdown experiment. On the second day, the wells 
in the plates were washed by 2ml of Opti-MEM medium to remove FBS. siRNA duplex for p68 
was purchased from Dharmacon RNA Technologies. RNA duplex was dissolved in DEPC-
treated H2O to 40 pmol/ µl. 200 pmol of siRNA duplex was diluted in 250 µl of Opti-MEM 
medium. 5 µl of transfection reagent, lipofectamine RNAiMAX (invitrogen), was added into 250 
µl of Opti-MEM medium. These two solutions were added together and the mixture was 
incubated for 30 minutes at room temperature. 0.75ml of Opti-MEM medium was added into 
each well. Then, the mixture was added into each well gradually. Fresh medium might be added 
into each well on the second day. In order to re-express the corresponding wide type or mutant 
proteins in the cells, those knockdown cells were transfected the corresponding plasmid using 
FuGene 24 hours later. Cells were released from the wells by scratching or trypsinization after 
additional 48 hours and were then harvested by centrifuging at 1,000 rpm for 10 minutes at 4 °C.  
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2.4.5 Growth factor treatment 
In order to stimulate the cells get into the migration status, certain growth factors 
including EGF and HGF were tested. Mammalian cells were starved for 6-12 hours with Opti-
MEM medium before the addition of the growth factor. Growth factors were dissolved in Opti-
MEM medium. The starved cells were cultured in growth factor containing Opti-MEM medium 
for a given amount of time (3-5hours). Opti-MEM was used as a control. The cells were 
harvested once the treatment has done and the cell lysate was stored at -80 °C.  For the images 
assay, the cells were fixed after the treatment of the growth factors. 
2.4.6 Monolayer scratch treatment 
A scratch or multiple scratches using pipette tips were introduced into a 6 well cell 
culture plate. The cells were further cultured under serum starvation for 30 minutes, and were 
subsequently cultured for an additional indicated time. The scratch-treated cells were either 
directly visualized by microscopes or the cells were fixed and subsequently examined by 
immunostaining. Alternatively, the cells were collected and lysized. The prepared cellular 
extracts were then used for other analyses. 
2.4.7 Whole cell lysate preparation (both RIPA buffer and grind method) 
Mammalian cells were washed twice with cold 1X PBS and were collected by 
centrifuging at 1,000 rpm for 10 minutes at 4ºC. 1X RIPA buffer (50 mM Tris-HCl, pH7.4, 150 
mM NaCl, 0.25 % deoxycholic acid, 1 % NP-40 and 1 mM EDTA) supplemented with Protease 
Inhibitors Cocktail (PIC) (Sigma) and phosphatase inhibitors cocktail (Pierce) was used to lysis 
the collected cells at 4°C for few hours.  The volume of the RIPA depends on the amount of the 
cells needs to be lysized. A rotary plate at 4 ºC was used to incubate the lysing cells. Then, cell 
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lysis solution was centrifuged at 13,200 rpm for 10 minutes at 4°C to spin down the cell debris. 
The supernatant was collected carefully and stored at -80 ºC for later applications.  
2.4.8 Nuclear extract and cytoplasmic extract preparation 
A nuclear extraction kit from Active Motif.Nuclear can be used to isolate cytosolic 
proteins and nuclear proteins from mammalian cells. The collected cells were washed with cold 
1X PBS added with PIC twice to remove culture medium. The centrifuge was used to spin down 
the cells and 1,500 rpm for 10 minutes at 4 ºC was applied. In general, 1 ml of 1X hydrophobic 
buffer supplemented with PIC was used to resuspend 1X10
6
 cells and the cells were incubated on 
ice for 15 minutes. Then, 50 µl of detergent was added into the suspended cells to break the 
cytoplasmic membrane and the tube was vortexed at maximum speed for 30 seconds. The 
supernatant was collected after the cell suspension was spin down. The supernatant was stored at 
-80 ºC up to 2 months. The cold 1XPBS was used to wash the pellet, which contains the nucleus, 
for twice to get rid of the cytoplasmic protein. Then, AM1 lysis buffer containing PIC and 1 mM 
DTT was used to resuspend the nuclear pellet and the mixture was incubated at 4 ºC for 1hour. 
Next, the tube was centrifuged at 13,200 rpm for 10 minutes at 4 ºC to collect the supernatant 
which was the nuclear extracts. The nuclear extract was collected and stored at -80ºC for further 
applications.  
2.4.9 Immunoprecipitation (IP) and co-immunoprecipitation (Co-IP) 
IP and Co-IP experiments were performed in 1X NET buffer (150 mM NaCl, 50 mM 
Tris-HCl [pH 7.5], 5 mM EDTA, 0.05 % NP-40) supplemented with 1X PIC (EDTA free) and 
phosphatase inhibitors (1mM SoV, 5mM NaF). 500 µg of whole cell lysate or subcellular extract 
were incubated with appropriate primary antibody in 1X NET buffer overnight at 4°C. The next 
day, 50 µl of protein G agarose bead slurry was washed five times with NET buffer and was then 
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added into the reaction tube and incubated on a rotating platform for additional 2 hours at 4 °C. 
The tubes were centrifuged at 1,000 rpm for 5 minute at 4 °C. The immuno-complex samples 
were denatured in 30 µl of 2X SDS-PAGE loading buffer by heating at 100 °C for 10 minutes. 
The supernatant which contains the immuno precipitated proteins were separated in SDS-
polyacrylamide gel electrophoresis (PAGE) and the specific protein bands were detected by 
using the corresponding antibodies. 
2.4.10 Calmodulin beads pull-down and GST beads pull-down 
Calmodulin beads (50 µl /assay) were washed with the NET buffer for 4 times. 500 µg of 
the whole cell lysate was added to the washed calmodulin bead (around 25 µl). Ca
2+
 or EGTA 
was added into the mixture accordingly. The mixture was incubated for 3 hours at 4°C, and the 
calmodulin beads were then collected at 5000rpm, 4°C for 1 minute. The beads were washed 
with the corresponding buffer for 3 times with the same setting. The washed beads were finally 
loaded with 30 µl of 2X SDS loading buffer and heated at 100°C for 8 minutes. The supernatant 
was collected and was analyzed by the Western-blot technique. 
The method for the GST beads pull-down assay is similar to the calmodulin beads pull 
down assay. The difference for the GST beads pull-down assay is that the beads pulled down the 
GST tagged protein (or protein complex) instead of the calmodulin binding proteins. Different 
buffer was used based on the purpose of the experiment.  
2.4.11 Western Blot 
Protein samples, including the recombinant proteins, whole cell lysate, subcellular lysate 
or immuno-complex, were added with 5X SDS-PAGE loading buffer. The protein samples were 
denatured by heating at 100 ºC for 10 minutes. Multiple proteins were separated in 8~10% SDS-
PAGE according to the molecular weight of proteins and were transferred to nitrocellular 
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membranes. Nitrocellular membranes, sponges and filter papers were soaked in transfer buffer 
(Tris-HCl, pH8.3, Glycine and 40 % methanol) for 10 minutes. The transfer sandwich was 
assembled as the manufacturer’s instructions indicated. The transferring was carried out at 105 
mA for 3 hour. The transfer sandwich was disassembled after the transferring has done. The 
nitrocellular membranes was stained with Pancrea S dye for 10 seconds and destained with 
ddH2O for 1 minute to remove extra dye. Multiple protein bands would be visualized on the 
membranes. The membranes can be cut into several strips based on the molecular marker. The 
strips of the membrane were washed with TBST for 10 minutes to remove Panceau S dye and the 
strips can be blocked with 5% BSA for 30-60 minutes. The membranes were incubated with 
primary antibody in 2% BSA-TBST buffer at 4 °C for 2 hours to overnight. The next day, the 
membranes were washed with TBST buffer for three times. The time for the washing would be 
around 5 -10 minutes each time. Then, the strips were incubated with the secondary antibody 
(1:2,000 dilutions in 2% BSA-TBST buffer) for 2 hours at room temperature. The strips were 
then washed for three times again to remove the non-specific binding of the antibodies. The 
strips were incubated with SuperSignal West Dura Extended Duration Substrate (Pierce) for 2 
minutes and the western blotting signals were detected in a UVP machine. 
2.4.12 Boyden chamber assay 
CHEMICON® QCM™ 24-well Cell Migration Assay (ECM508) was used to measure 
the migration capability of the epithelial cells including SW480 and SW620 cells. The capability 
of cell migration was examined when the cells were knocked down with endogenous p68 and /or 
transfected with corresponding vectors.  The treated cells were collected and counted. Around 
3X10
5
 of the cells were seeded into the inserted wells in FBS free medium (L-15). The lower 
chamber was loaded with FBS free medium in order to let the cells to starve for 5 hours. 5 hours 
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later, the medium in the lower chamber was changed to 10% FBS medium. The cells were then 
incubated in the incubator for 16 hours (overnight) to let the transmigration through the 
membrane occur. 225 µl of prewarmed cell detachment solution was prepared and loaded into 
new well in the 24-well plate. The insert well with the cells was carefully washed twice and the 
medium was removed completely. The insert was then moved to the new wells with the pre-
warmed cell detachment solution. The incubation of the insert in the detachment solution took 30 
minutes. The detachment solution in the well was added with 225 µl of lysis buffer after the 
insert was removed. 300 µl of the mixture were reloaded into the 96-well plate. The absorbance 
was obtained.  
2.4.13 Recombinant adenovirus generation and infection in mammalian cells 
The DNA sequences of four truncated p68 were cloned from pHM6-p68 vector. 
Recombinant adenoviruses expressing four truncates of p68 were constructed according to the 
method generated by Dr. Tong-Chuan He (Luo J et al, Nature protocols, 2007, 2(5), 1236-1247). 
Briefly, truncated p68 DNA sequnces were cloned into a shuttle vector pAdEasy-1 with EcoRI 
and NotI restriction endonuclease sites respectively. The resultant plasmid was digested with 
Pme1 and transformed into competent AdEasier cells containing the adenoviral backbone 
plasmid pAdEasy-1 by electroporation method (BJ5183-AD-1, Stratagene). Recombinants were 
selected for kanamycin resistance and further confirmed by restriction endonuclease analyses. 
The confirmed plasmid with the truncated p68 DNA was digested with PacI restriction 
endonuclease and transformed into HEK-293 cells expressing adenovirus E1 (Stratagene). The 
production of recombinant adenoviruses in HEK-293 cells was examined with GFP expression 
under fluorescent microscope. The amplified virus was released from HEK-293 cells by four 
freeze-thaw-vortex cycles. Cell debris was removed by centrifugation at 500 rpm at 4 °C for 15 
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minutes. The recombinant adenoviruses were amplified three rounds in HEK-293 cells to get 
higher titers. Titers were measured with GFP expression in HEK-293 cells with a series of 10 
folds dilutions of virus lysate. The titer in the initial lysate was around 1.43X10
9
 pfu/ml. After 
three rounds of amplification the titer reached 1.09X10
13
 pfu/ml. All viral lysates was stored in -
80 °C for further applications. To infect cells, cells were seeded in 48-well plates to 70~80 % 
confluence one day before infection. 50 µl of viral lysate (1.09X10
13
 pfu/ml) was added to each 
well of a 48-well plate and incubated with cells for 3-5 hours. For 24-well and 6-well plates, the 
scales were increased according to the plate sizes. Fresh medium was changed 3~5 hours later. 
The expression of HA tagged truncated p68 proteins were examined by Western blot 48 hours 
later.  
2.4.14 Cell proliferation assay 
Cell proliferation was measured by counting the cells or was measured with BrdU cell 
proliferation assay (Calbiochem). In brief, cells were seeded into a 96 well culture plate (1X10
4
 
cells/well). Cells were treated with the growth factor or IQ peptide. 24 hours post treatment, 
BrdU was added in a working solution with fresh culture medium. 20 µl of working solution was 
added into each well and the plate was put in a cell culture incubator. 24 hours later, culture 
medium was removed and cells were fixed with 50 µl of Fixative/Denaturing solution. 20 µl of 
anti-BrdU antibodies was then added into the well. The cells were incubated for 1 hour at room 
temperature. The cells were washed with the washing buffer, and the secondary antibody 
conjugated with HRP was added into the wells and incubated with cells for 30 minutes at room 
temperature. The plates were washed with ddH2O and the cells were incubated with substrate 
solution for 15 minutes. A spectrophotometric plate reader (Wallac 1420 multilabel counter) at 
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wavelengths of 450-540nm was used to measure the absorbance after each well was added with 
50 µl of stop solution.   
2.4.15 Living cell imaging and fixed cell imaging 
When the cells were exogenously expressed with fluorescent protein or fluorescent 
tagged protein (including DsRed and GFP proteins), the fluorescent signal can be detected under 
fluorescent microscope or Confocal microscope in living cells. The confluency of the cell in the 
chamber can be 30%-50%. A special chamber was used to observe the living cells under 
confocal microscope with high resolution. Phenol red free medium may improve the detection of 
fluorescent signals.  
Immunostaining technique was used to examine the location of a specific protein in the 
cells. Immunostaining are often done in the fixed cells. In simple, cells in a specific chamber 
were washed by pre-warmed 1XPBS buffer twice. The cells were then fixed in pre-warmed 3.7% 
formaldehyder for 10 minutes. The cells were washed with 1X PBS for three times. The cells 
were treated with 0.2% Triton-100 for 5 minutes. The cells were washed by 1X PBS for three 
times. The cells were incubated with signal enhancer solution for 30 minutes. The cells were 
rinsed with 1X PBS. The first antibody to a specific protein was added into 1X PBS contains 
2.5% BSA. And the cells were incubated withthe first antibody for 60 minutes at room 
temperature.  The cells were washed with 1X PBS for three times. The second antibody which 
conjugated with fluorescent signal was added into 1X PBS containing 2.5% BSA. The cells were 
incubated in the second antibody solution for 30 minutes.  The cells were loaded with the oil 
containing DAPI to stain the nucleus after the cells were washed with 1X PBS. The slide was 
then covered with a slide and the samples were ready to be observed under confocal microscope.   
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2.5 Animal experiment 
2.5.1 Tumor implanting (subcutaneous tumor injection) 
Cells from four 175 cm
2
 flasks were trypsinized with 4ml of trypsin and neutralized by 
adding 10ml of the 10% FBS added L-15 medium. The cells were then collected in the tube by 
centrifuging at 850rpm for 5 minutes. The cells were washed for three times with 40ml of pre-
chilled HBSS. The total amount of the cells was counted. 6x10
7
 of the cells (for 6 mice) was 
collected in two eppendorf tubes respectively. The cells were centrifuged and resuspended in 200 
µl of HBSS (total volume was around 300 µl). 300 µl of the BD matrigel was added and swirled 
with the cell suspensions. Then 100 µl of the cell mixture were subcutaneously implanted into 
the nude mouse at the right flank. Need to mention that, all the needle and pippet and HBSS 
needs to be pre-chilled before being used.  In this experiment, 6 mice were used for each group. 
2.5.2 Tumor size measurement and tumor weight measurement at the end point 
The volume of the tumor was measured and calculated after the nude mice were 
subcutaneously implanted with tumor cells for 5 days. The width/ length/height of the tumor 
were measured every two days. The formula: 4p/3 × (width/2)2 × (length/2) was used to 
calculate the volume of the tumors. After around one month later (4-5 weeks), the mice were 
euthanized. The tumors were isolated from the mice and the weights of the tumor were measured. 
2.5.3 Tumor spleenic metastasis examination 
The mRNA level of human keratin was detected in the spleen of mice by RT-PCR. The 
mice spleens were collected and submerged into the RNAlater RNA stabilization reagent (Cat. 
76104). For the tumor fraction with the size 0.5 cmX0.5cmX0.5cm was put into the reagent. The 
samples were kept at 4°C for overnight, and the samples were then moved to -20°C (for less than 
4 weeks). 1/3 of the spleen was used, and the total mRNA was isolated by the RNeasy Plus mini 
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kit (Cat. 74134, including the QIAshredder column, Cat. 79654). For the RT-PCR, 10 µg of the 
total mRNA was used. Primers for mouse b-actin, human b-actin, and human keratin 18 were 
used (The cDNA which was generated from 10 µg of the total mRNA may need to be purified 
before the PCR.).  In order to examine the green fluorescent signal from the spleen of mouse, the 
UVP machine with 488nm of the wavelength of the filter was used. Tumor grew from eGFP 
stable cells was used as a positive control.  
2.5.4 Tissue staining 
The tumors were isolated from the euthanized mice. The tumors were buried in Cryo-gel 
and were frozen in liquid Nitrogen till the gel freeze to form a white solid cubic. The samples 
were stored in -80°C.  Frozen tissue was then cut by cryostat. The cut splice (10 µm) was fixed 
by the 100% cold Acetone (-20°C) for 9 minutes. The slice was stained with the specific 
antibodies using the regular cell immunostaining method as described prevously. DAPI was used 
to stain the nucleus. The confocal was used to examine the expression of the corresponding of 
proteins as well as the location of the proteins. 
2.6 Materials 
Table 2 Antibodies and proteins 
Name Source Company Cat # 
P68 Rabbit 
Georgia State University, 
Animal center facility 
RGG#4 
P68-RGG Mouse 
Auburn University 
Hybridoma Facility 
6G7C8A2 
Anti-HA Mouse Roche 12CA5 
Anti-HA Fluorescein, 
high affinity (3F10) 
Mouse Roche 1 988 506 
Anti-HA poly Rabbit 
Georgia State University, 
Animal center facility 
-- 
His-Tag mAb Mouse Cell signaling 27E8 
CRM1 Rabbit Abcam Ab3459 
GAPDH Mouse Chemicon MAB374 
Lamin A/C Rabbbit Cell Signaling 2032 
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Beta-Actin Rabbit Cell signaling 4967 
Calmodulin Rabbit ZYMED 61-8500 
Calmodulin Mouse ZYMED 13-6900 
Calmodulin Rabbit Abcam 
Ab45689-
100 
Calmodulin Mouse Abcam 
Ab38841-
200 
Kinesin [KN-01] Mouse Abcam Ab9097-100 
Dynein intermediate 
chain 1 
Mouse Abcam Ab6304-100 
Alpha-tubulin, clone 
DM1A 
Mouse Sigma T9026 
Beta-tubulin, 
clone TUB2.1 
Mouse Sigma T4026 
GFP Rabbit Abcam Ab6556-25 
GFP Rabbit Cell signaling 2555 
His tag [HIS.H8] Mouse Abcam 
Ab18184-
100 
DDX17 Rabbit Abcam 
Ab52826-
100 
GRB2 [Y237] Rabbit Abcam Ab32037 
Kinesin HC motor 
domain protein 
--- Cytoskeleton KR01 
Karyopherin-a2 --- CALBIOCHEM 420370 
Karyopherin-b1 --- CALBIOCHEM 420375 
Calmodulin --- Abcam Ab53982-1 
Beta-catenin Mouse Upstate 8E4 
Stat3 Mouse Cell sigaling 124H6 
γ-tubulin Rabbit Abcam 
Ab11317-
100 
Jak2 Rabbit Cell signaling D2E12 
Phospho-Stat3 Rabbit Cell signaling D3A7 
Eg5 Rabbit Abcam 
Ab38095-
200 
Lamin B1 Rabbit Abcam 
Ab16048-
100 
MAP2K5 antibody Mouse Abnova 1B4 
MAP2K5(pSer311/T
hr315) 
Rabbit AnaSpec 29770 
NTF97/importin β Mouse Abcam Ab2811 
PKM2 Rabbit 
Georgia State University, 
Animal center facility 
--- 
Phosphotyrosine Mouse Abcam PY20 
Phosphotyrosine Mouse Cell signaling P-Tyr-100 
Caspase-3 (3G2) Mouse Cell  signaling 9668 
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Cleaved Caspase-3 
(Asp 175) 
Rabbit Cell signaling 9661S 
Caspase-8 (1C12) Mouse Cell signaling 9746 
 
Table 3 Primers 
Construction Primers (5’-3’) Vector 
NLS3 deletion 
GGGGATGGGTGGCCTGCCATGGGT 
GGGGGTTTCCACAAAAACAATGGTTTTATT 
PCDNA3.1-
eGFP-p68 
NLS4 deletion 
GGGGGTGGATTTAATACCTTTAGAG 
GGGACCTGAACCTCTGTCTTCGAC 
PCDNA3.1-
eGFP-p68 
Mutation 1 
GGCCTTATCTGGAAAGGAGTTTGGAAACCCTGGG 
pHM6-p68 
Mutation 2 
GGAAACCCTGGGGAGAAATTAGTTAAAGAGAAGT
GGAATCTT 
pHM6-p68 
Mutation 3 
CCCTGATTTGGCTAGGGCCACAGCACAAGAGGTG 
pHM6-p68 
Mutation 4 
CACAAGAGGTGGAAACATACAGAGCAAGCAAGG
AAATTACAGTTAGAG 
pHM6-p68 
Mutation 5 
CCATTGTTTTTGTGGAAACCAAAGCAAGATGTGAT
GAGCTTACCAGA 
pHM6-p68 
Mutation 6 
TGATGAGCTTACCAGAAAAATGGCGAGAGATGGG
TGGCCT 
pHM6-p68 
Mutation 7 
CATTGTTTTTGTGGAAACCAAAGCAGCATGTGATG
AGCTTACCAGAAAAATG 
pHM6-p68 
Mutation 8 
ATGTGATGAGCTTACCAGAGCAATGGCGAGAGAT
GGGTGG 
pHM6-p68 
Mutation 
NES2 
GGATCTGGGAAAACATTGTCTTATGCGCTTCCTGC
CGCTGCCCACATCAATCATCAGCCA 
pHM6-p68 
Mutation 
NES5-1 
CAAAAGAAGTAAGACAGCTTGCTGAAGATGCCGC
GAAAGACTATATTCATATAAACATTGGTG 
pHM6-p68 
Mutation 
NES5-2 
AGACTATATTCATATAAACATTGGTGCAGCTGAAC
TGAGTGCAAACCACA 
pHM6-p68 
Mutation 
NES5-3 
AGATGCCGCGAAAGACTATATTCATGCAAACATT
GGTGCAGCTGA 
pHM6-p68 
Mutation 
NES8-1 
CTAATAACATAAAGCAAGTGAGCGACGCTGCCTC
TGTGCTTCGTGAAGCTAATCAAG 
pHM6-p68 
Mutation 
NLS4-1 
GGTTCAGGTCGTTCCGCGGGTAGAGGAGGCAT 
pHM6-p68 
Mutation 
NLS4-2 
GCATGAAGGATGACCGTGCGGACAGATACTCTGC 
pHM6-p68 
Mutation 
NLS4-3 
CGGGACAGATACTCTGCGGGCGCAAGGGGTGGAT
TTAATACC 
pHM6-p68 
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NLS-1 forward 
And reverse 
AATTCCGATGAAGAAGTTTGGAAACCCTGGGGAG
AAATTAGTTAAAAAGAAG 
GATCCTTCTTTTTAACTAATTTCTCCCCAGGGTTTC
CAAACTTCTT CATCGG 
DsRed 
NLS-2 forward 
And reverse 
AATTCCGATGAGGCGCACAGCACAAGAGGTGGAA
ACATACAGAAGAAGCAAG  
GATCCTTGCTTCTTCTGTATGTTTCCACCTCTTGTG
CTGTGCGCCT CATCGG 
DsRed 
NLS-3 forward 
And reverse 
AATTCCGATGAAAAGAAGATGTGATGAGCTTACC
AGAAAAATGAGG  
GATCCCTCATTTTTCTGGTAAGCTCATCACATCTTC
TTTTCATCGG 
DsRed 
NLS-4 forward 
And reverse 
AATTCCGATGCGTTCCAGGGGTAGAGGAGGCATG
AAGGATGACCGTCGGGACAGATACTCTGCGGACA
AAAGG 
GATCCCTTTTGTCCGCAGAGTATCTGTCCCGACGG
TCATCCTTCATGCCTCCTCTACCCCTGGAACGCAT
CGG 
DsRed 
NLS3-M 
 
AATTCCGATGAAAGCAGCATGTGATGAGCTTACC
AGAGCAATGGCGAGG  
GATCCCTCGCCATTGCTCTGGTAAGCTCATCACAT
GCTGCTTTCATCGG 
DsRed 
NLS4-M 
AATTCCGATGCGTTCCGCGGGTAGAGGAGGCATG
AAGGATGACCGTGCGGACAGATACTCTGCGGGCG
CAAGG 
GATCCCTTGCGCCCGCAGAGTATCTGTCCGCACGG
TCATCCTTCATGCCTCCTCTACCCGCGGAACGCAT
CGG 
DsRed 
Putative NES-1 
AATTCCGATGCAGGGATGGCCAGTTGCTCTAAGT
GGATTGGATATGGTTGGAGTGGCG 
GATCCGCCACTCCAACCATATCCAATCCACTTAGA
GCAACTGGCCATCCCTGCATCGG 
DsRed 
Putative NES-2 
AATTCCGATGTCTGGGAAAACATTGTCTTATTTGC
TTCCTGCCATTGTCCACATCCAG  
GATCCTGGATGTGGACAATGGCAGGAAGCAAATA
AGACAATGTTTTCCCAGACATCGG 
DsRed 
Putative NES-3 
AATTCCGATGAAGGGACCACAAATACGTGATTTG
GAGAGAGGTGTGGAAATCTGTATTGCG 
GATCCGCAATACAGATTTCCACACCTCTCTCCAAA
TCACGTATTTGTGGTCCCTTCATCGG 
DsRed 
Putative NES-4 
AATTCCGATGCTTGATATGGGCTTTGAACCCCAAA
TAAGGAAGATTGTGGATCAAATAAGG  
GATCCCTTATTTGATCCACAATCTTCCTTATTTGGG
GTTCAAAGCCCATATCAAGCATCGG 
DsRed 
Putative NES-5 
AATTCCGATGTGGCCAAAAGAAGTAAGACAGCTT
GCTGAAGATTTCCTGAAAGACTATATTCATATAAA
DsRed 
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CATTGGTGCACTTGAACTGGGG 
GATCCCCCAGTTCAAGTGCACCAATGTTTATATGA
ATATAGTCTTTCAGGAAATCTTCAGCAAGCTGTCT
TACTTCTTTTGGCCACATCGG 
Putative NES-6 
AATTCCGATGGCAAACCACAACATTCTTCAGATTG
TGGATGTGTGTCATGACGTAGAG  
GATCCTCTACGTCATGACACACATCCACAATCTGA
AGAATGTTGTGGTTTGCCATCGG 
DsRed 
Putative NES-7 
AATTCCGATGGCCTCCAGAGGGCTAGATGTGGAA
GATGTGAAATTTGTCATCCAG 
GATCCTGGATGACAAATTTCACATCTTCCACATCT
AGCCCTCTGGAGGC CATCGG 
DsRed 
Putative NES-8 
AATTCCGATGACACCTAATAACATAAAGCAAGTG
AGCGACCTTATCTCTGTGCTTCGG  
GATCCCGAAGCACAGAGATAAGGTCGCTCACTTG
CTTTATGTTATTAGGTGTCATCGG 
DsRed 
NES2-M 
 
AATTCCGATGTCTGGGAAAACATTGTCTTATGCGC
TTCCTGCCGCTGCCCACATCCAG  
GATCCTGGATGTGGGCAGCGGCAGGAAGCGCATA
AGACAATGTTTTCCCAGACATCGG 
DsRed 
NES5-M 
AATTCCGATGTGGCCAAAAGAAGTAAGACAGCTT
GCTGAAGATGCCGCGAAAGACTATATTCATGCAA
ACATTGGTGCAGCTGAACTGGGG 
GATCCCCCAGTTCAGCTGCACCAATGTTTGCATGA
ATATAGTCTTTCGCGGCATCTTCAGCAAGCTGTCT
TACTTCTTTTGGCCACATCGG 
DsRed 
NES8-M 
 
AATTCCGATGACACCTAATAACATAAAGCAAGTG
AGCGACGCTGCCTCTGTGCTTCGG 
GATCCCGAAGCACAGAGGCAGCGTCGCTCACTTG
CTTTATGTTATTAGGTGTCATCGG 
DsRed 
Primer for 
sequencing 
NLS4+NES8 
GGAAAAGCTCCTATTCTGATTG 
 --- 
Primer for 
sequencing 
NES 2 
CAAGGAAATTACAGTTAGAGGTC 
 --- 
Primer for 
sequencing 
NES5 
CAATCTGAGAAGAACAACCTAC 
 --- 
DII-forward 
And reverse 
GGGGGTGGATTTAATACCTTTAGAG 
GGGACCTGAACCTCTGTCTTCGAC 
PCDNA3.1-
eGFP 
175+500 -1 
GTTTGGTGCTGGCACCAACTCGGGAACTGGC 
pHM6-p68 
175+500 -2 
GGACAGATACTCTGCGGGCAAAAGGGGTGGATTT
A 
pHM6-p68 
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Delete NLS3 
AGGAGAATAAAACCATTGTTTTTGTGGAAACCGA
TGGGTGGCCTGCCATGGGTATCCA 
TGGATACCCATGGCAGGCCACCCATCGGTTTCCAC
AAAAACAATGGTTTTATTCTCCT 
pHM6-p68 
Delete NLS4 
CAGTTGCTTCAGTTGGTCGAAGACAGAGGTTCAG
GTGGTGGATTTAATACCTTTAGAGACAGGG 
CCCTGTCTCTAAAGGTATTAAATCCACCACCTGAA
CCTCTGTCTTCGACCAACTGAAGCAACTTG 
pHM6-p68 
NLS3-M 
AATTCCGATGAAAGCAGCATGTGATGAGCTTACC
AGAGCAATGGCGAGG  
GATCCCTCGCCATTGCTCTGGTAAGCTCATCACAT
GCTGCTTTCATCGG 
DsRed 
NLS4-M 
 
AATTCCGATGCGTTCCGCGGGTAGAGGAGGCATG
AAGGATGACCGTGCGGACAGATACTCTGCGGGCG
CAAGG 
GATCCCTTGCGCCCGCAGAGTATCTGTCCgcACGG
TCATCCTTCATGCCTCCTCTACCCGCGGAACGCAT
CGG 
DsRed 
NES2-M 
 
AATTCCGATGTCTGGGAAAACATTGTCTTATGCGC
TTCCTGCCGCTGCCCACATCCAG  
GATCCTGGATGTGGGCAGCGGCAGGAAGCGCATA
AGACAATGTTTTCCCAGACATCGG 
DsRed 
NES5-M 
 
AATTCCGATGTGGCCAAAAGAAGTAAGACAGCTT
GCTGAAGATGCCGCGAAAGACTATATTCATGCAA
ACATTGGTGCAGCTGAACTGGGG  
GATCCCCCAGTTCAGCTGCACCAATGTTTGCATGA
ATATAGTCTTTCGCGGCATCTTCAGCAAGCTGTCT
TACTTCTTTTGGCCACATCGG 
DsRed 
NES2 mutation 
GGATCTGGGAAAACATTGTCTTATGCGCTTCCTGC
CGCTGCCCACATCAATCATCAGCCA 
pHM6-p68 
NES5 mutation 
CAAAAGAAGTAAGACAGCTTGCTGAAGATGCCGC
GAAAGCATATATTCATATAAACATTGGTG 
AGACTATATTCATATAAACATTGGTGCAGCTGAAC
TGAGTGCAAACCACA 
AGATGCCGCGAAAGACTATATTCATGCAAACATT
GGTGCAGCTGA (this primer based on above two) 
pHM6-p68 
NES8 mutation 
CTAATAACATAAAGCAAGTGAGCGACGCTGCCTC
TGTGCTTCGTGAAGCTAATCAAG 
pHM6-p68 
NES8-M 
 
AATTCCGATGACACCTAATAACATAAAGCAAGTG
AGCGACGCTGCCTCTGTGCTTCGG  
GATCCCGAAGCACAGAGGCAGCGTCGCTCACTTG
CTTTATGTTATTAGGTGTCATCGG 
DsRed 
Primer for 
fragment 1 
GGGAAGCTTATATTCGAGTGACCGAGACCG 
GGGCGGCCGCTTAGTCTGCTTCATCAAGGACAAG
G 
pHM6 
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Primer for 
fragment 2 
GGGAAGCTTAAGAATGCTTGATATGGGCTTTG 
GGGCGGCCGCTTAATCTTCCACATCTAGCCCTCT 
pHM6 
Primer for 
fragment 3 
GGGAAGCTTAGTGAAATTTGTCATCAATTATGAC 
GGGCGGCCGCTTAGTCCCGACGGTCATCCTTC 
pHM6 
Primer for 
fragment 4 
GGGAAGCTTACGATACTCTGCGGGCAAAAGG 
GGGCGGCCGCTTATTGGGAATATCCTGTTGGCATT 
pHM6 
N-terminal of 
p68 
TGGCCATCCCTGAGCTTGA 
GTCTAGAGGGCCCGTTTAAA 
PCDNA3.1-
eGFP 
Truncate 
before NLS-3 
GGTTTCCACAAAAACAATGGTT 
GTCTAGAGGGCCCGTTTAAA 
PCDNA3.1-
eGFP 
Truncate after 
NLS-3 
GATGGGTGGCCTGCCATG 
ATATCTGCAGAATTCTGACTTG 
PCDNA3.1-
eGFP 
C-terminal of 
p68 
CGTGAAGCTAATCAAGCAATTA 
ATATCTGCAGAATTCTGACTTG 
PCDNA3.1-
eGFP 
(DIII)D2 
(a.a.0-a.a.126) 
Reverse primer 
TGGCCATCCCTGAGCTTGA 
PCDNA3.1-
eGFP 
D3 (a.a.0-
a.a.350) 
Reverse primer 
GGTTTCCACAAAAACAATGGTT 
 
PCDNA3.1-
eGFP 
Forward CaM 
GGGGGTACCATGGCTGACCAGCTTACTGAA 
pHM6 
Reverse CaM 
GGGGCGGCCGCTCTACTTCGCTGTCATCATTTG 
pHM6 
Sequencing 
primer for 
CaM 
CAATGGTATGAACCAACAGGC 
 --- 
His-p68-CaM 
fusion protein 
Forward and 
reverse primers 
GGGGGATCCGTCCCAGACTACGCTGGA  
GGGGCGGCCGCTCTACTTCGC  PET-30 
vector 
65 
 
Table 4 Mammalian cell lines 
Name Company Origin Culture medium 
SW480 ATCC 
Human colorectal 
adenocarcinoma cells 
Leibovitz L-15 +10% 
FBS 
SW620 ATCC 
Human colorectal 
adenocarcinoma cells derived 
from metastatic site: lymph 
node 
Leibovitz L-15 +10% 
FBS 
WM115 ATCC Human skin melanoma cells MEM + 10% FBS 
WM266 ATCC 
Human skin metastatic 
melanoma cells 
MEM + 10% FBS 
H460 ATCC Human primary lung DMEM + 10% FBS 
H146 ATCC Human metastatic lung DMEM + 10% FBS 
T98G ATCC 
Human brain glioblastoma 
cells 
MEM + 10% FBS 
+1mM pyruvate kinase 
+1mM non-essential 
amino acid 
U-87 MG ATCC Human brain astrocytoma cells 
MEM +10%FBS 
+1mM pyruvate kinase 
+1mM non-essential 
amino acid 
HEK293 ATCC 
Human kidney epithelial cells 
immortalized by adenovirus 5 
DNA 
DMEM+ 10% FBS 
HEL 299 ATCC 
Human lung normal fibroblast 
cells 
MEM + 10% FBS 
NIH/3T3 ATCC Mouse embryo fibroblast cells DMEM + 10% FBS 
4T1 
(Luciferase) 
Gifted from Dr. 
Aneja Ritu 
Mouse breast cancer cells DMEM+10% FBS 
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Table 5 Chemicals 
Name of chemical Company 
α-Cyano-4-hydroxycinnamic acid Agilent Tech, Santa Clara 
2-Mercaptoethanol Sigma Aldrich, St. Louis 
Acetic acid VWR International, West Chester 
Acetone VWR International, West Chester 
Acrylamide/bisacrylamide solutions Fisher BioReagent, Fairlawn 
Agar Sigma-Aldrich, Saint Louis 
Agarose MP Biomedicals, Aurora 
Ammonium persulfate Sigma-Aldrich, Saint Louis 
Anhydrous acetonitrille Applied Biosystems, Foster City 
Bacto Yeast Extract BD Bioscience, Spark 
Bacto Tryptone BD Bioscience, Spark 
Bovine serum albumin Promega, Madison 
Bromophenol Blue EMD Biosciences, San Diego 
Coomassie blue Sigma-Aldrich, Saint Louis 
Deep purple total protein stain Amersham Biosciences, Piscataway 
Dithiothreitol Shelton Scientific, Shelton 
Ethanol 
AAPER Alcohol & Chemical, 
Shelbyville 
Ethidium bromide Sigma-Aldrich, Saint Louis 
Ethylenedinitro-tetraacetic acid (EDTA) Sigma-Aldrich, Saint Louis 
Fetal calf serum HyClone, Logan 
Formaldehyde Calbiochem, San Diego 
Formic acid EMD Biosciences, San Diego 
FuGENE 6 Transfection Reagent Roche Applied Science, Indianapolis 
GelCode Blue Stain Reagent Pierce, Rochford 
Glycine MP Biomedicals, Aurora 
HiTrap affinity columns Amersham Biosciences, Piscataway 
Hydrochloric acid VWR International, West Chester 
Imidazole Sigma-Aldrich, Saint Louis 
Isopropyl-ß-D-thiogalactopyranosid Sigma-Aldrich, Saint Louis 
Isopropanol VWR International, West Chester 
Kanamycin solution Teknova, Hollister 
Lipofectamine 2000 Invitrogen, Carlsbad 
Lipofectamin RNAiMAX Invitrogen, Carlsbad 
Lysozyme Sigma-Aldrich, Saint Louis 
Magnesium Chloride Fisher Biotech, Fairlawn 
Methanol VWR International, West Chester 
Molecular weight marker (DNA) MBI Fermentas, Hanover 
Molecular weight marker (protein) MBI Fermentas, Hanover 
N- (2-hydroxyethyl) piperazine-N`-(2-
ethanesulfonic acid) (HEPES) 
Sigma-Aldrich, Saint Louis 
Nickel-nitrilotriacetic acid (Ni-NTA) agarose Qiagen, Hilden 
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Ni-TED™ Silica Active Motif, Carlsbad 
N, N, N’, N’-Tetramethylethylenediamine Promega, Madison 
Nonidet P40 Roche Applied Science, Indianapolis 
Normal goat serum (10%) KPL, Gaithersburg 
Phenol/Chloroform Promega, Madison 
Phenylmethylsulfonyl fluride Fluka, Switzerland 
Phosphatase inhibitor cocktail Sigma-Aldrich, Saint Louis 
Poly-L-lysine solution Sigma-Aldrich, Saint Louis 
Ponceau S Sigma-Aldrich, Saint Louis 
Protease inhibitor cocktail tablets Roche, Germany 
Protein G agarose Upstate, Charlottesville 
Protein G sepharose 4 fast flow Amersham Biosciences, Piscataway 
Sephadex G-25 Amersham Biosciences, Piscataway 
Superdex 200 HR 10/30 Amersham Biosciences, Piscataway 
Sodium acetate Promega, Madison 
Sodium azide Fluka, Switzerland 
Sodium bicarbonate Sigma-Aldrich, Saint Louis 
Sodium chloride Fisher BioReagent, Fairlawn 
Sodium dodecyl sulfate Fisher BioReagent, Fairlawn 
Sodium fluoride Fluka, Switzerland 
Sodium hydroxide Fisher BioReagent, Fairlawn 
Sodium orthovanadate EMD Biosciences, San Diego 
Sodium pyruvate Cellgro, Herndon 
Triton X-100 Sigma-Aldrich, Saint Louis 
Trypan Blue Sigma-Aldrich, Saint Louis 
Trypsin proteomics grade Sigma-Aldrich, Saint Louis 
Tween-20 Sigma-Aldrich, Saint Louis 
Urea Fisher Biotech, Fairlawn 
X-tremeGene siRNA Transfection Reagent Roche, Germany 
RNA stabilization reagent Qiagen 
 
 
 
 
 
 
 
 
68 
 
Table 6 Experimental kits 
Name Company 
Glucose Assay Kit BioVision, Moutain View 
BrdU cell proliferation assay Calbiochem, 
Pyruvate Assay Kit BioVision, Moutain View 
Kinesin/dynein Motility Kit Cytoskeleton 
Tubulin Polymerization Assay Cytoskeleton 
Improm-II Reverse Transcription System Promega, Madison 
MinElute PCR Purification Kit Qiagen, Valencia 
Nuclear Extract Kit Active Motif, Carlsbad 
ProteoSliver Plu Sliver Stain Kit Sigma-Aldrich, Saint Louis 
Shredder column Qiagen, Valencia 
RNeasy Plus Kit Qiagen, Valencia 
Qiaprep Spin Mini-Prep Qiagen, Valencia 
Qiaquick Gel Extraction Kit Qiagen, Valencia 
QuickChange II XL site-directed 
Mutagenesis Kit 
Stratagene, La Jolla 
Trypsin Profile IGD kit for in-gel digests Sigma-Aldrich, Saint Louis 
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CHAPTER 3 
P68 RNA HELICASE IS A NUCLEOCYTOPLASMIC SHUTTLING PROTEIN 
3.1 Abstract 
P68 RNA helicase is a prototypical DEAD box RNA helicase. The protein plays a very 
important role in early organ development and maturation. In consistence with the function of 
the protein in transcriptional regulation and pre-mRNA splicing, p68 was found to predominately 
localize in the cell nucleus. However, recent experiments demonstrate a transient cytoplasmic 
localization of the protein. We report here that p68 shuttles between the nucleus and the 
cytoplasm. The nucleocytoplasmic shuttling of p68 is mediated by two nuclear localization 
signal (NLS) and two nuclear exporting signal (NES) sequence elements. Our experiments reveal 
that p68 shuttles via a classical RanGTPase dependent pathway. 
3.2 Introduction 
In eukaryotic cells, the nucleus is separated from the cytoplasm. Maintenance of cellular 
functions requires trafficking of many bio-macromolecules into and out of the nucleus. Proteins 
that are targeted to the nucleus are marked by one or more sequence elements termed Nuclear 
Localization Signal (NLS) (Goldfarb, Gariepy et al. 1986; Schneider, Schindewolf et al. 1988), 
while the proteins that are transported out of the nucleus carry one or more Nuclear Exporting 
Signal (NES) sequence tags (Wen, Meinkoth et al. 1995). Nucleocytoplasmic trafficking occurs 
via the nuclear pore complex (NPC). Most protein transportation through the NPC is mediated 
by specific cargo and a nuclear receptor system, importins and exportins (Gorlich and Kutay 
1999; Nakielny and Dreyfuss 1999; Hill 2009). Interestingly, many proteins often carry both 
NLS and NES signals. This characteristic usually leads to shuttling of these proteins between the 
nucleus and the cytoplasm (Lusk, Blobel et al. 2007). The nuclear p68 RNA helicase (hereafter 
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referred to as p68) is a prototypical member of the DEAD box family of RNA helicases (Lane 
and Hoeffler 1980; Crawford, Leppard et al. 1982). As an early example of a cellular RNA 
helicase, the ATPase and the RNA unwinding activities of p68 RNA helicase were previously 
documented (Ford, Anton et al. 1988; Hirling, Scheffner et al. 1989; Iggo and Lane 1989). 
Expression of p68 correlates with cell proliferation and early organ maturation (Stevenson, 
Hamilton et al. 1998). We have previously reported that p68 is phosphorylated at multiple amino 
acid residues, including serine/threonine and tyrosine (Yang and Liu 2004; Yang, Lin et al. 
2005). Tyrosine phosphorylation of p68 correlates with tumor progression (Yang, Lin et al. 
2005). Phosphorylation of p68 at Y593 mediates the effects of growth factors in promoting 
epithelial-mesenchymal-transition (EMT). The phosphor-p68 promotes EMT by facilitating β-
catenin nuclear translocation (Yang, Lin et al. 2006). In the present study, we demonstrate that 
p68 shuttles between the nucleus and the cytoplasm. P68 shuttling is mediated by two NLSs and 
two NESs sequence elements. Our data show that p68 shuttles via the classical RanGTPase 
dependent pathway. 
3.3 Results 
3.3.1 P68 RNA helicase shuttles between the nucleus and the cytoplasm 
We previously reported that Y593 phosphorylated p68 facilitates cytoplasmic β-catenin 
nuclear translocation by displacing the cytoplasmic β-catenin anchor protein axin (Yang, Lin et 
al. 2006). P68 RNA helicase has been shown to predominantly localize in the nucleus (Nicol, 
Causevic et al. 2000). Thus, an interesting question is how p68 translocates to the cytoplasm. We 
reasoned whether phosphorylation of p68 at Y593 facilitated p68 cytoplasmic translocation. To 
test this possibility, we employed a panel of cell lines; SW620, a metastatic colon cancer cell, 
SW480 and HT-29, non-metastatic colon cancer cell lines, and T98G, a cell line derived from 
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glioblastoma. P68 is not phosphorylated at tyrosine residues in HT-29 cells (Yang, Lin et al. 
2006) but is phosphorylated at high levels in T98G cells (Yang, Lin et al. 2007). P68 is highly 
phosphorylated at tyrosine residue in SW620 cells and low levels in SW480 cells (Fig. 3.1A, and 
data not shown). Consistent with our previous observations, high levels of β-catenin were 
detected in the nucleus of SW620 cells. Nuclear β-catenin was significantly reduced in the cells 
in which the endogenous p68 was replaced by the Y593F mutant, suggesting that 
phosphorylation of p68 at Y593 contributed to β-catenin nuclear localization in SW620 cells 
(Fig. 3.1B). Immuno-staining using the antibody p68-RGG showed that p68 was almost 
completely localized in the nucleus in all four cell lines (Fig. 3.1C), indicating that 
phosphorylation of p68 did not change the predominant nuclear localization of the protein. 
Another possibility for the cytoplasmic localization is that p68 shuttles between the nucleus and 
the cytoplasm. A number of nuclear localized proteins have been shown to be nucleocytoplasm 
shuttles (Cartwright and Helin 2000; Zhu and McKeon 2000). We thus employed a heterokaryon 
assay (Fan and Steitz 1998) using SW620 cells and NIH3T3 cells to test whether p68 shuttles 
between the nucleus and the cytoplasm. HAtagged p68s were exogenously expressed in SW620. 
After fusing the SW620 with NIH3T3 cells, the HA-p68s were detected in the nucleus of 
NIH3T3 cells (Fig. 3.2, upper panel). As a negative control, the non-shuttling protein MS2-DEK 
(Shibuya, Tange et al. 2004) expressed in SW620 cells could not be detected in the nucleus of 
NIH3T3 cells (Fig. 3.2, bottom panel). The experimental results suggest that p68 is a nucleus – 
cytoplasm shuttling protein with a much longer residence time in the nucleus. 
3.3.2 Identification of NLSs and NESs of p68 
Most nucleocytoplasm shuttling proteins carry sequence elements of both NLS and NES. 
We analyzed the amino acid sequence of p68 and found a number of sequence segments that 
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resemble NLSs and NESs (Fig. 3.3A and 3.4A). To test the functionality of these putative NLSs 
and NESs in p68, we first fused each individual putative NLS or NES with a fluorescent protein 
DsRed. The fusion proteins were expressed in SW620 cells. It was clear that only NLS3 and 
NLS4 led to a substantial nuclear accumulation of the fluorescent protein (Fig. 3.3B). On the 
other hand, fusion of NES2 and NES5 with the fluorescent protein resulted in high levels of 
cytoplasmic fluorescent protein (Fig. 3.4B). Interestingly, fusion of NES8 with DsRed led to 
slightly higher levels of fluorescent protein localization in the cytoplasm (Fig. 3.4B), indicating 
that NES8 is a weak nuclear export signal. Treatment of cells with leptomycin B (LMB) 
abolished the cytoplasmic localization patterns of DsRed fusion proteins (NES2, NES5, and 
NES8) (Fig. 3.4C). The results suggest that NLS3 and NLS4 potentially function as nuclear 
localization signals, and NES2, NES5 and NES8 potentially function as nuclear export signals of 
p68. To verify the functionality of NLS3 and NLS4, we made mutations in NLS3 (R352A, 
R353A, K360A, and R362A) or NLS4 (R484A, R494A and K501A) in the context of full length 
p68. The HA-tagged mutants were expressed in SW620 cells. Immunostain of the exogenously 
expressed HA-p68, wild type and mutants, indicated that nuclear localization of the HA-mutants 
was dramatically reduced (Fig. 3.3C). Quantification of fluorescence intensity in the nucleus and 
the cytoplasm of a random group of cells confirmed the reduction of nuclear HA-p68 (the mean 
average of Cyto/Nu fluorescence intensity ratio were 0.038 +/- 0.026 for wt, 1.477 +/- 0.029 for 
NLS3-M, and 1.489 +/- 0.097 for NLS4-M). The results suggested that NLS3 and NLS4 indeed 
functioned as nuclear localization signals of p68. To further test the functions of nuclear 
localization signals and nuclear export signals of p68, we constructed several p68 deletion 
mutants (Fig. 3.5A). These deletion mutants were expressed in SW620 cells either as HA-tag 
proteins or eGFP-fused proteins (due to small sizes of truncates). Locations of each putative 
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NLSs and NESs of p68 in the p68 truncation proteins are indicated. The localizations of these 
p68 truncates were analyzed by immunostaining with anti-HA antibody or imaging of eGFP. DII 
and DIII localized to the nucleus, indicating that NLS4 is a functional NLS, while the NES1 and 
NES 7-8 are not functional NES. Strong cytoplasmic DIV and DV were observed, suggesting 
that one or more of NES 2 – 6 are functional NES. The stronger fluorescence in DV than that of 
DIV and certain levels of cytoplasmic localization of DVI indicate function of NLS3. In 
summery, these results supported that NLS3 and NLS4 may function as nuclear localization 
signals of p68 while NES2 and NES5 may function as nuclear exporting signals of p68. 
Consistent with our experimental results, NLS3 is located in an exposed helical secondary 
structure while NLS4 is located in an exposed loop that is flanked by two α-helixes in a 
computer simulated p68 model structure (Fig. 3.5B). Both NES5 and NES8 are also located on 
the exposed surface in the model structure, while NES2 is buried under an α-helix in the model 
structure. This structure model provided additional support for the identification of the NLSs and 
NESs of p68. We next mutated both NLS3 and NLS4 by the same mutations described above 
(hereafter referred to as NLS-M). The mutant was expressed in SW620, T98G, and SW480 cells. 
Immunofluorescence staining demonstrated that no significant levels of p68 mutant localized in 
the cell nucleus (Fig. 3.3D). The results were further verified by immunoblot analyses of 
exogenously expressed HA-p68s (wt and the mutant) in the cytoplasmic and nuclear extracts 
made from HA-p68s expressing T98G cells (Fig. 3.3E). It was also clear that the mutant no 
longer shuttled between the nucleus and the cytoplasm as demonstrated by the heterokaryon 
assay (Fig. 3.2, 2nd panel from top). The distribution pattern did not change significantly when 
the heterokaron cells were treated with LMB (data not shown). In our structure model, NES5 and 
NES8 are well exposed, while NES2 is buried. Thus, we constructed the p68 NES mutant by 
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mutations at both NES5 and NES8, F293A, L294A, L298A, L305A, L456A, and I457A 
(hereafter referred to as NES-M). Immuno fluorescence staining of SW620 cells that expressed 
the mutant showed an exclusive nuclear localization of the mutant (Fig. 3.4D). Heterokaryon 
assay demonstrated that the nucleocytoplasmic shuttling of p68 was almost completely abolished 
by the mutations (Fig. 3.2, 3rd panel from top). In contrast, mutations separately on either NES5 
or NES8 (same mutations) did not completely abolish but certainly reduced the shuttle of HA-
p68 to the NIH3T3 cell nucleus (Fig. 3.2, 4th and 5th panels from top). Our mutational analyses 
confirmed that the NLS3/NLS4 and NES5/NES8 were functional NLSs and NESs, and these 
NLSs and NESs were required for p68 nuceocytoplasmic shuttling. 
3.3.3 P68 shuttles via a RanGTPase dependent pathway 
CRM1 is an export receptor mediating nuclear export of proteins that carry leucine-rich 
nuclear exporting signals (Fornerod, Ohno et al. 1997; Watanabe, Fukuda et al. 1999). We 
demonstrated that p68 RNA helicase carries NLSs and NESs sequences that mediate 
nucleocytoplasmic shuttling. We reasoned whether overexpression of CRM1 would affect the 
localization of p68. We exogenously expressed CRM1 in SW620 cells (Fig. 3.6A). Immunoblot 
of p68 indicated that there were significantly higher levels of cytoplasmic p68 after CRM1 was 
exogenously expressed in the cells, and the increases in cytoplasmic p68 were inhibited by LMB 
treatment (Fig. 3.6B). Increases in cytoplasmic p68 by expression of CRM1 were not observed 
with p68 mutant that carries mutations at both NES5 and NES8 (Fig. 3.6C). The results suggest 
that p68 RNA helicase was exported from the nucleus mediated by exportin pathway. The effects 
of exogenous expression of CRM1 on p68 export were further confirmed by immunostaining 
analyses. It was evident that staining of p68 in the cytoplasm was significantly increased upon 
the expression of CRM1, and the increases were inhibited by LMB (Fig. 3.6D). To further verify 
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that the p68 nucleocytoplasmic shuttling is mediated by RanGTPase pathway, we tested whether 
p68 interacts with importin in vitro. We used a commercially available his-tag importin α2. 
When his-importin α2 was incubated with recombinant GST-p68, GST-p68 could not be pulled-
down by his-importin α2 (Fig. 3.7A). It is known that importin α2 functions as a hetero-dimer 
with importin β (Lindsay, Plafker et al. 2002; Goldfarb, Corbett et al. 2004). Therefore, we 
added another commercially available recombinant importin β1. It was clear that GST-p68 
coprecipitated with his-importin α2 when importin β1 was also present, but the p68 NLS mutant 
(NLS-M) did not co-precipitate with his-importin α2 under any condition (Fig. 3.7A). We also 
carried out co-precipitation experiments with immunopurified HA-p68 from HEK293 cells. The 
His-importin α2/importin β1 co-immunoprecipitated with the purified HA-p68 using anti-HA 
antibody. However, the importins did not immunoprecipitate with HA-p68 NLS mutant (Fig. 
3.7B). The observations suggested that p68 interacts with the importin α2/β1 dimer, providing 
additional support for the nucleocytoplasmic shuttling of p68 via the RanGTPase pathway. 
3.4 Discussion 
P68 RNA helicase was shown to predominately localize in the cell nucleus (Nicol, 
Causevic et al. 2000). However, recent experiments carried out in Janknecht’s and our 
laboratories showed a transient cytoplasmic localization of the protein (Rossow and Janknecht 
2003). In this report, we presented data demonstrating the nucleocytoplasm shuttling of p68 
RNA helicase. Our experiments showed that p68 shuttling is mediated by two NLSs and two 
NESs sequence elements. The p68 nuclear export and import follow a RanGTPase dependent 
pathway. Interestingly, a number of DEAD/DExH box RNA helicases have also been shown to 
shuttle between the nucleus and cytoplasm, including eIF-4AIII, An3, and RNA helicase A 
(Askjaer, Bachi et al. 1999; Shibuya, Tange et al. 2004; Aratani, Oishi et al. 2006). 
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However, the functional role of the shuttling of these RNA helicase is not well known. 
The cellular function(s) of the p68 RNA helicase nucleocytoplasmic shuttling is an open 
question. In general, proteins that shuttle between the nucleus and the cytoplasm usually have 
distinct cellular functions in these two separated sub-cellular compartments. They often 
relocalize to the nucleus or the cytoplasm to fulfill specific functional role(s) in response to a 
particular cellular signal stimuli (Kau, Way et al. 2004; Xu and Massague 2004). Alternatively, 
nucleocytoplasmic shuttling of a protein can function as a ‘chaperons’ to help nuclear import or 
export of other proteins or RNAs. (Fried and Kutay 2003; Loyola and Almouzni 2004). Cellular 
functions of p68 helicase in the cell nucleus are well documented. The protein is functionally 
involved in gene transcription (Endoh, Maruyama et al. 1999; Bates, Nicol et al. 2005; Buszczak 
and Spradling 2006; Yang, Lin et al. 2007), pre-mRNA (Liu 2002; Lin, Yang et al. 2005), pre-
rRNA, and premiRNA processing (Fukuda, Yamagata et al. 2007; Davis, Hilyard et al. 2008). 
Whether p68 RNA helicase has any potential function(s) in the cytoplasm is currently not very 
clear. Hong et al. detected the interaction of p68 with HCVNS5B in the cytoplasm in the viral 
infected or NS5B expressing 293 cells and the interaction is essential for viral replication (Goh, 
Tan et al. 2004). In another independent study, D. Harris and co-workers found that the 3’-
nontranslated region of HCV interact with p68 in an RNA affinity capture experiments with the 
cytoplasmic extracts of 293 cells that express viral replicon (Harris, Zhang et al. 2006). These 
observations are consistent with our experimental results indicating that p68 localizes both in the 
nucleus and the cytoplasm. However, despite the demonstration of the function of p68 in HCV 
replication in the cytoplasm of virus infected cells, the evidence that suggest the involvement of 
p68 in any cellular process in the cytoplasm is currently lack. We have observed a significant 
increases in cytoplasmic p68 levels upon treatment of cells with several growth factors and 
77 
 
chemokines (Yang, Lin et al. 2006), indicating that p68 may functions in the cytoplasm under 
specific cellular conditions, such as abnormal growth or cell migration in response to growth 
factor or chemokine stimulations. 
Localization of p68 is intriguing. The protein is shuttling between the nucleus and the 
cytoplasm, while the protein predominantly resides in the cell nucleus, and is nearly undetectable 
outside of the nucleus by immunostaining or by immunoblot analyses of cytoplasmic extracts. 
The phenomenon suggests that the function of the NESs of p68 is tightly regulated. It is possible 
that an interacting partner(s) in the nucleus masks the p68 NESs sequences. Nuclear export of 
p68 depends on the dissociation of the interaction partner(s). Our data demonstrated that p68 has 
three sequence elements that potentially function as NESs. On the other hand, structural 
modeling of p68 helicase core showed that one of the potential NES (NES2) is buried under an 
α-helix. Therefore, it is possible that a specific post-translational modification drives 
conformational changes which subsequently expose this buried NES sequences for p68 export 
(Wrighton, Lin et al. 2009). Very similar regulatory mechanisms were observed in nuclear 
exporting and importing of Dok1 and NF-AT1 (Okamura, Aramburu et al. 2000; Niu, Roy et al. 
2006). In consistent with this notion, we observed a substantially increased cytoplasmic p68 
levels in cells when the cells were treated with several growth factors andchemokines (Yang, Lin 
et al. 2006), suggesting a possibility that the growth factors and chemokines treatments trigger 
the exposure of the NES sequences for nuclear export of p68. 
There are two NLS sequences. Mutation of either NLS reduced nuclear localization 
(increased cytoplasmic p68, Fig. 3.3C), indicating that both NLSs contribute partly to nuclear 
localization of p68. 
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3.5 Materials and methods 
3.5.1 Reagents, antibodies, and cells 
Leptomycin B (LMB), PEG3350, cycloheximide, HA peptide, and protease inhibitor 
cocktail were purchased from Calbiochem, Sigma, and Roche respectively. Antibodies against 
HA and His tags, phospho-tyrosine, GAPDH, Lamin A/C, β-actin, and Histone 2A were 
purchased from Roche, Cell signaling, Upstate, and Chemicon respectively. Cell lines SW480, 
SW620, HT29, NIH3T3, and T98G were purchased from ATCC and cultured by following the 
vendor’s instructions. 
3.5.2 Plasmids construction 
The HA-tagged p68s expression plasmids (wild type, and Y593F, Y595F, LGLD, and 
NLS-M mutants) were constructed in pHM6 vectors as previously reported (Yang, Lin et al. 
2006). The vectors for expression of eGFP and DsRed fusion proteins were constructed using 
eGFP-pcDNA-3.1(+) or pDsRed1–N1 vectors. Full length p68 or deletion mutants of p68 
variants were sub-cloned into the vector by EcoR321 and NotI restriction sites. The p68 or 
deletion mutants were fused at the C-terminal of the fluorescent protein tag. Different putative 
NLSs or NESs tagged DsRed were constructed by cloning into pDsRed-N1 vectors at 5’ (BamHI 
and EcoRI sites) with the addition of a starting methionine at the N-terminal of each NLS or 
NES respectively. Site directed mutagenesis was performed using QuikChange® Multi Site-
Directed Mutagenesis Kit (Stratagene). All the DNA clones and mutations were verified by auto-
DNA sequencing at GSU. The procedures for transfection of expression vectors of HA-p68, 
fluorescent proteins, and Crm1 and duplex RNAi were similar to our previous reports (Yang, Lin 
et al. 2006). 
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3.5.3 Expression and purification of recombinant GST-p68 
Recombinant GST-p68 was expressed and purified as described in our previous report 
(Huang and Liu 2002). 
3.5.4 Interactions between p68 and importins 
Recombinant GST-p68 (8 μg) was incubated with commercial his-importin α2 (8 μg) 
and/or importin β1 (Calbiochem) overnight at 4°C in 500 μl in PBS buffer. After incubation, the 
protein complex was pulled-down by Ni-TED silica beads. The pull-down proteins were 
separated by 10% SDS-PAGE, and were analyzed by immunoblot using anti-GST or anti-his-tag 
antibodies. The presence of importin β1 was visualized by ponceau S staining. For 
coimmunoprecipitation of HA-p68 with importin α2, HA-p68s, wt or mutant, were expressed in 
HEK cells and were immunoprecipated using 30 μl anti-HA antibody. Protein G agarose (50 μl) 
was added to the mixture. After extensive washing, HA-p68s were eluted from the beads by 
competition using HA peptide (100 μg/ml). The eluted HA-p68s were dialyzed against PBS. The 
recombinant importin α2 and/or β1 was incubated with the purified HA-p68 in PBS for 4 hours. 
The protein mixtures were immunoprecipated using anti-HA antibody. The precipitated complex 
was separated in 10% SDS-PAGE followed by immunoblot using anti-his-tag antibody. The 
presence of HA-p68 was detected by immunoblot using the antibody p68-rgg. 
3.5.5 Heterokaryon analyses and immunofluoresence imaging 
The experimental procedures for immunofluoresence staining and imaging were similar 
to our previous reports (Wang, Liu et al. 2007). For heterokaryon analyses, SW620 cells were 
first transfected with HA-p68s (wt or mutants) or MS2-DEK. The cells were mixed with an equal 
number of mouse NIH3T3 cells 24 hour post-transfection and reseeded in 4-well chambers. 
Subsequently, 50 μg/ml of cycloheximide was added to the culture medium to inhibit protein 
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synthesis. After 3h, the co-cultured cells were fused using 50% PEG3350 for 2 minutes, washed, 
and incubated with the medium containing 75 μg/ml cycloheximide for 3 hours. The treated cells 
were then fixed and immunostained as described above. Rabbit polyclonal anti-MS2 antibody 
was employed to stain MS2-DEK, followed by Alex Fluor 555 goat anti-rabbit IgG antibody. In 
a random group of 30 cells, the numbers of cells with both NIH3T3 and SW620 nucleus and with 
HA-p68 in NIH3T3 nucleus or in the cytoplasm of fused cells were counted. The percentage of 
HA-p68 in the nucleus or cytoplasm of fused cells equals fused cells with HA-p68 in NIH3T3 
nucleus or cytoplasm / total fused cells with expression of HA-p68. 
3.5.6 Computational homology structure modeling the helicase core of p68 
The sequence alignment of p68 RNA helicase core with homologous RNA helicase cores 
of several DEAD box family proteins (e.g. vasa, eIF4A, Dhhlp, and UAP56) was performed by 
the program ClustalW. The secondary structure elements were predicted based on the consensus 
analysis using computational programs JPRED, PHD, and PSIPRED (Cuff, Clamp et al. 1998; 
McGuffin, Bryson et al. 2000). The homologymodeling of the p68 RNA helicase structure was 
constructed using the homology-modeling server SWISS-MODEL based on X-ray crystal 
structure of Drosophila vasa (Sengoku, Nureki et al. 2006), which has the highest alignment 
score with p68 RNA helicase core. The putative NLSs and NESs were indicated in the modeling 
structure. 
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Figure 3.1 Phosphor-p68 promotes β-catenin nuclear localization in SW620 cells 
 (A) Tyrosine phosphorylation of p68 RNA helicase in SW620 cells. P68 was 
immunoprecipitated (IP) from whole cell lysate using Pab-p68 or rabbit IgG, followed by 
immunoblot (IB) with appropriate antibody (indicated). The IBs with antibody p68-rgg are the 
loading controls. Ponceau S staining IgG heavy chain is a loading control (Ponceasu S:HC). (B) 
Nuclear β-catenin was examined by IB of nuclear extracts made from p68 knockdown 
(SiRNA(p68)/NT) SW620 cells. HA-p68s (WT or Y593F, Vec means vector alone) were 
expressed in p68 knockdown cells. The cellular levels of p68 were shown by IB using antibody 
p68-rgg (IB:p68-rgg). The cellular levels of HA-p68s were shown by IB using anti-HA antibody 
(IB:HA). Cellular levels of β-catenin were IB of β-catenin in 10% of whole cell extracts 
(IB:8E4). The IB of LaminA/C and GAPDH in the extracts were loading controls. All the 
immunoblot experiments were repeated three times and similar results were obtained. (C) 
Representative images of immunostaining of p68 RNA helicase using antibody p68-rgg in 
different cell lines (indicated). The green signal represents staining of p68. The blue signal 
represents staining of DNA. The images are an overlay of green and blue stains. The numbers are 
percentage of cells showing similar (nuclear or cytoplasm) staining pattern in a random group of 
50 cells. 
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Figure 3.2 P68 shuttles between the nucleus and the cytoplasm    
Representative images of SW620 cells expressing HA-p68s (WT, NLS-M, NES-M, NES5-M, 
and NES8-M). After fusion with NIH3T3 cells, the HA-p68s were immunostained using anti-HA 
antibody (Ab). The green signal represents staining of HA-p68s. DAPI stains DNA in the cell 
nucleus of the fused cells (DAPI). The same treated cells were also revealed by phase contrast 
microscopy (Phase). MS2-DEK (immunostained by antibody against MS2) was a negative 
control for nucleocytoplasm shuttling assays. Arrows indicate the nucleus of mouse NIH3T3 
cells. The numbers on the right side of images are the percentages cells with the HA-p68s 
detected in NIH3T3 nucleus (HA-3T3/NE) or in the cytoplasm (HA-Cyto) of the fusion cells 
based on counting a random group of 30 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
 
86 
 
Figure 3.3 NLSs of p68 
(A) Putative sequence segments of p68 that resemble NLS. (B) Representative of confocal 
fluorescent microscopy images show the localizations of p68 putative NLSs (N-terminal NLS1, 
NLS2, NLS3, NLS4) fused with DsRed in SW620 cells. The fused proteins were expressed in 
the cells. The red signal represents the expressed fusion proteins. The control is the expressed 
DsRed protein without the NLS fusion. (C) Examples of confocal images show sub-cellular 
localizations of the exogenously expressed HA-p68s in SW620 cells by immunostaining using 
anti-HA antibody (HA-p68). The green signal represents staining of HA-tag. The blue signal 
represents staining of DNA. HA-p68s, wild-type (WT) NLS mutant (NLS3-M, NLS4-M), were 
expressed in the cells. The right panels are overlay of anti-HA and DAPI stains. (D) HA-p68 
NLS mutant (NLS-M) was expressed in different cell lines (indicated). Examples of confocal 
images of the cells show sub-cellular localizations of the NLS-M by immunostaining using anti- 
HA antibody. The top panel is the overlay of anti-HA and DAPI stains. The bottom panel is the 
phase contrast image of the stained cells. In (B), (C), and (D), the numbers are percentage of 
cells showing similar image pattern (nuclear vs cytoplasm staining) in a random group of 50 
cells. (E) The levels of exogenously expressed HA-p68s, wild type (WT) or NLS-Mutant 
(NLSM) in the extracts made from the cytoplasm or the nucleus of T98G cells were examined by 
immunoblot using anti-HA antibody (IB:HA) (upper panel). The IBs with antibodies against 
lamin A/C and GAPDH are the loading controls. The bottom panel is the quantization of an 
average four separate experiments of the IB signals and presented as ratio of cytoplasmic over 
nuclear HA-p68s (WT or NLS-M). 
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Figure 3.4 NESs of p68 
(A) Putative sequence segments of p68 that resemble NES. (B) Examples of confocal fluorescent 
microscopy images of SW620 cells show localizations of p68 putative NESs (N-terminal fusion) 
fused DsRed. The fused proteins were expressed in the cells. The red signals are the fluorescence 
of the expressed fusion proteins. (C) Inhibition of the exporting of selected putative p68 NESs 
(NES2, NES5, and NES8) fused with DsRed protein by LMB. The fusion proteins were 
expressed in SW620 cells. The cells were treated with LMB 24 hrs post fusion protein 
expression. The confocal florescence images were taken 3 hours post drug treatments. (D) 
Examples of confocal fluorescent microscopy images of SW620 cells show the sub-cellular 
localizations of the p68 NES mutants (NES-M, NES5-M, and NES8-M) in by immunostaining 
using anti-HA antibody. The green signal represents staining of HA-tag. The blue signal 
represents staining of DNA. In (B), (C) and (D), the numbers are percentage of cells showing 
similar localization pattern in a random group of 50 cells.  
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Figure 3.5 NESs and NLSs of p68 
(A) P68 truncates (illustrated in the left panel) containing different putative NLSs and NESs 
either fusion C-terminal flank eGFP or N-terminal HA-tag were expressed in SW620 cells. The 
numbers indicate the molecular weight of each fusion protein. The black bars indicate the 
location of NLSs. The gray bars indicate NESs. The white bars indicate that the corresponding 
NLSs were deleted. (right panel) Examples of confocal fluorescent microscopy images show the 
localizations of eGFP fused or HA-tagged p68 truncates in SW620 cells. The HA-tagged p68 
truncates in SW620 cells were immunostained with anti-HA antibody (Green). The numbers are 
percentage of cells showing similar localization pattern in a random group of 50 cells. (B) Model 
structure of p68 RNA helicase core domain. The model structure was constructed based on the 
X-ray crystal structure of another DEAD box RNA helicase drosophila vasa. The positions of 
NLS3 and NLS4, NES2, NES5, and NES8 are indicated by arrows. 
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Figure 3.6 P68 nucleocytoplasm shuttling is RanGTPase pathway dependent 
(A) Exogenous expression of HA-p68s, wild-type (WT) and mutant (NES-M), and HA-CRM1 in 
SW620 cells were analyzed by immunoblot of whole cell lysate (WCL) using anti-HA antibody 
(IB:HA). (B) Cytoplasmic (Cyto) p68 levels of SW620 cells were analyzed by immunoblot using 
the antibody p68-rgg (IB:p68-RGG). Immunoblots of p68 in whole cell lysate (IB:p68-RGG) 
indicate cellular levels of p68. (C) The cytoplasmic (Cyto) levels of exogenously expressed 
HAp68s (WT and NES-M) were analyzed by immunoblot of cytoplasmic extracts using anti-HA 
antibody (IB:HA). In (A), (B), and (C), IBs of β-actin (IB:actin) and GAPDH (IB:GAPDH) are 
loading controls. The SW620 cells were transfected with vector alone (Vec), the vector for 
CRM1 (HA-CRM1), and the vector for CRM1 plus treatment with LMB (HA-CRM1 + LMB). 
(D) Examples of confocal fluorescent microscopy images of SW620 cells show the cellular 
localizations of endogenous p68 (P68) and exogenously expressed HA-CRM1 (HA-CRM1). The 
cells were treated (+) or untreated (-) with LMB. Red signals are staining p68. The green signal 
represents staining of HA-tag. The blue signal represents staining of DNA. Overlay images are 
overlay of staining of p68, HA-CRM1, and DNA. The numbers are percentage of cells showing 
similar image pattern in a random group of 50 cells. 
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Figure 3.7 P68 interacts with importins in vitro 
(A) Immunoblot analyses of GST-p68 (IB:GST) and his-importin α2 (IB:His) in His-pull-down 
proteins (His Pull-down) from a protein mixture of GST-p68 wild-type (WT) or GST-p68 NLSM 
with; his-importin α2 (α2), his-importin α2 and importin β1 (α2+β1), and Ni-TED beads alone 
(Beads). (B) Immunoblot analyses of his-importin α2 (IB:His) and HA-p68 (IB:HA) in 
coimmunoprecipitates (IP:HA) from a protein mixture of HA-p68 wild-type (WT), HA-p68 
mutant NLS-M (NLS-M), rabbit IgG (IgG), or protein G beads (Beads) with; his-importin α2 
(α2), his importin α2 and importin β1 (α2+β1). Ponceau S staining IgG heavy chain (Ponceasu 
S:HC) is a loading control. In (A) and (B), importin β1 is visualized by ponceau S staining 
(Ponceau S). 
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CHAPTER 4 
P68 RNA HELICASE AND CALMODULIN INTERACTION REGULATES CELL 
MOTILITY BY ACTING AS A MICROTUBULE MOTOR 
4.1 Abstract 
P68 RNA helicase is a prototypical RNA helicase. The RNA unwinding activity is well 
documented. The protein has been implicated in various cellular processes. In this report, we 
present evidence to show that p68 plays a role in cell migration by interacting with Ca
2+
-
calmodulin. A peptide that interrupts the interaction between p68 and calmodulin abolishes cell 
migration. The peptide strongly inhibits cancer metastasis in animal model, suggesting an 
important physiological function of the p68-calmodulin interaction. Our results indicate that the 
p68-calmodulin interaction is essential for the formation of lamellipodia and filopodia structures 
in the migrating cells. P68 upon binding to calmodulin functions as a microtubule motor to 
transport calmodulin to the leading edge of migrating cells. P68 interacts with microtubule in the 
presence of calmodulin. Our experiment shows that p68 ATPase activity is initiated by 
interacting with microtubule. Further, microtubule gliding assays demonstrate that p68 may 
function as a microtubule motor. Our study uncovered a new molecular microtubule motor which 
specifically functioned in the migrating cells.  
4.2 Introduction  
 Migration is an essential characteristic of cells in numerous fundamental biological 
processes(Ridley, Schwartz et al. 2003; Vicente-Manzanares, Webb et al. 2005; Bretscher 2008; 
Kurosaka and Kashina 2008; Montell 2008; Zoller 2009). Cell migration is accomplished by a 
series of highly organized cyclic processes. First, the cells polarize and extend protrusion 
towards the direction of migration stimuli. The polarization and protrusion is led by lamellipodia 
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or spike-shaped filopodia structures (Le Clainche and Carlier 2008). Accompanying the 
protrusion, an extensive rearrangement of cell adhesions to the extracellular matrix stabilizes the 
protrusion and functions as an anchor for traction during migration (Webb, Parsons et al. 2002; 
Le Clainche and Carlier 2008). Following the protrusion, the cell adhesion at the rear side 
detaches from the extracellular matrix, and the cell moves forward (Horwitz and Webb 2003). It 
is believed that the formation of migration leading edges (lamellipodia or filopodia structures) is 
driven by microfilament polymerization (Pollard and Borisy 2003; Mattila and Lappalainen 2008; 
Pollard and Cooper 2009). A number of proteins have been shown to play a role in regulating the 
cytoskeleton rearrangement during cell migration (Le Roy and Wrana 2005). Another important 
feature accompanying the cell migration is that many important molecules that play critical 
role(s) in cell migration re-distribute to the migration leading edge (de Curtis 2001; Insall and 
Machesky 2009). It is believed that transporting along the microtubule structure by a family of 
microtubule motor molecules is the main mechanism by which proteins and organelles 
translocate toward directions of migration(Hirokawa, Noda et al. 2009; Lowery and Van Vactor 
2009; Vallee, Seale et al. 2009; Verhey and Hammond 2009).   
Calmodulin is a calcium binding protein with four EF-hand structure modules. The 
protein activates a wide range of cellular targets to regulate multiple important processes in 
response to Ca
2+
 signals (Clapham 2007). One important molecular mechanism that contributes 
to the capability of calmodulin in regulating many cellular processes is the rapid redistribution of 
calmodulin to subcellular compartments in response to various signal stimuli (Shariat-Madar, 
Goldsmith et al. 1997; Pezzella-D'Alessandro, Le Moal et al. 2001). It is well recognized that 
calmodulin is a major player in connecting Ca
2+
 signaling to cell motility of many cell types 
(Hinrichsen 1993; Chin and Means 2000). Migration signals trigger spatiatemporal redistribution 
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of calmodulin to the leading edge of the migrating cell, which is essential for cell motility (Evans 
and Falke 2007; Collins and Meyer 2009; Wei, Wang et al. 2009). Although, redistribution of 
calmodulin has long been recognized as an important mechanism that regulates complex cellular 
Ca
2+
 signals, little is known about how redistribution of calmodulin to subcellular compartments 
is accomplished. 
4.3 Results 
4.3.1 A peptide from p68 (aa 549–568) and GFP fusion of the peptide inhibit cancer cells 
metastasizing to spleen 
 P68 interacts with calmodulin in the cells is well known. However, what is the function 
of this interaction in the cells is unknown. In this study, we tried to figure out the biological 
function of this interaction. As we did not know what the mechanism leads to the interaction 
between p68 and calmodulin, therefore we tried to disrupt the interaction between those two 
proteins to study the potential function of this protein complex in tumor. The region at aa 549 – 
568 at the C-terminal of p68 is responsible for the interaction between p68 and calmodulin. 
Therefore we designed a peptide generated from that region to competitively disrupt the 
interaction between p68 and calmodulin (ref to as Pep IQ) to study its biological function. A 
scramble peptide (ref to as Pep scramble) which contains the same component of amino acid 
residues but in a random order was used as control peptide. These two peptides were fused with 
TAT cell permeable sequence at the N-terminal (Fig. 4.1A). The peptides were used to treat the 
nude mice xenograft of SW620 cells at dose of 30ug/100ul (daily dose for two weeks). It is well 
known that nude mice xenograft of SW620 will metastasize to spleen. Interestingly, the cancer 
metastasis was dramatically inhibited by the PepIQ (Fig. 4.1B) but not by the scramble peptide. 
The tumor proliferation rate was not significantly affected by the treatment with any of the 
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peptides as demonstrated by the size of the tumors (Fig. 4.1C). We further verified the effects of 
the IQ peptide on the cancer metastasis by stable expression of an eGFP-IQ peptide fusion 
protein in SW620 cells (Fig. S4.1A). Expression of the eGFP-IQ greatly reduced cancer 
metastasis to spleen with the SW620 xenograft tumor, while the metastasis reduction was not 
observed with expression of eGFP. A fusion protein with mutations at IQ motif was used as a 
control (Fig. S4.1B). The reduction of the cancer metastasis was not due to changes in tumor 
growth upon the expression of fusion proteins (Fig. S 4.1C). 
4.3.2 The IQ peptide interrupts p68-calmodulin interaction that is essential for cell migration 
To understand the molecular mechanism by which the IQ peptide inhibited cancer 
metastasis, SW620 cells were treated by the PepIQ or a control peptide. Cell proliferation and 
cell migration were analyzed. Clearly, the PepIQ did not affect cell proliferation, while cell 
migration was almost completely abolished under the peptide treatment (Fig. 4.1D and Fig. 4.1E). 
Similarly, cell migration was also dramatically inhibited by stable expression of the eEGF-IQ in 
SW480 cells (Fig. S34.2A). We questioned why the peptide PepIQ was so effective in inhibiting 
cell migration. It was demonstrated that p68 interacts with the calmodulin in a number of in vitro 
binding studies and the IQ motif covered by the PepIQ harbors the p68- calmodulin interaction 
site (Shen, Valencia et al. 2005; Jang, Guo et al. 2007). Thus, it is possible that the PepIQ 
competed with p68 to interact with calmodulin in the cells therefore inhibited cell migration. 
Thus, we sought to test whether the IQ peptide interrupts the p68-calmodulin interaction and 
consequently inhibits cell migration. We first probed the p68 and calmodulin interaction by 
carrying out co-precipitation experiments with cell extracts made from colon cancer cells SW480 
using calmodulin beads. Clearly, p68 was precipitated down from the cellular extracts by the 
calmodulin beads, and the interaction was Ca
2+
 dependent (Fig. 4.2A). To test the role of the IQ 
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motif of p68 in the calmodulin binding, we created a mutant with mutation (IQ – MA, ref to as 
IQ-M). The calmodulin bead pull-down demonstrated that the mutant interacted with calmodulin 
with a substantially weak affinity, and the IQ-M: calmodulin interaction was Ca
2+
 independent 
(Fig. 4.2B). The results indicated that the strong Ca
2+
-dependent p68-calmodulin interaction is 
IQ motif-dependent. 
Since we observed that the PepIQ greatly inhibited cell migration, we reasoned whether 
there is a cell migration signal induced p68-calmodulin interaction and the peptide may interrupt 
the migration induced p68-calmodulin interaction. Thus, we first examined the p68 and 
calmodulin interaction under various cell migration stimuli. It is well known that treatment of 
cells with EGF can induce cell migration. Thus, we first carried out co-immunoprecipitation with 
cellular extracts made from SW480 cells using an antibody against calmodulin. The cells were 
pre-treated with EGF.  There was a strong increase in the p68 and calmodulin co-precipitation 
upon the EGF treatment (Fig. S4.3A and Fig. S4.3B). Measurement of the changes in cell 
migrations under the stimulation of EGF revealed a close correlation between the increase in the 
p68 and calmodulin interaction and cell migration (Fig. S4.1C). We next probed the p68 and 
calmodulin interaction by the co-immunoprecipitation with cell extracts prepared from SW480 
cells that were subjected to multiple scratch-wound treatment. A strong increase in the p68 and 
calmodulin co-immunoprecipitation was observed and the increase depended upon the number of 
scratches (Fig. 4.2E). The results suggest cell migration induced p68 and calmodulin interaction. 
Since the IQ motif is the site for the strong Ca
2+
-dependent p68 and calmodulin interaction, we 
asked whether the increase in the p68 and calmodulin interaction induced by cell migration 
requires the IQ motif. HA-IQ-M was exogenously expressed in SW480 cells in which the 
endogenous p68 was knocked down. The scratch-wound dependent p68-calmodulin interaction 
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enhancement was not observed in the IQ-M mutant expressed cells (Fig. S4.3D). To test whether 
the peptide abolished the inducible p68-calmodulin interaction upon cell migration, we probed 
the p68-calmodulin interaction in cell lysate prepared from SW480 cells that were transiently 
expressed with eGFP-IQ. The p68-calmodulin interaction was not strengthened upon migration 
stimuli in SW480 cells in which the eGFP-IQ was stably expressed (Fig. S4.2B). Clearly, our 
experiments supported the notion that the cell migration induced p68 and calmodulin interaction, 
and the IQ peptide interrupted the induced p68-calmodulin interaction thus inhibited cell 
migration.  
Based on the preceding experiments, we suspected that the p68-calmodulin interaction 
would be critical for cell migration. The hypothesis was tested by both boyden chamber assay 
and scratch-wound assay. The endogenous p68 was knocked down in SW480 cells and HA-p68s, 
wt, IQ-M, LGLD (An ATPase activity deficiency mutant (Lin, Yang et al. 2005)), or Y593F 
(Yang, Lin et al. 2006), was expressed in the cells (Fig. S4.3E). Boyden chamber assays showed 
that knockdown of p68 resulted in dramatic reduction in cell migration and the cell migration 
could be fully recovered by reexpression of wt p68, but not by the IQ-M mutant. As a control, 
the cell migration could also be recovered by expression of a mutant that carries mutation at an 
irrelevant site (Y595F) (Fig. 4.3A). Interestingly, expression of an ATPase deficiency mutant 
LGLD in the p68 knockdown cells did not recover cell migration, indicating that the ATPase 
activity of p68 is required for cell migration (Fig. 4.3A). We further confirmed the functional 
role of the p68 and calmodulin interaction in cell migration by the scratch-wound assay. Scratch-
wound was introduced to the plates that cultured SW480 cells expressing p68 wt, IQ-M, LGLD, 
or Y593F. The amount of cells expressing IQ-M or LGLD migration to the wound was much 
less than those of p68 wt and Y593F expressing cells (Fig. 4.3B). Immunofluorecence staining of 
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HA-tag revealed that no IQ-M and LGLD expressing cells migrated to the wounds, while p68 wt 
expressing cells migrated to the wound areas normally (Fig. 4.3C). These experiments showed 
that the p68-calmodulin interaction is required for cell migration. 
4.3.3 The p68 and calmodulin interaction affect the localization of both calmodulin and p68 to 
the cytoplasm and to the leading edge of the migrating cells 
In the immunostaining experiments, we noted two interesting phenomenon. (1) We 
observed a strong cytoplasm p68 staining only in the migration cells. When the cells reached the 
migration destination, p68 re-localized exclusively back to the cell nucleus (Fig. 4.3D). (2) There 
were very high levels of p68 staining in the cytoplasm and at the leading edge of the migration 
cells and this staining pattern was not observed in the non-migration cells (Fig. 4.3C). Since p68 
interacted with calmodulin in migration cells, we probed whether p68 and calmodulin would 
exhibit similar localization patterns. To this end, scratch-wound was introduced to the SW480 
cell culture plates. The cells were then analyzed by immunostaining. Clearly, p68 and 
calmodulin co-localized, especially at the leading edge of the migration cells. In the non-
migration cells, p68 localized exclusively in the nucleus, while calmodulin could be detected 
almost everywhere in the cells. However, there were significant increases in calmodulin levels at 
the cell migration leading edges and the nucleus in the migration cells compared to that in non-
migration cells (Fig. 4.3D). Similar p68 and calmodulin localization patterns in migration cells 
were also observed with exogenously expressed HA-p68 and endogenous calmodulin (Fig. 
S4.5A). 
We further examined the localization patterns of exogenously expressed HA-p68 mutants 
LGLD and IQ-M and the effects of their expression on the cellular localization of calmodulin 
under scratch-wound conditions. The endogenous p68 was knocked down. The HA-p68s, wt, 
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LGLD, or IQ-M was expressed in p68 knockdown cells. Scratch-wound was subsequently 
introduced. Immunostaining using anti-HA antibody showed that the exogenously expressed wt 
HA-p68 localized to the leading edge of migrating cells. The ATPase deficiency mutant LGLD, 
although detected in the nucleus and the cytoplasm, failed to accumulate at the membrane edge. 
Interestingly, the IQ-M almost exclusively localized in the cell nucleus (Fig. 4.3E). 
Immunostaining of the calmodulin in the same HA-p68s expressing cells revealed that 
calmodulin also failed to accumulate at the membrane edge of the cells that expressed LGLD or 
IQ-M mutant under the scratch-wound condition (Fig. 4.3E). The results suggested that the p68 
and calmodulin interaction and the ATPase activity of p68 were required for the localization of 
calmodulin to the leading edge during cell migration. 
We next examined whether the cytoplasmic localization of p68 indeed occurs in 
migrating cells in tissue samples. We carried out the IHC analyses with the colon cancer tissue 
arrays. Since p68 has function in cell differentiation, we analyzed the cytosol p68 level in 
different stage of the tumors (high stage number indicates more extensive disease in colon cancer) 
but in the similar differentiation level (same grade). The cancer cells in higher stage tumor have 
higher capability of cell migration than the cells in lower stage. Interestingly, we found there 
were more cytosol p68 in higher stage of the tumor than in the lower stage of the tumor (Fig. 
S4.6A). Specifically, we found that there was more cytosol of p68 in T4N2M0 colon tissue than 
in T4N1M0 (Fig. 4.4A). To further analyze the cytoplasm localization of p68, we prepared tissue 
sections of the SW620 xenograft six weeks after implantation. The tissue sections were prepared 
from edge of the tumors or the middle of the tumors. It was clear that there were dramatically 
higher cytoplasmic p68 levels in the tissue sections prepared from edge of the tumors than those 
prepared from middle of the tumors (Fig 4.4B). Interestingly, treatment of the tumor with the 
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PepIQ dramatically reduced the cytoplasmic p68 (Fig. 4.4B). The results suggested that there is 
strong correlation between cell migration status and cytoplasmic localization of p68. 
4.3.4 P68 RNA helicase exhibits a calmodulin dependent microtubule motor activity 
 Redistribution of calmodulin to the leading edge areas is essential for cell migration 
(Pezzella-D'Alessandro, Le Moal et al. 2001; Bolsover 2005). However, the molecular 
mechanism by which the calmodulin is localized to the leading edge of migrating cells in 
response to cell migration stimulus is not well understood. Our preceding experiments indicated 
that the p68 and calmodulin interaction and the ATPase activity of p68 are required for 
calmodulin to localize to the leading edge of the migration cells. We reasoned whether p68 plays 
a functional role in translocation of calmodulin to the leading edge in the migrating cells by 
acting as an unconventional microtubule associated motor (de Curtis 2001; Insall and Machesky 
2009). To test this conjecture, we first analyzed whether p68 and/or calmodulin interact with 
microtubule. The p68/calmodulin and microtubule interaction were first analyzed by the 
microtubule co-precipitation assay. We carried out co-precipitation experiments with 
exogenously expressed HA-p68 that was immunopurified from lysates of SW480 cells 
with/without multiple scratch-wound (20 scratches) treatments. The purified HA-p68 was 
incubated with microtubule. After precipitation of the microtubule by centrifugation, the 
presence of the HA-p68 in the microtubule precipitates was examined by immunoblot using an 
anti-HA antibody. HA-p68 that was purified from cells that were treated by multiple scratch-
wound co-precipitated with the microtubule in the presence of calmodulin. On the contrary, HA-
p68 immunopurified from SW480 cells that were not treated by scratch-wound did not co-
precipitate with the microtubule even in the presence of calmodulin (Fig. 4.5C). The HA-p68 did 
not co-precipitate with unpolymerized - and - tubulin in the presence and absence of Ca2+ and 
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calmodulin (Fig. S4.5B). Interestingly, co-precipitation of HA-p68 with microtubule in the 
presence of calmodulin was completely Ca
2+
 dependent, while the ATP was dispensable as the 
HA-p68 co-precipitated with the microtubule in the presence and absence of ATP, and in the 
presence of non-hydrolysable ATP analogue AMP-PNP (Fig. 4.5B).  
 The interaction of p68-calmodulin with the microtubule was further examined by binding 
of rhodamine labelled microtubule to HA-p68 that was fixed on a glass slide. Binding of the 
microtubule to the glass slide was then visualized by fluorescence microscope. Clearly, the 
microtubule bound to the HA-p68 purified from scratch-wound treated SW480 cells in the 
presence of calmodulin and Ca
2+
. The microtubule did not bind to HA-p68 without addition of 
calmodulin (Fig. 4.5D). The microtubule also did not bind to HA-p68 that was purified from 
SW480 cells that were not subjected to multiple scratch-wound treatments (Fig. 4.5D). Binding 
of p68 to microtubule was further verified by co-immunostaining of p68 and microtubule in 
SW480 cells with/without scratch-wound treatments. Clearly, the p68 co-localized with 
microtubule in the migrating cells under scratch-wound treatment, while p68 exclusively 
localized in the nucleus in the cells without scratch-wound treatment. We further examined the 
co-localization of exogenously expressed DsRed-p68 with microtubule labeled by eGFP. Under 
scratch-wound treatment, DsRed-p68 clearly co-localized with eGFP labeled microtubule (Fig. 
4.5F). Thus, we could draw the conclusion that p68 interacts with microtubule and the 
interaction is dependent upon the p68-calmodulin interaction. 
 If p68 could function as a microtubule motor-like molecule, we would expect that 
microtubule would stimulate ATPase activity of p68. Thus, ATPase activity of the HA-p68 that 
was immunopurified from SW480 cells that were treated with multiple scratch-wound was 
analyzed in the presence of various different possible substrates including RNA and microtubule. 
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As previously reported (Huang and Liu 2002), HA-p68 exhibited strong RNA-dependent 
ATPase activity. Interestingly, the protein demonstrated an even stronger microtubule stimulated 
ATPase activity (Fig. 4.6A), and the microtubule stimulated ATPase activity was Ca
2+
 dependent 
as addition of EGTA diminished the ATPase activity (Fig. S4.7B). The observed microtubule 
stimulated ATPase activity came from p68 as the mutation that abolishes p68 ATPase activity 
(LGLD) also abolished the microtubule stimulated ATPase activity of the protein (Fig. 4.6B).  
We next probed whether the p68 has a microtubule motor activity. To this end, we 
employed the microtubule gliding assay. The HA-p68 was purified from SW480 cells with 
scratch-wound treatment and attached to a glass slide. Rhodamine labeled microtubule was then 
added to the glass slide. Migration of the microtubule in the presence and absence of ATP was 
then recorded using confocal microscope by the time-lapse photography. First, migration of 
microtubule was clearly visualized with a positive control motor protein kinesin (Fig. 4.7A). 
Migration of the microtubule on the glass slide with HA-p68 attached was also clearly evident in 
the presence of calmodulin and Ca
2+
. In contrary, the migration of the microtubule was not 
observed on the glass slide with HA-p68 that purified from SW480 cell extracts without scratch-
wound treatment. As a negative control, the migration was not observed without addition of ATP 
(Fig. 4.7A). Statistical analyses indicated that the HA-p68/calmodulin exhibited motor activity 
on the microtubule very similar to that of a control motor protein kinesin (the number of gliding 
microtubles, mean gliding speed, and maximum gliding speed in a random selected group of 50 
are similar, Fig. 4.7B). One possibility is that the observed HA-p68 motor activity is due to co-
purification of residues other cellular motor proteins. We therefore examined the possible co-
existence of two very common microtubule associated motor proteins in the purified HA-p68. 
Immunoblot analyses clearly demonstrated that no microtubule associated motor proteins were 
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detected in the HA-p68 purifications (Fig. S4.7C). To further exclude the possibility that the 
motor activity was due to contaminations during purification, we construct a p68-calmodulin 
fusion protein (Fig. 4.2C). Expression of HA-p68-calmodulin fusion protein in SW480 cells led 
to greatly increased cell migration rates and the expressed fusion protein localized to the leading 
edge of the migrating cells (Fig. 4.2D). In fact, expression of the fusion protein promoted 
formation of the lamellipodia/filopodia structure without scratch-wound treatment (Fig. 4.2D). 
These observations indicated that the fusion protein functionally resemble the p68-calmodulin 
interaction induced by cell migration signals. We then expressed and purified the His-p68-
calmodulin from bacterial E. coli. The gliding assay was performed with this bacterially 
expressed protein. Clearly, the bacterially expressed His-p68-calmodulin had microtubule motor 
activity (Fig. 4.7A). 
We next examined whether p68 indeed migrated along microtubule in the cells that were 
induced for migration. P68 fused with DsRed (DsRed-p68) and eGFP labeled -tubulin were 
exogenously co-expressed in SW480 cells. Cell migration was induced by scratch-wound 
treatment in cell culture plate.  Movement of the DsRed-p68 along the eGFP-labeled microtubule 
was recorded using confocal microscope with multi-photon excitation for imaging of living cells 
with time-lapse photography. The fluorescence images clearly indicated that p68 migrated along 
the microtubule under cell migration induction. The movements were toward the migration 
leading edge (Fig. 4.7C). The results strongly suggest that by interacting with calmodulin, p68 
RNA helicase can function as a microtubule motor. 
 
 
4.4 Discussion 
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 In the present report, we demonstrated that the interaction of p68 RNA helicase with 
calmodulin is required for cell migration. P68 RNA helicase was shown to interact with 
calmodulin by several independent in vitro binding analyses (Buelt, Glidden et al. 1994; Shen, 
Valencia et al. 2005; Jang, Guo et al. 2007). However, the biological function of this interaction 
is not known. According to the prediction and primary results, we found that p68 has multiple 
CaM binding sites (a.a.222-246, a.a.466-486, a.a.515-537, and a.a.549-568). The IQ motif CaM 
binding site is Ca2+ dependent and has a function in cell migration. We reasoned that other CaM 
binding sites are Ca2+ independent as the IQ mutant of p68 binds to CaM beads is Ca2+ 
independent. Meanwhile the binding capability of IQ mutant of p68 to CaM in the presence of or 
without Ca2+ is similar. Our experimental results suggested that the p68 and calmodulin 
interaction at the IQ motif is necessary for the localization of calmodulin to the migration leading 
edge, which is an essential event during cell migration. P68, by interacting with calmodulin, 
exhibited a microtubule motor activity. Apparently, this motor activity allows calmodulin to be 
transported to the leading edge of the migration cells. Based on our current findings, our working 
model for the functional role of p68 in cell migration is illustrated in Figure 4.6.  Interestingly, 
p68 stays with calmodulin at the leading edge of the migration cells until the cell reaches its 
migration destination as demonstrated by the immunostaining, indicating possible additional 
functions of p68 at the migration leading edge during cell migration. One possibility is that the 
p68 may also play a role in the migrating cell leading edge protrusion, e.g. actinfilament 
polymerization in the lamellipodia and filopodia.     
Calmodulin regulates various cellular processes by targeting over a hundred proteins 
downstream. A key feature for such functional diversity of calmodulin is temporal and spatial 
redistribution of the protein under stimulation of various different signaling pathways (Shariat-
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Madar, Goldsmith et al. 1997; Pezzella-D'Alessandro, Le Moal et al. 2001). A long standing 
question is how calmodulin is translocalized to a specific subcellular compartment upon the 
stimulation of various signals. Our experiments demonstrated an excellent example here that p68 
interacted with calmodulin upon the cell migration stimulation. This interaction allows p68 to 
interact with microtubule and subsequently act as a microtubule motor molecule, which 
consequently transports the bound calmodulin to the leading edge of the migrating cells. An open 
question is whether a similar mechanism is also used to re-localize calmodulin in other cellular 
processes that require temporal and spatial redistribution of calmodulin, such as cytokinesis and 
mitosis.    
It is traditionally believed that DEAD box RNA helicase uses RNA as a substrate to 
stimulate its ATPase activity. The energy derived from ATP hydrolysis is then used to displace 
duplex RNA or protein that bind the RNA substrate. Along with our previously published report 
(Yang, Lin et al. 2006), this is the second example that p68 DEAD box RNA helicase can use 
protein as a substrate to stimulate its ATPase activity. It is conceivable here that the energy 
derived from ATP hydrolysis can then be used for translocation along the microtubule (motor 
like protein). However, a typical microtubule motor molecule binds microtubule with two “motor 
head”. The movement along the microtubule is usually derived by cyclic hydrolysis of ATP at 
the two heads (Gennerich and Vale 2009). Thus, an open question is how the p68 RNA helicase 
motor action on microtubule is achieved by one ATP hydrolysis site. One possibility is that the 
bound calmodulin may function as an anchor, while ATP hydrolysis in p68 powers the 
movement. This scenario would require that calmodulin interact with microtubule. Nevertheless, 
the interaction between calmodulin and microtubule is not observed. Alternatively, p68 RNA 
helicase may travel along the microtubule using a mechanism similar to that used by a DEAD 
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box RNA helicase that translocats along the RNA substrate. It is reported that DEAD box RNA 
helicase Ded1 can displace RNA bound protein without RNA unwound. It was suggested that the 
Ded1 can act like an RNA motor to remove the bound protein during translocation along the 
RNA chain by its motor action (Fairman, Maroney et al. 2004). It is plausible that p68 may adapt 
a similar mechanism. However in this case, the microtubule instead of RNA chain is used as 
substrate.  
4. 5 Materials and methods 
4.5.1 Scratch-wound treatments  
A scratch or multiple scratches using pipette tips were introduced into a 6 well cell culture plate. 
The cells were further cultured under serum starvation for 30 minutes, and were subsequently 
cultured for an additional indicated time. The scratch-treated cells were either directly visualized 
by microscopes or the cells were fixed and subsequently examined by immunostaining. 
Alternatively, the cells were collected and lysized. The prepared cellular extracts were then used 
for other analyses. 
4.5.2 Microtubule pull-down  
Microtubule purchased was reconstituted in warm PM buffer (15 mM Pipes pH 7.0, 1 mM 
MgCl2) with the addition of taxol as instructed by the vendor. The MTs were ready to use after 
15 minutes incubation at room temperature. The test protein(s) was incubated with the 
reconstituted MTs under various conditions. The MTs with the bound proteins were separated 
from the incubation solution by centrifugation at 100,000g for 30 minutes. Co-precipitates with 
the MTs were re-suspended in 50 l of 2 x SDS PAGE loading buffer and heated to 85 oC for 10 
minutes and subsequently analyzed by immunoblots. 
4.5.3 Microtubule gliding assay 
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The protein HA-p68, His-p68-calmodulin (10 μl) or Kinesin was loaded onto a glass slide. The 
slide was blocked with the blocking buffer. For the slide loaded with HA-p68, 10 μl of 
calmodulin with 0.5 mM of Ca
2+
 was added to the slide and was incubated for 10 minutes. After 
loading the slide was washed with the Ca
2+ 
containing wash buffer to remove the unbound 
proteins. The prepared Rodamine labeled microtubules were then loaded onto the slide. The 
same Ca
2+ 
containing wash buffer was used to remove unbound microtubules. The movement of 
microtubules was then recorded by the confocal microscope when the ATP containing buffer 
was added. 
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Figure 4.1 Pep IQ inhibited the cancer metastasis 
(A) The sequences for Pep IQ and Pep scramble. (B) RT-PCR method was used to detect the 
trace amount of human colon cancer SW620 cells. Human Keratin-18 (H Kera-18) is the marker 
protein for human colon cancer cells, which was used to indicate the amount of the SW620 cells 
migrated to the spleen. Mouse beta-actin (M b-actin) was used as the RNA loading control. (C) 
The sizes of the subcutaneously implanted tumor at the end point. The left image was the SW620 
tumors at the end point; the right graph is the tumor weight at the end point. And the tumor mass 
was statistically analyzed by the T-test.  The cell proliferation of SW480 cells and SW620 cells 
were not significantly affected when the cells were incubated with Pep IQ or Pep scramble for 24 
hours (D). The scratch induced migration of SW620 cells was significantly inhibited when the 
cells were incubated with Pep IQ (E). 
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Figure 4.2 P68 and Calmodulin interactions 
Interaction of endogenous p68 (A) and exogenously expressed HA-p68s, wt and IQ mutant, (B) 
with calmodulin in the presence of 2 mM CaCl2 (Ca
2+
) and 5 mM EGTA (EGTA) was probed by 
calmodulin beads pull-down (PD: calmodulin beads) followed by immunoblot using antibody 
against p68 (IB:p68-RGG) or anti-HA antibody (IB:HA). Cons are the control immunoblot of the 
cellular extracts using indicated antibody without calmodulin beads pull-down. (C) Schematic 
illustration of the p68 and calmodulin fusion protein. Specific sequence motifs in p68 are high-
lighted in colors. (D) (left panel) Representative images of SW480 cells expressing HA-p68 (p68) 
and HA-p68- calmodulin (p68-CaM). The HA-p68 and HA-p68-calmodulin were 
immunostained using anti-HA antibody (Ab:HA, green). DAPI stains (blue) DNA in the cell 
nucleus of the HA-p68s expression cells. Merge is overlay of the images of Ab:HA stains and 
DAPI stains. (right panel) The levels of exogenously expressed HA-p68 (WT) or HA-p68- 
calmodulin (p68-CaM) in p68 knockdown SW480 cells were examined by immunoblot of whole 
cell lysate (WCL) using anti-HA antibody (IB:HA). Immunoblot of GAPDH is a loading control. 
Vec is the cells transfected with the empty vector. (E) P68 and calmodulin interaction in extracts 
prepared from SW480 cells that were subjected to multiple scratch-wound treatment (number of 
scratches was indicated) was analyzed by immunoprecipitation of calmodulin (IP:CaM). The 
extracts were prepared three hours after scratches. P68 co-precipitated with the IP calmodulin 
was examined by immunoblot using the antibody p68-RGG (IB:p68-RGG). Immunoblot 
analyses of precipitated calmodulin (IB:CaM) indicated amounts of calmodulin that were 
precipitated from each IP reaction.  
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Figure 4.3 P68 and calmodulin interaction is essential for cell migration and for localization 
of calmodulin to the leading edge of migrating cells 
(A) Migration of SW480 cells in which endogenous p68 was knocked down by RNAi (SiRNA) 
and HA-p68s, wild type (WT) and mutants (indicated), were exogenously expressed was 
analyzed by boyden chamber assays. The number of cells migrated to the lower chamber was 
measured and presented as relative migrated cell number by defining the number of migrating 
cells in which p68 was knocked down and the empty vector was transfected as 1. (B) (Upper 
panel) Migration of SW480 cells in which endogenous p68 was knocked down by RNAi (SiRNA) 
and HA-p68s, wild type (WT) and mutants (indicated), were exogenously expressed was 
revealed by phase contrast microscopy 0 hour (0h) and 12 hours (12h) after scratch-wound was 
introduced into the cell culture plates. (Lower panel) Quantization of the cells in a fixed 
microscopic areas that migrated to the scratch areas. (C) Representative images of SW480 cells 
in which endogenous p68 was knocked down by RNAi (SiRNA) and HA-p68s, wild type (WT) 
and mutants (indicated), were exogenously expressed. The HA-p68 and HA-p68-calmodulin 
were immunostained using anti-HA antibody (Ab:HA, green). Endogenous p68 was stained with 
the antibody p68-RGG (Ab:p68-RGG). DAPI stains (blue) DNA in the cell nucleus of the HA-
p68s expression cells. Merge is overlay of the images of Ab:HA (or Ab:p68-RGG) stains and 
DAPI stains. (D) Immunofluorescence staining of p68 (red) and calmodulin (green) in SW480 
cells using antibodies against p68 (Ab:p68-RGG) and calmodulin (Ab:CaM). The cells were 
treated by a scratch-wound in the culture plate. The left panel focused on the cells that located on 
the scratch edges, while the right panel focused on the middle of scratch wound areas. (E) 
Immunofluorescence staining of p68 (Ab:p68-RGG, green) or exogenously expressed HA-p68s 
(Ab:HA, green), wild type (WT) or mutants (indicated), and calmodulin (Ab: CaM, red) in 
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SW480 cells. The endogenous p68 was knocked down by RNAi. The cells were treated by a 
scratch-wound (Scratch) or no scratch-wound (No scratch) in the culture plate. The merges in (D) 
and (E) are overlays of the images of calmodulin and p68 staining. Error bars in (A) and (B) are 
standard deviations of three independent measurements. Vec is the cells transfected with the 
empty vector. NT represents the cells treated with non-target RNAi.  
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Surrounding normal colon tissue 
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Figure 4.4 The localization of p68 in colon cancer tissues and xenograft tumor tissues 
(A) IHC staining of p68 in the colon cancer tissues isolated from the colon cancer patients who 
were diagnosed at Grade 2 stage III. The brown color was the staining of p68; the blue spots was 
the staining of nuclei of cells. (B) Immunofluorescent staining of p68 (Red) in the tumor tissues 
which grew from the subcutaneously implanted SW620 cells. Blue staining (DAPI) indicated the 
location of the nuclei. Edge refers to the out layer of the tumor; Middle refers to the center layer 
of the tumor. (C) IHC staining of p68 in the surrounding normal colon tissue. 
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Figure 4.5 P68 and calmodulin interact with microtubule 
(A) HA-p68 and HA-p68-calmodulin immunopurified from SW480 cells that were 
treated/untreated with multiple scratch-wounds were analyzed by immunoblot using the anti-HA 
antibody. PonS:HC is the ponceau S stain of antibody heavy chain. (B) Precipitation of purified 
HA-p68-calmodulin (p68-CaM) with in vitro assembled microtubule (PD: Microtubule) by 
ultracentrifugation in the absence of ATP or in the presence of non-hydrolysable ATP analogue 
AMP-PNP was probed by immunoblot of the precipitated pellets using the antibody p68-RGG 
(IB:p68-RGG). Immunoblot analyses of -tubulin (IB:Tubulin) is the loading control indicating 
amounts of precipitated microtubule. (C) Precipitation of purified HA-p68-calmodulin (HA-p68-
CaM) and HA-p68 in the presence of calmodulin (HA-p68/CaM) with in vitro assembled 
microtubule (PD:Microtubule) in the presence of 0.5 mM CaCl2 (Ca
2+
) or 5 mM EGTA (EGTA) 
was probed by immunoblot of the precipitated pellets using the anti-HA antibody (IB:HA). The 
HA-p68 was purified from SW480 cells treated by multiple scratch-wounds (left, Scratch). The 
HA-p68 and HA-p68-calmodulin were purified from SW480 cells without scratch-wound 
treatment (middle, Non scratch and right). Immunoblot analyses of -tubulin (IB:Tubulin) is the 
loading control indicating amounts of precipitated microtubule. Immunoblot of calmodulin 
(IB:CaM) in the microtubule precipitates indicated the co-precipitation of calmodulin with HA-
p68 and microtubule. (D) Bindings of Rhodamine labeled microtubule (Rhodamine-MT) to the 
glass slides on which the HA-p68-calmodulin or HA-p68 (in the presence of calmodulin and 
Ca
2+
 [HA-p68/CaM-Ca] and absence of calmodulin [HA-p68]) that was immunopurified from 
SW480 cells were revealed by fluorescence microscopy. The cells from which HA-p68 was 
purified were treated by either 20 scratch-wound (Scratch) or no scratch-wound (No nscratch) in 
the culture plate. (E) Immunofluorescence staining of exogenously expressed HA-p68-
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calmodulin (Ab:HA, green) or endogenous p68 (Ab:p68-RGG, green) and microtubule (Ab:MT, 
red) in SW480 cells. The cells were treated by a scratch-wound (Scratch) or no scratch-wound 
(Non scratch) in the culture plate. (F) Representative fluorescence microscopy images of SW480 
cells that expressed DsRed-p68 and eGFP--tubulin. The cells were treated by scratch-wound. 
The arrows indicated the DsRed-p68. 
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Figure 4.6 Microtubule stimulates the ATPase activity of p68 
ATPase activities of (A, left) HA-p68 (p68) and HA-p68-calmodulin (p68-CaM) in the presence 
of various different substrates (Sub, indicated), (A, right) the p68-calmodulin in the presence of 
various different substrates (Sub). (B) the HA-p68-calmodulin (wild type and indicated mutants) 
with microtubule as substrate, and (C) the recombinant calmodulin and/or the HA-p68 
immunopurified from scratch-wound treated SW480 cells in the presence of 0.5 mM CaCl2 
(Ca
2+
), 5 mM EGTA (EGTA) were analyzed by measuring inorganic phosphate released from 
ATP hydrolysis. In the ATPase assays, 4 mM ATP was always added unless specified (-ATP). 
The ATPase activity was expressed as mole of inorganic phosphate hydrolyzed from ATP. In 
(A) and (C), MT is in vitro assembled microtubule. RNA is total RNA extracts from yeast. 
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Figure 4.7 P68-calmodulin has a microtubule dependent motor activity 
(A) The movements of Rhodamine labeled microtubules on kinesin, p68/Ca
2+
-CaM, or His-p68-
CaM (0.5mM CaCl2) were recorded by the time lapse photography with confocal fluorescence 
microscopy. p68 with HA tagged was immunopurified from scratch-wound treated SW480 cells. 
His-p68-CaM was purified from E. coli. (B) Summary of quantitative (statistical) analyses of the 
movements of Rhodamine labeled microtubules in the gliding assays. 50 microtubules per each 
group was counted. The mean gliding speed was the average of speed of the randomly selected 
50 microtubules per each group. The standard deviation was obtained from examinations of three 
randomly selected groups of microtubules. (C) Movements of DsRed-p68 along eGFP labeled 
microtubules in SW480 cells that were treated by scratch-wound were recorded by time lapse 
photography with confocal fluorescence microscopy. 
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Figure Supplement 4.1 eGFP-IQ expression affected SW620 cells metastasize to spleen 
 (A) Schematic illustration of the eGFP-IQ and eGFP-MA fusion proteins. (B) RT-PCR indicated 
the spleen metastasis of different cell lines (including SW620 and eGFP/eGFP-IQ/eGFP-MA 
stably expressing SW620 cells) which were subcutaneously implanted to the nude mice at the 
right flank. H Kera-18 referred to the mRNA level of human keratin 18 marker protein; M B-
actin referred to the mRNA level of mouse beta-actin which was used as the loading control. (C) 
The sizes of the tumors at the end point. Left images were the tumors which grew from four 
different cell lines. Right graph was the tumor weights at the end point. The tumor mass were 
statistically analyzed by T-test. (D) The expression level of eGFP or eGFP fusion proteins in the 
tumor mass. The expression level of p68 and calmodulin was tested in the different tumors. The 
IB of GAPDH was used as the loading control. 
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Figure Supplement 4.2 eGFP-IQ expression affected the interaction between p68 and 
calmodulin and cell migration 
(A) The scratch induced cell migration was affected by stably expressing eGFP-IQ. # indicated 
the clone number of the stable cells. (B) The interaction between p68 and calmodulin was 
affected by transiently expressing eGFP-IQ. The interaction was examined by employing 
calmodulin beads pull down assay. IB: GFP indicated the expression level of the eGFP/eGFP-IQ 
proteins in the cells. The endogenous expression level of p68 and calmodulin were illustrated by 
the IBs of p68 and calmodulin. IB of GAPDH was used as the loading control for the whole cell 
lysate. 
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Figure Supplement 4.3  
 (A) The interaction between p68 and calmodulin was increased when the cells were treated EGF 
for 3 hours. The interaction was confirmed by the Co-IP. Poly Ab of calmodulin was used to pull 
down the protein complex. Mono Ab of p68 was used to indicate the amount of p68 interacted 
with calmodulin. The interaction between p68 and calmodulin was further confirmed in (B). 
SW480 cells were first exogenously expressed with HA-p68. Poly Ab of HA was used to pull 
down the protein complex this time. Mono Ab of calmodulin was used to indicate the amount of 
calmodulin interacted with HA-p68. The cell migration capability was tested under the treatment 
of different dose of EGF by carrying with Boyden Chamber Assay (C). The interaction between 
p68 and calmodulin was found to depend on the IQ motif of p68 as the interaction between the 
IQ mutant of p68 and calmodulin no longer increased when the cells were stimulated with the 
scratch (D). In order to test how the different mutant of p68 functions in cell migration, the 
endogenous p68 was knocked down and different mutant p68 was expressed in the p68 knock-
down cells. The knock down efficiency of p68 was examined by the IB of the whole cell lysate 
showed in the left panel in (E). The expression levels of the different mutant of p68 in the cells 
were examined in the right panel in (E).  
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Figure Supplement 4.4  
Overexpression of the fusion protein of p68 and calmodulin promoted the cell into migration 
status. In order to test how the fusion protein functions in cell migration, the endogenous p68 
was knocked down and the knock down efficiency was illustrated in the left panel in (A), and the 
expression levels of p68-calmodulin fusion protein and IQ-M-calmodulin fusion protein were 
illustrated in the right panel in (A). The cell migration capabilities were then tested by the 
Boyden Chamber Asaay (B). The cell migration capabilities of those cells were also tested by the 
monolayer scratch assay (C). The image showed the migration results which were stimulated by 
the monolayer scratch. The graph was the statistically analyzed result. The cellular location of 
p68/fusion protein (green) in scratch induced migrating cells was illustrated in (D). 
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Figure Supplement 4.5  
 (A) The cellular location of HA-p68 (green) and calmodulin (Red) in migrating cells (located at 
the scratch edge) and in resting cells (located at the middle region of the scratch area). The 
interaction between HA-p68/HA-fusion protein and subunits of microtubule were tested (B). 
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Figure Supplement 4.6 
IHC staining of the human colon cancer tissues in the arrays. The cytoplasmic levels of p68 
(brown color) at the different stages but in the same grade were compared. 
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Figure Supplement 4.7 
The purity of the HA-p68/fusion proteins was illustrated in (A). HC indicated the heavy chain of 
poly Abs for HA and was used as the loading control. The ATPase activity of HA-p68-
calmodulin was tested in the presence of the Ca2+/EGTA (B). Whether the HA-p68/HA-fusion 
proteins interact with two classical microtubule motors (kinesin-1 and dynein-1) were tested (C). 
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CHAPTER 5 
PYRUVATE KINASE M2 REGULATES GENE TRANSCRIPTION BY ACTING AS A 
PROTEIN KINASE 
5.1 Abstract 
Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme catalyzing conversion of 
phosphoenolpyruvate (PEP) to pyruvate with transferring a phosphate from PEP to ADP. We 
report here that PKM2 localizes to the cell nucleus. The levels of nuclear PKM2 correlate with 
cell proliferation. PKM2 activates transcription of MEK5 by phosphorylating stat3 at Y705. In 
vitro phosphorylation assays show that PKM2 is a protein kinase using PEP as phosphate donor. 
The protein substrate is bound at the ADP binding site. Our experiments suggest that PKM2 
dimer is an active protein kinase, while the tetramer is an active pyruvate kinase. Expression a 
PKM2 mutant that exists as a dimer promotes cell proliferation, indicating that protein kinase 
activity of PKM2 plays a role in promoting cell proliferation. PKM2 interacts with tyrosine 
phosphorylated p68. Binding of the tyrosyl phosphorylated proteins at the FBP binding site 
converts the tetrameric PKM2 to a dimer, and reciprocally regulates the pyruvate kinase and 
protein kinase activities of PKM2. Growth factor stimulations significantly increase the 
dimer/tretramer PKM2 ratio in cells and consequently activate the protein kinase activity of 
PKM2. Our study reveals an important link between metabolism alteration and gene expression 
during tumor transformation and progression. 
5.2 Introduction 
An important molecular feature of tumor development is the expression of pyruvate 
kinase isoenzyme M2 (PKM2) (Elbers, van Unnik et al. 1991; Hacker, Steinberg et al. 1998). 
The glycolysis catalytically active PKM2 exists as a tetramer and associates with a glycolytic 
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enzyme complex (Altenberg and Greulich 2004; Dombrauckas, Santarsiero et al. 2005; Spoden, 
Morandell et al. 2009). In tumor cells, PKM2 forms a dimer, and appears to be catalytically 
inactive for conversion of PEP to pyruvate (Ashizawa, Willingham et al. 1991; Mazurek, 
Boschek et al. 2005). It is believed that the inactive PKM2 actually provides growth advantage 
for tumor progression as it helps to channel the carbon source from glycolytic intermediates to 
biosynthesis, especially syntheses of nucleic acids, lipids, and proteins, to meet the demands for 
tumor cell proliferation. Recent studies have suggested that PKM2 changes its pyruvate kinase 
activity, consequently facilitating cell proliferation by binding to tyrosine phosphor-peptide 
(Christofk, Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008), indicating that 
growth signals regulate the activity of PKM2 in glucose metabolism. 
5.3 Results 
5.3.1 Nuclear PKM2 activates transcription of MEK5 by phosphorylating stat3 
We and others have observed that the PKM2 localizes to the cell nucleus (Schneider, Neu 
et al. 2002; Hoshino, Hirst et al. 2007; Stetak, Veress et al. 2007). To understand the functional 
significance of nuclear localization of PKM2, we examined nuclear PKM2 levels in ten different 
cancer cell lines by immunoblot using an antibody raised against a peptide spanning aa 399 – 
412 of PKM2 (PabPKM2). These ten different cell lines represent different cancer progression 
stages and are derived from cancers of different organs/tissue types. Cell proliferation analyses 
demonstrated that M4C1, SW620, WM266, and H146 are more proliferated than their 
corresponding lines in the matched pairs (Fig. S4.1A). Immunoblot analyses indicated much 
higher nuclear levels of PKM2 in the more proliferated cancer cells than those in the 
corresponding less proliferated cells (Fig. 5.1A), The higher nuclear PKM2 levels were not 
because of differences in PKM2 expression, as shown in figure 5.1A whereas no significant 
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differences were observed in total PKM2 in cell lysates. The detection of PKM2 in the nuclear 
extracts was not due to contamination of cytoplasmic proteins as demonstrated by lack of 
GAPDH in the immunoblot analyses of the nuclear extracts. 
To explore a possibility that nuclear PKM2 is involved in regulation of gene expressions, 
we carried out gene expression array analyses with SW620 cells expressing HA-PKM2. 
Expressions of 350 genes were upregulated, and expressions of 359 genes were downregulated, 
by at least two fold (Table S1). Among those affected genes, expression of MEK5 was affected 
by over six fold. We verified the role of PKM2 in expression of MEK5 by RT-PCR. Consistent 
with the gene array analyses, RT-PCR demonstrated a dramatic change in the MEK5 expression 
in SW620 cells, while only a marginal increase in SW480 cells, following the expression of 
PKM2 (Fig. 5.1B). Similar patterns were also observed with another pair of cell lines, WM115 
and WM266. The effects PKM2 on the expressions of MEK5 were further confirmed by 
immunoblot analyses of cellular MEK5. It was clear that the cellular MEK5 levels increased 
subsequent to expression of PKM2. The more proliferated cancer cells experienced more 
dramatic increases in MEK5 levels (Fig. 5.1C). Interestingly, immunoblot of MEK5 using 
antibody against the phosphorylated MEK5 revealed a strong increase in the cellular levels of 
phosphorylated MEK5 in more proliferated cancer cells compared to the less proliferated cancer 
cells upon exogenous expression of PKM2 (Fig. 5.1C). To further verify the role of PKM2 in 
transcriptional regulation of MEK5, PKM2 was knocked down in SW620 and SW480 cells (Fig. 
5.1D). It was evident that MEK5 expression was slightly reduced in SW480. However, the 
reduction in cellular levels of MEK5 in SW620 cells was dramatic upon knockdown of PKM2 
(Fig. 5.1D). We also analyzed the MEK5 mRNA levels in SW620 and WM266 cells upon PKM2 
knockdown. Quantitative  RTPCR analyses demonstrated a strong reduction in cellular MEK5 
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mRNA (Fig. 5.1E). We further used chromatin immunoprecipitation (ChIP) to probe whether 
PKM2 interacted with the MEK5 promoter. We carried out the ChIP experiments with SW620 
cells using the PCR primer pair that spanned the region of nt –1,621 – -1,366 of MEK5 promoter. 
Our ChIP assays clearly demonstrated that PKM2 indeed interacted with the MEK5 promoter 
(Fig. 5.1F). We next sought to test whether up-regulation of MEK5 by PKM2 contributed to cell 
proliferation. MEK5 was first knocked down in SW620 and WM266 cells. As a result, the cell 
proliferation rate was dramatically reduced (Fig. S5.1B). The proliferation rate increases 
stimulated by expression of HA-PKM2 in the MEK5 knockdown SW620 and WM266 cells were 
also largely reduced (Fig. S5.1B), suggesting that up-regulation of MEK5, at least partially, 
mediated the effects of HA-PKM2 overexpression on cell proliferation. Moreover, we analyzed 
the MEK5 expression levels in these ten different cancer cell lines. MEK5 was expressed in all 
ten cell lines, but there were substantially higher levels of MEK5 in the more proliferated cancer 
cells than in the less proliferated cancer cells. Strikingly, the levels of phosphorylated MEK5 
were also consistently higher in more proliferated cells than in less proliferated cells among the 
selected cancer cell line pairs (Fig. S5.1C). Clearly, there is a close correlation between cellular 
MEK5 expression levels and nuclear PKM2 levels, and both were correlated closely with the cell 
proliferation status of the cells (comparing Fig. S5.1C with Fig. 5.1A). We concluded from these 
studies that up-regulation of MEK5 by nuclear PKM2 contributed to cell proliferation. How 
would PKM2 function in regulation of gene transcription? Sequence analyses did not reveal any 
known DNA binding domain/motifs in PKM2. One possibility is that PKM2 may activate 
particular transcription factors. Thus, we attempted to probe the interaction of PKM2 with 
several known transcription factors in nuclear extracts of SW620 and SW480 cells by 
immunoprecipitation, such as Oct-1, Oct-4, Gadd45, SOX4-1, and stat3. Among these selected 
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targets, stat3 and SOX4 were involved in transcription of MEK5 (Song, Jin et al. 2004; Aaboe, 
Birkenkamp-Demtroder et al. 2006), while Oct-4 was reported to interact with PKM2 in extracts 
made from ESC (Lee, Kim et al. 2008). Our experiments showed that stat3 was the only 
transcriptional factor among the selected targets that interacted with PKM2 (Data not shown, Fig. 
5.2A, and Fig. S5.2 A&B). It was likely due to the differences between ESC and cancer cells, we 
did not detect the PKM2 and Oct-4 interaction in the extracts prepared from cancer cells of 
several cell lines. We noted that stat3 interacts with MEK5 promoter at -1776 nt – -1520 nt 
region by ChIP (Song, Jin et al. 2004). Interestingly, PKM2 also interacts with MEK5 promoter 
at the same region by ChIP (Fig. 5.1F). To address whether the activation of stat3 mediates the 
effects of PKM2 on upregulation of MEK5 transcription, we first knocked down stat3 in 
SW620/SW480 and WM266/WM115 cells, and HA-PKM2 was subsequently expressed. It was 
clear that expression of HA-PKM2 could no longer upregulate MEK5 as measured by cellular 
levels of both mRNA and protein of MEK5 (Fig. 5.2 B&C, D&E). To further test the role of 
stat3 in mediating the effects of PKM2 on upregulation of MEK5 transcription, we used a 
dominant-negative mutant stat3 (Y705F) (Xie, Huang et al. 2006). The mutant was co-expressed 
with HA-PKM2 in SW620/SW480 and WM266/WM115 cells. It was evident that expression of 
the dominate-negative mutant largely diminished the effects of PKM2 on upregulating MEK5 
transcription (Fig. S5.2 C&D, E&F). As a control, expression of stat3-DN in PKM2 knockdown 
SW480/SW620 cells did not result in upregulation of MEK5 expression (Fig. S5.2C). It is well 
documented that the activity of the active stat3 can be inhibited by specific inhibitor (Xu, Cole et 
al. 2008). We therefore tested the effects of a stat3 inhibitor on the upregulation of MEK5 by 
expression of HA-PKM2 in SW620 and WM266 cells. Treatment of the HA-PKM2 expressing 
cells with the inhibitor resulted in a decrease in MEK5 transcription (Fig. S5.2 G&H). Thus, we 
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concluded that activation of stat3 mediated the regulatory effects of PKM2 on MEK5 
transcription.  
We next investigated whether expression of PKM2 affected the stat3 binding to its target 
DNA at the MEK5 promoter. To probe whether knockdown or expression of PKM2 affected the 
interaction of stat3 with the MEK5 promoter, we performed ChIP experiments in SW620 cells in 
which the endogenous PKM2 was knocked down or HA-PKM2 was expressed. Clearly, the stat3 
and MEK5 promoter interaction was strengthened by HA-PKM2 expression and was weakened 
by PKM2 knockdown (Fig. 5.3A). We then analyzed the effects of PKM2 on the interaction 
between stat3 and its target DNA by gel mobility shift assays using a 32P-labled oligonucleotide 
duplex containing a stat3 binding sequence (Xie, Huang et al. 2006). The gel-shift experiments 
were carried out with nuclear extracts of SW620 cells with/without PKM2 knockdown or 
with/without HA-PKM2 expression. Autoradiography indicated that a slow migration complex 
was assembled with the labeled oligonucleotide and addition of the antibody against stat3 
resulted in a supershift complex (Fig. 5.3B). Interestingly, knockdown of PKM2 substantially 
decreased the assembly of the oligo-protein complex and assembly of stat3 in the complex (the 
weak supershift) (Fig. 5.3D), while expression of HA-PKM2 dramatically increased assembled 
complex and assembly of stat3 in the complex (Fig. 5.3C). 
Stat3 is a transcription activator that is activated by phosphorylation at Y705 mainly by 
JAK or Src kinase. The phosphorylation increased the stat3 and DNA binding affinity (Sehgal 
2008). We observed that PKM2 increased the stat3 binding to its target sequence both in vitro 
and in vivo. We suspected that PKM2 may play a role in stat3 phosphorylation at Y705. To test 
this conjecture, we analyzed the stat3 phosphorylation at Y705 in the nuclear extracts prepared 
from SW620 cells in which the HA-PKM2 was expressed using an antibody against the Y705 
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phosphorylated stat3 (P-y705/stat3). Clearly, a significant increase in Y705 phosphorylation of 
stat3 in the nuclear extracts was evident. Examination of the cellular levels of stat3 indicated that 
the expression levels of stat3 were not affected by the PKM2 expression (Fig. 5.3E). We also 
observed a significant reduction in the stat3 phosphorylation in SW620 cells upon PKM2 
knockdown (Fig. 5.3F). It is known that JAK2 and c-Src are the most common protein tyrosine 
kinases that phosphorylate stat3. We therefore probed whether JAK2 and c-Src were activated by 
the HA-PKM2 expression. Using antibodies against JAK2, the phosphorylated JAK2, c-Src, and 
the phosphorylated c-Src, our experiments showed that JAK2 and c-Src were not activated upon 
the HA-PKM2 expression (Fig. S5.3 A&B). Furthermore, treatment of cells with JAK2 
inhibitors did not lead to any significant changes of the PKM2-depedent stat3 phosphorylations 
(Fig. S5.3C), suggesting that stat3 phosphorylation was not due to activation of JAK2 or c-Src. 
5.3.2 Dimeric PKM2 is the active protein kinase 
Expression of PKM2 increased stat3 phosphorylation at Y705. We sought to verify 
whether PKM2 could act as a protein kinase that directly phosphorylated stat3. An in vitro 
phosphorylation assay using both the E. coli expressed recombinant PKM2 (rPKM2) and the 
HA-PKM2 immunopurified from nuclear extracts of SW620 cells in the presence of ATP did not 
yield phosphorylation of a commercially available GST-stat3. Since PKM2 use PEP as 
phosphate donor to phosphorylate ADP in the glycolysis, we reasoned that the protein may use 
the same phosphate donor to phosphorylate a protein substrate. Thus, we replaced ATP by PEP 
in our in vitro phosphorylation reaction. Immunoblot using the antibody P-y705/stat3 
demonstrated that the GST-stat3 was phosphorylated by the HA-PKM2 in the presence of PEP. 
Consistently, stat3 was not phosphorylated in the presence of ATP (Fig. 5.4 A&B). These 
experimental results indicated that PKM2 is a protein kinase using PEP as the phosphate donor. 
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The kinase activity of the nuclear HA-PKM2 in phosphorylation of stat3 was substantially higher 
than that of the rPKM2 expressed in E. coli. The results led us to compare the protein kinase 
activity of the nuclear PKM2 and the cytoplasmic PKM2. The HA-PKM2 was immnopurified 
from nuclear or cytoplasmic extracts of SW620 cells. The same in vitro phosphorylation 
reactions were performed with the immunopurified HA-PKM2 in the presence of PEP or ATP. It 
was evident that both the HA-PKM2 purified from the nuclear extracts and the cytoplasmic 
extracts were active in phosphorylating stat3. However, it was also clear that the HA-PKM2 
from the nuclear extracts had much higher activity than that of protein from the cytoplasmic 
extracts (Fig. 5.4 C&D). 
It was reported that the catalytically active tetramer and inactive dimer of PKM2 co-exist 
in cells with high proliferation rate (Mazurek, Boschek et al. 2005). We therefore questioned 
whether the differences in the protein kinase activity of nuclear/cytoplasmic HA-PKM2 and the 
rPKM2 were due to dimer or tetramer of the protein. To investigated whether PKM2 is a dimer 
or a tetramer both in the nucleus and in the cytoplasm, we first fractioned the nuclear extracts 
and cytoplasmic extracts of SW620 cells by size exclusion chromatography. Non-specific 
protein-protein interactions were disrupted by treatment of the extracts with 600 mM 6-
aminocaproic acid (6- AcA). The levels of PKM2 in each chromatography fraction were 
examined by immunoblot using the antibody PabPKM2. Nuclear PKM2 was only detected in 
fractions 14 – 16, while cytoplasmic PKM2 was mainly detected in fractions 11 – 16 with the 
highest concentrations in fractions 11 – 13. Based on the molecular weight calibration standard 
(Fig. S5.4 A&B), fraction 11 co-elutes with a molecular weight near 240 kDa, while fraction 14 
co-elutes with a molecular weight near 120 kDa (Fig. 5.4E). The gel-filtration chromatography 
suggested that nuclear PKM2 was completely dimer (120 kDa), while the cytoplasmic PKM2 
150 
 
existed in both dimer and tetramer with a higher population of tetramers. The same 
chromatography procedure was also employed to analyze whether the rPKM2 is a dimer or 
tetramer. It was evident that the rPKM2 was detected in the fractions 11 – 14, which indicated 
that the bacterially expressed rPKM2 is mostly tetramer with very small amount of dimer (Fig. 
5.5B). To further probe the dimer/tetramer status of nuclear and cytoplasmic PKM2, nuclear 
extracts and cytoplasmic extracts of SW620 cells were separated by a non-denaturing PAGE (8% 
acrylamide:bisacrylamide= 40:1) and subjected to immunoblot analyses using the antibody 
PabPKM2. It was clear that the nuclear PKM2 migrated slightly faster than the BSA dimer (132 
kDa). Conversely, the majority of the cytoplasmic PKM2 approximately co-migrated with 
Urease (272 kDa) (Fig. S5.4C). Thus, we concluded that PKM2 is a dimer in the nucleus and a 
dimer/tetramer mix in the cytoplasm. The rPKM2 mainly exist as tetramer.  
Based on the proceeding observations, we speculated that the dimer form of PKM2 is the 
active protein kinase, while tetramer is an active pyruvate kinase. Close examination of the 
crystal structure of the tetramer human PKM2 (Dombrauckas, Santarsiero et al. 2005) reveals 
that a positive charged residue R399 may plays a critical role in forming the tetramer of PKM2. 
It is notable that the R399 forms stable charge-charge interactions with residues E418 and E396 
of PKM2 located on the other dimer of the tetramer PKM2 (Fig. 5.5A). We therefore created a 
mutant R399E to disrupt the charge-charge interaction. Size exclusion chromatography analyses 
demonstrated that the R399E mutant was mostly dimer (Fig. 5.5B). We reasoned that the dimeric 
R399E mutant would be more active in phosphorylating stat3 compared to the wild-type rPKM2. 
Thus, the in vitro phosphorylation reactions were carried out with the wild-type rPKM2 and the 
R399E mutant. It was evident that the protein kinase activity of the R399E mutant was 
substantially higher than that of the wild-type rPKM2 (Fig. 5.5C), while the pyruvate kinase 
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activity of the mutant was dramatically lower than that of the rPKM2 (Fig. 5.5D). The results 
supported our speculation that dimeric PKM2 is an active protein kinase. 
To further verify the phosphorylation of stat3 by PKM2, we prepared [
32
P]-labeled PEP 
according to the report by Roossien FF. and co-workers (Roossien, Brink et al. 1983). The same 
in vitro phosphorylation reaction was carried out with the rPKM2, the rPKM1, and the R399E 
mutant using the [
32
P]-PEP. The phosphorylation reaction mixture was separated by SDS-PAGE 
and subjected to autoradiography. It was clear that the GST-stat3 was phosphorylated by the 
R399E mutant. The phosphorylation of the GST-stat3 by the rPKM2 was very weak (can only be 
visualized by a substantial overexposure in autoradiograph). The GST-stat3 was not 
phosphorylated by the rPKM1 in the presence of the [
32
P]-PEP (Fig. S5.5A). No phosphorylation 
can be detected even under very high overexposure in the autoradiograph. To ensure that the in 
vitro phosphorylation of stat3 by PKM2 and the R399E mutant was at comparable physiological 
conditions, we compared the phosphorylation of the GST-stat3 by JAK2 and R399E. Clearly, 
similar levels of stat3 phosphorylations were observed by both kinases (Fig. S5.5B). The same 
phosphorylation reaction could not phosphorylate other protein substrates, such as stat5 and BSA 
(Fig S5.5 C&D), indicating that PKM2 only phosphorylates specific protein substrate(s).  
Extensive analyses of enzyme kinetic of pyruvate kinase in various tissue samples (Km = 0.07 –
1.2 mM range) indicate that the physiological concentration of PEP likely to be at μM - mM (van 
Veelen, Verbiest et al. 1978)(To test whether PKM2 and the R399E mutant would phosphorylate 
stat3 at the physiological PEP concentrations, we carried out the in vitro phosphorylation at 
various PEP concentrations. The levels of phosphorylated stat3 remained almost constant down 
to 100 μM of PEP. However, there was a clear decrease in stat3 phosphorylation when PEP 
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concentration fell below 10 μM (Fig. S5.5E). These experiments indicated that phosphorylation 
of stat3 by PKM2 and the mutant were at physiological comparable conditions. 
5.3.3 Expression of R399E increased stat3 phosphorylation in cells and promoted cell 
proliferation 
We employed a PKM2 mutant R399E. Our experiments showed that the recombinant 
R399E existed mostly as a dimer and the mutant exhibited strong activity in phosphorylation of 
GST-stat3. We therefore questioned whether the R399E mutant would be active in 
phosphorylation of stat3 in cells. To this end, the HA-R399E was exogenously expressed in 
SW480 cells. Immunoblot of the nuclear extracts indicated a significant increase in the levels of 
phosphorylated stat3. This increase was not due to increase in cellular levels of stat3 (Fig. 5.5E). 
Size exclusion chromatography of cell lysate showed that, unlike the wild-type HA-PKM2, the 
HA-R399E was almost complete dimer (Fig. S5.5F) In vitro phosphorylation assays indicated 
that the purified HA-R399E phosphorylated GST-stat3 (Fig. 5.5F). We also tested here if 
expression of R399E in SW480 cells would lead to MEK5 up-regulation and cell proliferation. 
RT-PCR analyses clearly demonstrated that the cellular levels of mRNA of MEK5 increased 
significantly (Fig. 5.5G). Examination of cell proliferation using a commercial kit demonstrated 
that expression of R399E led to a strong increase in cell proliferation (Fig. 5.5H). To further 
verify the role of PKM2 protein kinase activity in promoting cell proliferation, we created a cell 
line by stable expression of R399E in SW480 cells (Fig. 5.6E). The derived cells were implanted 
to nude mice by s.c. Tumors were grown for four weeks. Clearly, the R399E mutant expressing 
tumors grew substantially bigger than the wild type PKM2 expression tumors did (Fig. 5.6 
A&B&C). Histology analyses using anti-Ki-67 antibody indicated that the R399E expressing 
tumors had much higher proliferation rate than that of the wild type PKM2 expressing tumors 
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(Fig. 5.6D). The results strongly support our hypothesis that protein kinase activity of PKM2 
promotes tumor/cell proliferation. 
5.3.4 PKM2 protein kinase substrates bind to the ADP binding site 
PKM2 directly phosphorylates stat3. One interesting question is how the protein substrate 
is bound to PKM2. Our results showed that PEP was used as phosphate donor. It is established 
that in the catalysis of ADP phosphorylation in the glycolysis, PKM2 binds phosphate donor 
PEP at one site and substrate ADP at the other. Thus, a very logic assumption is that the protein 
substrate may bind to the ADP site. To test this conjecture, we carried out competition binding 
analyses. The R399E mutant and stat3 interaction was analyzed in the presence and absence of 
ADP, PEP, and FBP. The GST-stat3 was immobilized on the glutathione-agarose beads. 
Recombinant R399E in mixing with buffer, ADP, PEP, or FBP were incubated with the beads. 
Binding of the R399E to the immobilized GST-stat3 was then analyzed by SDS-PAGE followed 
by immunoblot of R399E and stat3. It was clear that the interaction of R399E with GST-stat3 
was not affected in the presence of 5 mM FBP, while the interaction was almost not detectable in 
the presence of 5 mM ADP. The R339E and stat3 interaction was also weakened in the presence 
of 5 mM of PEP. This was most likely due to phosphorylation of stat3, as the reduction in stat3 
and R399E interaction was not PEP concentration dependent, while the R399E and GST-stat3 
interaction showed a clear ADP concentration dependent reduction (Fig. 5.5I), indicating the 
competition of ADP with stat3 in binding R399E. The notion that protein kinase substrate is 
bound at the ADP binding site of PKM2 was also supported by our early observations that 
addition of ADP decreased the activity of PKM2 in phosphorylation of stat3, while addition of 
FBP did not (see Fig. 5.4C/D and 5.5C). 
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5.3.5 Reciprocal regulation of protein kinase and pyruvate kinase activities of PKM2 by 
tyrosine phosphor-proteins 
Christofk and co-workers reported that PKM2 interacts with phosphor-tyrosine peptide 
and the interaction plays an important role in promoting cell proliferation (Christofk, Vander 
Heiden et al. 2008; Christofk, Vander Heiden et al. 2008), suggesting a possible pathway that 
growth signals promotes proliferation via protein tyrosine phosphorylation and subsequent action 
on PKM2. We previously demonstrated that P68 RNA helicase is phosphorylated in cancer cells, 
and tyrosine phosphorylation of p68 correlates with cancer progression (Yang, Lin et al. 2005). 
Phosphorylation of p68 at Y593 promotes EMT (Yang, Lin et al. 2006), while phosphorylation 
of p68 at Y593 and Y595 mediated resistance to apoptotic-induction (Yang, Lin et al. 2007). In 
an effort to probe interacting protein with the tyrosyl phosphorylated p68, we used a 14 amino 
acid segment that includes the Y593 or Y593/595 phosphorylation site (a.a. 587 to 600). The 
peptides either carried no phosphorylation (PepY593), Y593 phosphorylation (PhosPepY593), or 
Y593/595 double phosphorylations (D-PhosPepY593). We also used another control peptide that 
span different region of p68 (aa 561 – 574) with Y567 phosphorylation (PhosPepY567). The 
peptides were conjugated to agarose beads. Precipitation experiments with nuclear extracts of 
T98G cells demonstrated that the D-PhosPepY593 pulled-down a nuclear protein that migrated 
at ~60 kDa. The interacting protein was identified by MALDI (tof/tof) as PKM2 (Fig. 5.7A). The 
interaction between p68 and PKM2 was first verified by a peptide pull-down with recombinant 
PKM2 (rPKM2) and the pull-down with nuclear extracts of T98G cells using the rPKM2 as bait 
(Fig. 5.7B and S5.6A). We also verified the interaction by co-immunoprecipitation with nuclear 
extracts of T98G cells (Fig. 5.7C and Fig S5.6B). To test whether the PKM2 and p68 interaction 
is the p68 phosphorylation dependent, we carried out co-immunoprecipitation experiment with 
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the nuclear extracts of T98G cells in which HA-p68, wt or Y593F (a p68 mutant that cannot be 
phosphorylated), was expressed. It was clear that wt HA-p68 co-precipitated with PKM2, while 
the Y593F mutant did not (Fig. 5.7C), suggesting that p68 tyrosine phosphorylation is required 
for PKM2 and p68 interaction. 
We reasoned what is the function of the interaction between the phosphor-p68 and PKM2. 
It is believed that PKM2 exists as tetramer and dimer mixture in cells (Ashizawa, Willingham et 
al. 1991; Mazurek, Boschek et al. 2005). We speculated whether the interaction of PKM2 with 
the phosphor p68 might promote the conversion of PKM2 from a tetramer to a dimer. To test this 
conjecture, we employed three phosphorylated/unphosphorylated peptides, the D-PhosPepY593, 
the PhosPepY567, and the PepY593. We first examined the interaction of the selected peptides 
with the rPKM2 by monitoring the Trp fluorescence changes of the rPKM2 upon interaction. It 
was clear that the D-PhosPepY593 interacted with the rPKM2 with Kd around 30 μM, while the 
PhosPepY567 and the PepY593 did not (Fig. S5.7 A, B, and C). It was suggested that the 
tyrosine phosphor-peptide interacts with PKM2 at FBP binding site (Christofk, Vander Heiden et 
al. 2008). We therefore examined whether the D-PhosPepY593 interacts with the rPKM2 at FBP 
binding site by testing the interaction in the presence of excessive amounts of FBP. It was clear 
that FBP competed with the D-PhosPepY593 (Fig. S5.7 A, B, and C). The competition of FBP 
with p68 for binding to PKM2 was also revealed by co-immunoprecipitation experiment 
showing that coprecipitation of p68 with HA-PKM2 in T98G cell extracts decreased by 
supplementing the extracts with different concentrations of FBP (Fig. 5.7D). The similar co-
immunoprecipitation experiment was also carried out with the rPKM2 and the HA-p68 
immunopurified from T98G cell extracts in the presence of various concentrations of FBP. High 
concentration of FBP decreased the HA-p68 and the rPKM2 interaction (Fig. S5.7D). It is 
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reported that W515–G520 located at the activating loop of C-terminal of PKM2 is critical for the 
FBP binding (Dombrauckas, Santarsiero et al. 2005). Thus, we created a truncation mutant with 
deletion of W515 – G531. The interaction of the phosphor-p68 with the PKM2 truncation was 
examined by the coimmunoprecipitation procedure. It was evident that the deletion of the FBP 
binding activating loop abolished the interaction between p68 and PKM2 (Fig. 5.7E). Meanwhile, 
a mutation (K270M) that affects the glycolytic substrate binding (Dombrauckas, Santarsiero et al. 
2005) did not affect the interaction between p68 and PKM2 (Fig. 5.7E). These results are 
consistent with the observations by Christofk and co-workers (Christofk, Vander Heiden et al. 
2008), indicating that the phosphorpeptides D-PhosPepY593 and phosphor-p68 interact with 
PKM2 at the FBP binding site. We next examined the effects of binding the phosphor-peptides 
on the tetramer and dimer formation. We used size exclusion chromatography method to analyze 
the molecular sizes of the rPKM2 in the presence or absence of the three tyrosine 
phosphor/unphosphor-peptides and compared to the chromatography profile of molecular size 
standard. It was evident that there were substantially more dimeric PKM2 in the presence of D-
PhosPepY593, while the tetramer and dimer ratio of the rPKM2 was not affected in the presence 
of the PhosPepY567 and the non-phosphor-peptide PepY593 (Fig. 5.7F). The experiments 
apparently suggested that binding the tyrosyl phosphorpeptide converts tetramer PKM2 to a 
dimeric form. 
We then asked whether binding of the tyrosyl phosphor-protein//peptide would activate 
the protein kinase activity and inactive pyruvate kinase activity of PKM2. To this end, the in 
vitro phosphorylation reactions using GST-stat3 as substrate and PEP as phosphate donor were 
carried out with the rPKM2 in the presence of the different peptides. Examination of 
phosphorylation of stat3 by the immunoblot using the anti-phospho-stat3 antibody indicated that 
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phosphorylation of stat3 by the rPKM2 was dramatically increased in the presence of 
DPhosPepY593  (Fig. 5.8A). The phosphorylations of stat3 by the rPKM2 were not affected in 
the presence of the PepY593. The phosphorylation of stat3 was also not affected in the presence 
of peptide PhosPepY567 that did not bind to PKM2 (Fig. 5.8A). As a control, the peptide 
DPhosPepY593 did not affect the phosphorylation of GST-stat3 by R399E, and the peptide alone 
did not lead to stat3 phosphorylation (Fig S5.8A). We next tested whether indeed presence of 
phosphor-p68 would activate the protein kinase activity of PKM2. To this end, HA-p68 was 
immunopurified from nuclear extracts of T98G cells. Phosphorylation of GST-stat3 by the 
rPKM2 in the presence or absence of the immunopurified HA-p68 was examined. Clearly, stat3 
was much strongly phosphorylated by the rPKM2 in the presence of the purified HA-p68 (Fig. 
5.8B). On the other hand, the protein kinase activity of PKM2 purified from p68 knockdown 
cells was significantly decreased (Fig S5.8B). The results support the notion that binding of the 
tyrosyl phosphor-protein activates the protein kinase activity of PKM2. 
PKM2 is a glycolysis enzyme. It is believed that the tetramer form of the protein is 
catalytic active in catalyzing the conversion of PEP to pyruvate in the glycolysis. Since the 
binding of the tyrosine phosphor-protein promoted the conversion from tetramer to dimer, we 
reasoned that binding the tyrosine phosphor-protein/peptide to PKM2 should result in protein 
that is less active in catalyzing the conversion of PEP to pyruvate. We used the method similar to 
that is described by Christofk and coworkers (Christofk, Vander Heiden et al. 2008) to monitor 
the pyruvate kinase activity of the rPKM2 in the presence of the tyrosine phosphor-peptides. The 
rPKM2 catalytic activity was dramatically reduced in the presence of D-PhosPepY593, while the 
activity was not affected in the presence of the peptides PhosPepY567 and PepY593 (Fig. 5.8C), 
which indicate that binding of PKM2 to the tyrosine phosphor-proteins converted the protein to 
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dimer and consequently reduced the glycolytic enzyme activity. The notion was further 
supported by the experiments that the pyruvate kinase activity of the R399E was dramatically 
decreased compared to that of recombinant wild-type (Fig. 5.5D). In addition, examination of 
p68 and stat3 phosphorylation levels in different cancer cells revealed a correlation (Fig S5.8 
C&D), suggesting a potential role of phosphor-p68 in activating the PKM2 protein kinase 
activity in phosphorylation of stat3 in cancer cells. 
Our experiments thus far demonstrate that tyrosine phosphor-p68 interacts with PKM2 at 
the FBP site and strengthen the protein kinase activity of the protein. We therefore predict a three 
ways interaction among the phosphor-p68, PKM2, and stat3. To test this possible protein 
interaction, we carried out the GST-pull down using the GST-stat3, the rPKM2 and HA-p68 that 
were immunopurified from T98G cell extracts. Immunoblot demonstrated that both the rPKM2 
and HA-p68 were co-precipitated with GST-stat3 (Fig. 5.8D). The three ways interaction was 
also probed by co-immunoprecipitation experiments using anti-HA antibody. The rPKM2 and 
GSTstat3 were co-precipitated with HA-p68 that was immunopurified from cellular extracts of 
T98G cells (Fig. 5.8E). These results provided additional support for the notion that interaction 
with tyrosyl phosphor-protein increase protein kinase activity of PKM2. The results also provide 
additional support for the notion that protein kinase substrate binds to the ADP binding site of 
PKM2. 
It is well documented that stimulation of cells by growth factors and cytokines results in 
activation of various protein tyrosine kinases that subsequently phosphorylates many protein 
substrates (Hunter and Cooper 1985). For instance, we previously demonstrated that PDGF or 
EGF stimulation led to tyrosine phosphorylation of p68 RNA helicase (Yang, Lin et al. 2005; 
Yang, Lin et al. 2007). Presently our experiments demonstrated that binding to tyrosine 
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phosphor-protein converted PKM2 from tetramer to dimer therefore activated the protein kinase 
activity. We reason whether treatment of cells with growth factors would affect PKM2. Thus, 
SW480 cells were treated with EGF. The same chromatography procedure used for detecting the 
PKM2 tetramer vs dimer in crude cell extracts was employed here to analyze the tetramer and 
dimer ratio of PKM2 in cells under the stimulation of EGF. It was clear that the levels of dimer 
PKM2 in growth factor stimulated cells were significantly higher than that in corresponding 
unstimulated cells (Fig. 5.9A). Immunoblot analyses of PKM2 in nuclear and cytoplasmic 
extracts suggested that growth factor stimulation led to increase in nuclear PKM2 levels (Fig. 
5.9B). Analyses of protein tyrosine phosphorylation and p68 tyrosine phosphorylation revealed 
that there was a substantial increase in protein tyrosine phosphorylation and tyrosine 
phosphorylation of p68 at tyrosine residue (Fig. 5.9C). These experiments suggested that indeed 
there is a clear correlation between the levels of protein tyrosine phosphorylations and dimeric 
PKM2 in cells, which is inducible by growth factors and cytokines. 
5.4 Discussion 
During tumor progression, growth signals stimulate the conversion of glycolytically 
active PKM2 to an inactive form, consequently regulating the glycolysis pathway to channel the 
carbon source from glucose for biosynthesis (Mazurek and Eigenbrodt 2003; Garber 2006; 
Christofk, Vander Heiden et al. 2008; Deberardinis, Sayed et al. 2008). It is conceivable that 
tumor cells need to coordinate the metabolism alterations with expression of genes that are 
related to cell proliferation. PKM2 has long been recognized as a so-called ‘moonlight’ enzyme 
that plays a very important role in tumor progression (Sriram, Martinez et al. 2005). Clearly, the 
protein kinase activity of PKM2 and subsequent activity in transcription regulation is an 
important ‘moonlight’ activity. The functions of PKM2 in regulating expression of genes fulfill 
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the role of feedback signaling from metabolic alterations to gene regulation during tumor 
malignancy transformation (see model in Fig. 5.9D). 
We show that protein kinase activity of PKM2 is associated with proliferation. Thus, it is 
conceivable that the growth signals must also regulate protein kinase activity of PKM2. Our 
studies demonstrate here that tyrosine phosphorylations of various cellular proteins under growth 
stimulations facilitate the interaction between tyrosine phosphor-protein and PKM2, which will 
result in tetramer to dimer conversion of PKM2. This conversion leads to inactivation of 
pyruvate kinase and activation of protein kinase activities of PKM2 (Fig. 5.9D). The reciprocal 
and reversible regulation of pyruvate kinase and protein kinase activities of PKM2 functions in 
altering cell metabolism and coordinating the metabolism adjustments with other cellular 
processes in response to growth stimulations. It is intriguing that interaction with FBP facilitates 
PKM2 to form a tetramer, while binding to tyrosine phosphor-proteins promotes a dimer 
formation. Why these phosphor-molecules have just opposite effects is an open question. It is 
intriguing that a glycolytic enzyme can function as a protein kinase and translocate to the nucleus 
acting on gene transcription. It was revealed from x-ray crystallography structural analyses of the 
tetramer PKM2 that the ADP binding site is formed by a large hydrophobic hole, indicating a 
great flexibility for nucleotide binding (Muirhead, Clayden et al. 1986; Dombrauckas, 
Santarsiero et al. 2005). The large hydrophobic hole at the nucleotide binding site is almost 
completely buried in a tetramer structure, while it would be completely accessible with the 
dimeric form. Thus, it is conceivable that the nucleotide binding site may be able to 
accommodate a protein substrate when PKM2 is converted to a dimer. It should be pointed out 
that our results could not exclude a possibility that ADP and stat3 do not bind at the same site. 
The competition is due to binding of ADP cause conformational changes at the stat3 binding site. 
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Stat3 is a transcription activator that is activated in response to inflammatory cytokines, such as 
IL-6 (Gao, Mark et al. 2007; Watson and Neoh 2008). Strikingly, activation of stat3 represents 
probably one of the most important molecular signatures involved in promoting cancer 
progression. It has been observed that activation of stat3 is detected in almost all cancer types 
(Frank 2007; Huang 2007; Kim, Chan et al. 2007; Groner, Lucks et al. 2008). However, it is 
generally believed that activations of stat3 in response to growth factor and cytokines are usually 
transient. A long standing question is “How do the malignant cancer cells maintain constitutive 
activation of stat3?” Currently, mutation(s) that lead to constitutive activation of stat3 have not 
been identified. Thus, activation of stat3 by PKM2 in malignant cancer cells potentially provides 
a very attractive explanation for this long-standing question. Whether stat3 is the only PKM2 
substrate for its protein kinase activity is an open question. PKM2 interacts with several other 
proteins (Garcia-Gonzalo, Cruz et al. 2003; Lee, Kim et al. 2008; Spoden, Morandell et al. 2009). 
It was also speculated that PKM2 purified from hepatoma tumour cells may be able to 
phosphorylate histone H1 (Ignacak and Stachurska 2003). Thus, it will be very interested to 
identify other PKM2 protein kinase substrates and uncover the putative cellular function of the 
corresponding protein phosphorylations. 
5.5 Materials and methods 
5.5.1 Reagents, cell lines, antibodies, and plasmids construction 
The KLH conjugated peptide spans a.a. 399 – 412 of PKM2 (IYHLQLFEELRRLAPI) 
was synthesized by Global Peptide Services. PKM2 polycolonal antibody and anti-HA antibody 
was raised in the animal facility of Georgia State University. The peptides, D-PhoPepY593, 
PepY593, and PhosPepY567, were synthesized by AnaSpec. Antibodies against stat3, 
stat3(pY705), HA-tag, GAPDH, Lamin A/C, and β-actin were purchased from Cell Signaling, 
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Abnova, SantaCruz, Abcam, and AnaSpec respectively. Recombinant GST-stat3 was purchased 
from Abcam. Cell lines SW480, SW620, T98G were purchased from ATCC and cultured by 
following the vendor’s instructions. Human full length cDNA of PKM2 and PKM1 were 
purchased from OriGene Technologies. The cDNA of PKM2 and PKM1 was subcloned into 
bacteria expression vector pET30a (+) as well as mammalian expression vectors pHM6. The 
PKM2 or its mutants were fused at the C-terminal of HA protein tag in pHM6 mammalian 
expression vector. Site directed mutagenesis were performed using QuikChange® Multi Site-
Directed Mutagenesis Kit (Stratagene). All the DNA clones and mutations were verified by auto-
DNA sequencing at GSU. The HA-tagged full length p68 (wild type, Y593F mutant) expression 
plasmids were constructed in pHM6 vectors as indicated in the previous papers from our lab 
(Yang et al., 2006). 
5.5.2 Expression and purification of recombinant PKM2 and PKM1 
The recombinant 6×his-PKM2, 6xhis-PKM1, or 6xhisPKM2 mutant was expressed in 
bacterial BL21-CodonPlus (DE3)-RIPL. The recombinant protein was expressed and 
accumulated in the bacterial inclusion body. After extensive washes, the bacterial inclusion 
bodies were dissolved into 8 M Urea pH = 7.5. The protein was then purified over a HiTrap® 
his-affinity column. The purified recombinant PKM2, PKM1, and PKM2 mutants was then 
refold by slow dilution into 10 folds refolding buffer (10 mM tris pH=7.5, 20% glycerol, 0.1 M 
KCl, 0.1 M EDTA, 1 mM DTT) and dialysis against refolding buffer. Purified protein was 
verified by immunobloting using antibody against PKM2. 
5.5.3 In vitro protein kinase and pyruvate kinase assays 
The bacterially expressed recombinant rPKM2/R399E or HA-PKM2/HA-R399E 
immunopurified from cellular extracts (10 μg/ml) were incubated with GST-stat3 (10 μg/ml) 
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under various conditions (indicated in the figure legends) with kinase buffer (50 mM Tris-HCl 
pH = 7.5, 100 mM KCl, 50 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, and 1 mM DTT) in 100 μl 
at room temperature for 1 hours. The phosphorylation reactions were carried out in the presence 
either 5 mM ATP or 5 mM PEP. The phosphorylation reactions were terminated by addition of 
20 μl of 4 x SDS-PAGE loading buffer and heated to 100 °C for 8 minutes. The reaction mixtures 
were then subjected to 10% SDS-PAGE separation and subsequent analyses. Pyruvate kinase 
activity was analyzed by following the experimental procedure similar to that was described by 
Christofk and co-workers (Christofk et al., 2008b). Briefly, the rPKM2 or the mutant R399E (at 
1 μM) was incubated with the buffer (100 mM Tris-HCl, pH=7.5, 100 mM KCl, 5 mM MgCl2) 
containing 1 mM ADP and 0.5 mM PEP. The reaction also contained 200 μM NADH and 10 μM 
FBP. After incubation at room temperature for 30 minutes, 8 units of LDH (Calbiochem) were 
added to the reaction. The reactions were then subsequently analyzed by measuring the 
absorbance at 340 nm. The pyruvate kinase activity was presented as relative pyruvate kinase 
activity by define the activity of the rPKM2 as 100. 
5.5.4 Gel-mobility shift and super-shift assays 
The mobility shift assays were carried out with oligonucleotide that harbors a stat3 binding 
sequence 5’-GATCCTTCTGGGAATTCCTAGATC-3’ (Xie et al., 2006). The oligonucleotide 
was 5’-end 32P-labeled. The labeled oligonucleotide (100 pmole) was incubated with 15% 
nuclear extracts (20 μl) prepared from appropriate cells as indicated in the figure legends for 30 
minutes at room temperature in the binding buffer (5% glycerol, 1mM MgCl2, 0.5mM EDTA, 
0.5mM DTT, 50mM NaCl, 10mM Tris-HCl, 0.05mg/ml poly(dI-dC)). The protein-
oligonucleotide complexes were separated in 4% native polyacrylamide gel (acrylamide: 
polyacrylamide 59:1). For supershift analyses, a monoclonal antibody against stat3 (invitrogen) 
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or the antibody PabPKM2 was added to the oligonucleotide-nuclear extracts mixture and 
incubated for additional 45 minutes. The complexes in gel were transferred to a membrane and 
subjected to autoradiography. 
5.5.5 Size-exclusion chromatography and non-denaturing gel electrophoresis 
Size exclusion chromatograph was performed with a Superdex 200 10/300GL column 
using the Akta purifier 100 FPLC system. The samples of cytoplasmic extracts, nuclear extract, 
the rPKM2, the recombinant PKM2 mutants, and the immunopurified HA-PKM2/HA-R399E 
were prepared in tris-HCl buffer (50 mM tris, 0.15 M NaCl pH 7.2). 6-AcA (600 mM) was 
added to the protein samples to disrupt the non-specific protein-protein interactions. For the 
crude cellular extracts, the samples were prepared in 5 – 7 mg/ml of total protein. For the 
recombinant or the immunopurified proteins, the samples were prepared in concentration of 15 
μM. 100 μl of prepared sample was loaded into the Superdex 200 10/300GL column and eluted 
with elution buffer (50 mM phosphate, 0.15M NaCl pH7.2). The fraction of 300 μl was collected, 
and 50 μl of each fraction was analyzed by 10 % SDS-PAGE and followed by immunoblot using 
appropriate antibody. The elution profiles were compared to that of a size exclusion 
chromatograph calibration kits (GE Healthcare) under identical conditions. The elution profile 
was recorded based on the absorbance of elution fractions at 280 nm. The elution profile was 
plotted against LogMW according to vendor’s instructions. The treated cytoplasmic or the 
nuclear extracts (6 μl) were loaded on an 8% nondenaturing polyacrylamide gel (40:1 – 
acrylamide: bis-acrylamide). The gel was subject to immunoblot using the antibody PabPKM2. 
The molecular weight markers, BSA and Urease (Sigma), were loaded on the same gel and were 
visualized by ponceau S staining. 
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5.5.6 PKM2 and peptide interaction 
Interactions between the rPKM2 and its derived mutants were analyzed by monitoring the 
changes of tryptophan fluorescence of the recombinant protein PKM2 or the mutants (λex =285 
nm, λem =310-410 nm). The binding analyses were carried out with protein concentration 4 μM 
in the reaction buffer (50 mM tris, pH7.5, 100 mM KCl). Different peptides (100 μM) were 
titrated into the protein solution. All spectra were recorded at ambient temperature using a PTI 
spectrofluorimeter with a 1 cm path length cuvette. FBP was added in the protein solution with a 
final concentration of 2 mM. 
5.5.7 Nude mice xenograft 
Nude mice (nu/nu, 5 to 6 weeks old, Harlan Laboratory) were subcutaneously injected 
with 5 × 106 SW480 cells stably expressing PKM2 wild type, R399E mutant, or vector alone (6 
mice each group). Tumor formation and volumes were assessed every 2 days. Tumor volumes 
were measured by two perpendicular diameters of the tumors over a 4-week time course with the 
formula 4p/3 × (width/2)2 × (length/2). The tumors were collected and weighed at the end of the 
experiments. Tissue sections were prepared from harvested tumors, and stained using a 
commercially available antibody for Ki-67. Statistical analyses were done in comparison to the 
control group with a paired Student’s t test. 
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Figure 5.1 PKM2 regulates MEK5 transcription 
 (A) Nuclear localization of PKM2 in different cancer cells. Immunoblot analyses of PKM2 
using the antibody PabPKM2 (IB:PKM2) in nuclear extracts (NE) and whole cell lysates (WCL) 
of tendifferent cell lines (indicated). Blot of GAPDH (IB:GAPDH) is a control indicate no 
cytoplasmic protein contaminations in nuclear extracts. Blots of lamin A/C and H2A are loading 
controls. (B) RT-PCR analyses of cellular MEK5 mRNA levels in two pairs of cancer cells 
(indicated) in which PKM2 was exogenously expressed using the adeno-viral expression kit. The 
results are presented as fold increase in PCR products before and 48 hours after PKM2 
exogenous expression in the same cells. The level of PCR product from each cell line before 
PKM2 exogenous expression was defined as 1. (C) Expressions (IB:MEK5) and phosphorylation 
(IB: p-MEK5) of MEK5 in different cancer cells (indicated on top) were analyzed by 
immunoblot using antibodies against MEK5 and phosphorylated MEK5. HA-PKM2 was 
expressed (HAPK) in the cells using the adeno-viral expression kit (IB:HA). Vec were the cells 
infected with virus that carry the empty vector. (D) Expressions (IB:MEK5) and phosphorylation 
(IB:p-MEK5) of MEK5 in SW480 and SW620 cells (indicated) in which PKM2 was knocked 
down (PK) using the smart pool RNAi were analyzed by immunoblot using antibodies against 
MEK5 and phosphorylated MEK5. The cellular levels of PKM2 were analyzed by immunoblot 
of PKM2 (IB:PKM2). (E) (Bottom panel) RT-PCR analyses of cellular MEK5 mRNA levels in 
SW620 and WM266 cells (indicated) in which PKM2 was knocked down using a smart-pool 
RNAi (PK). NT represents the cells treated with non-target RNAi. The results are presented as 
fold changes in PCR products before and 48 hours after PKM2 knockdown in the same cells. 
The level of PCR products from each cell line that was treated with non-target RNAi was defined 
as 1. (Upper panel) Immunoblot analyses of cellular PKM2 in SW620 and WM266 cells 
(indicated) in which PKM2 was knocked down using a smart-pool RNAi (PK). (F) ChIP of the 
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MEK5 promoter (MEK5 promoter) using antibody against PKM2 in SW620 cells (αPK). ChIP 
using rabbit IgG was a negative control. ChIP using PCR primer pair targeting a region of exon 
1(MEK5 exon 1) of MEK5 gene (nt 342 – nt 542) is a negative control. ChIP targeting GAPDH 
promoter (GAPDH promoter) using antibody against PKM2 was another negative control. The 
primer pair positions are indicated. Inputs were PCR products from DNA extracts without ChIP. 
In (C), (D), and (E), Immunoblot of β-actin (IB:β-actin), and immunoblot of Lamin A/C 
(IB:Lamin A/C) in (A) are loading controls. Error bars in (B) and (E) are standard deviations of 
three measurements. 
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Figure 5.2 PKM2 upregulates MEK5 transcription via activation of Stat3 
 (A) Co-immunoprecipitation of PKM2 with stat3. PKM2 was immunoprecipitated from nuclear 
extracts prepared from SW620 and SW480 cells using the antibody PabPKM2 (IP:αPK). The 
immunoprecipitates were analyzed by immunoblot using antibodies against stat3 (IB:Stat3) or 
PKM2 (IB:PKM2). Ponceau S staining of IgG heavy chain (IgG HC) in the immunoprecipitates 
is the loading control. Immunoprecipitation using rabbit IgG (IP:IgG) was the control 
immunoprecipitation. (B) & (D) Expressions of MEK5 (IB:MEK5) in SW620/SW480 (B) and 
WM115/WM266 cells (D) (indicated) were analyzed by immunoblot the cell lysate (WCL) 
prepared from the cells in which stat3 was knocked down by RNAi (stat3, IB:Stat3). HA-PKM2 
was exogenously expressed in the stat3 knockdown cells (IB:HA). The blot of β-actin (IB: β- 
actin) are the loading controls. (C) & (E) RT-PCR analyses of cellular MEK5 mRNA levels in 
SW620/SW480 (C) and WM266/WM115 cells (E) (indicated) in which stat3 was knocked down 
by RNAi (stat3, IB:Stat3). HA-PKM2 was exogenously expressed in the stat3 knockdown cells 
(IB:HA). The results are presented as fold changes in PCR products before and 48 hours after 
stat3 knockdown and HA-PKM2 expression in the same cells. The level of PCR products from 
each cell line that was treated with non-target RNAi was defined as 1. In (B), (C), (D), and (E), 
NT represents the cells treated with non-target RNAi. Vec were the cells infected with virus that 
carry the empty vector. Error bars in (C) and (E) are standard deviations of three measurements. 
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Figure 5.3 PKM2 upregulates MEK5 transcription by promoting Stat3 DNA interaction 
and phosphorylation of Stat3 
(A) (Upper panels) ChIP of the MEK5 promoter (MEK5 promoter) using antibody against stat3 
in SW620 cells (αStat3). The cells were treated non-target RNAi (left, NT) or with RNAi target 
PKM2 (right, RNAi-PK), or HA-PKM2 was exogenously expressed in the cells (middle, HAPK). 
ChIP using rabbit IgG (IgG) was a negative control. Inputs were PCR products from DNA 
extracts without ChIP. The primer pair positions are indicated. (Lower panels) the cellular 
PKM2 (right) and HA-PKM2 (left) levels in SW620 cells that were treated with RNAi target 
PKM2 (PK) or with non-target RNAi (NT), or infected with virus that carry HA-PKM2 
expression vector (HAPK) or vector alone (Vec). (B) DNA-protein complex (Complex) 
assembled on a 32P-labeled oligonucleotide containing the stat3 targeting sequence in nuclear 
extracts prepared from SW620 cells (left panel) was detected by gel-shift and autoradiography. 
Probe indicates the free 32P-labeled oligonucleotide probe without addition of nuclear extracts. 
The antibodies against PKM2 (αPK), stat3 (αStat3), or no antibody (NoAb) was added to the 
complex to create supershift (Supershift) (right panel). (C) & (D) Supershift complex assembled 
with the 32P-labeled oligonucleotide and antibodies (indicated) in the nuclear extracts prepared 
from SW620 cells in which (D) PKM2 was knocked down by RNAi (PK) or (C) HA-PKM2 was 
exogenously expressed (HAPK) was detected by gel-shift and autoradiography. Probe only is the 
free probe without addition of nuclear extracts. The free probe (low exposure) is the loading 
control with 1/10 of exposure time in autoradiography. The quantification of the 
assembledcomplex and super shift complex were presented as percentage (Shifted/total x102) of 
probe in the shift complex calculated by Intensities of complex [complex (grey bars) or 
supershift (open bars)] divided by Intensities of total [free probe + complex + supershift). 
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Immunoblots at bottom of each panel indicate cellular levels of HA-PKM2 (IB:HA) and 
endogenous PKM2 (IB:PKM2). (E) & (F) The levels of Y705 phosphorylated stat3 (IB:p-Tyr-
Stat3) in the cell nucleus were analyzed by immunoblot of nuclear extracts (NE) prepared from 
SW620 cells in which HAPKM2 was expressed (E. HAPK) or endogenous PKM2 was knocked 
down using the smartpool RNAi (F, PK). The total cellular stat3 levels were analyzed by 
immunoblot analyses of stat3 (IB:Stat3) in whole cell lysate (WCL). In (E), immunoblot of HA-
tag (IB:HA) indicates the HA-PKM2 expression levels in the cells. In (F), immunoblot of PKM2 
(IB:PKM2) represents cellular PKM2 levels in the cells. Immunoblot of lamin A/C in (E) and 
(F), and β-actin in (A), (C), (D), (E), and (F) are the loading controls. NTs in (A), (C), (D), (E), 
and (F) mean the cells were treated with non-target RNAi. Vec in (A), (C), (D), (E), and (F) 
means the cells were infected with virus that carry the empty vector. 
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Figure 5.4 Phosphorylation of GST-Stat3 by the rPKM2 
Phosphorylation of GST-stat3 by the rPKM2 (A) and HA-PKM2 immunopurified from nuclear 
extracts of SW620 cells (B) in the presence of 5 mM ATP (ATP) or 5 mM of PEP (PEP) was 
revealed by immunoblot assays using antibody against Y705 phosphorylated stat3 (IB:pY-stat3). 
Immunoblot analyses using antibody against stat3 (IB:Stat3) indicates the amounts of GST-stat3 
used in each phosphorylation reaction. The bottom panels in (A) & (B) are the quantitative 
analyses of immunoblot signals. The error bars represent the standard deviations of four 
measurements. Phosphorylation of GST-stat3 by the HA-PKM2 (HA-PK) immunopurified 
fromthe nuclear (C) and the cytoplasmic (D) extracts of SW620 cells in the presence of 5 mM 
ATP (ATP) or 5 mM of PEP (PEP) was revealed by immunoblot assays using antibody against 
Y705 phosphorylated stat3 (IB:pY-stat3). The phosphorylation reactions were also carried out in 
the presence/absence of 5 mM of FBP (FBP), or 5 mM of ADP (ADP). The immunoblot of HA 
(IB:HA) indicates the amounts of HA-PKM2 used in each reaction. IgG HC is the ponceau S 
stain of antibody heavy chain, representing the amounts of antibody used in immunopurification 
of HA-PKM2 from the extracts. Coomassie blue staining (CBS) indicates the amounts of 
GSTstat3 and BSA used in each phosphorylation reaction. Vec were the cells infected with virus 
that carry an empty vector. (E) Size exclusion chromatography fractionation of nuclear (NE) and 
cytoplasmic (Cyto) extracts (100 μl) from SW620 cells. The fractions were collected using a 
FPLC at 300 μl per fraction. The collected fractions 6 to 17 from cytoplasmic extracts and 
fraction 9 to 18 from nuclear extracts were immunoblotted using the antibody PabPKM2. 
Fraction 11 (F11) co-eluted with 240 kDa and fraction 14 (F14) co-eluted with 120 kDa on the 
same column under identical conditions determined by size exclusion chromatography molecular 
weight calibration standard (see on-line supplementary Fig. S5 C&D). 
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Figure 5.5 Dimeric PKM2 is active protein kinase and expression of the R399E mutant 
promotes cell proliferation 
(A) Part of x-ray crystal structure of human PKM2. The structure was obtained from PDB 
bank DOI: 10.1021/bi0474923. The residue R399 and its interactive residues E418, D357, and 
E396 are high lighted in color. (B) Size exclusion chromatography fractionation of the wild-type 
rPKM2 and R399E mutant. The recombinant proteins 100 μl in 1.5 μM were loaded onto 
column. The chromatography fractions F10 – F18 were collected using a FPLC at 300 μl 
perfraction. The collected fractions were analyzed by immunoblot using the antibody PabPKM2 
(IB:PKM2). (C) Phosphorylation of GST-stat3 by the rPKM2 (10 μg/ml) (rPKM2) and R399E 
mutant (10 μg/ml) (R399E) in the presence of 5 mM ATP (ATP), 5 mM of PEP (PEP), 5 mM of 
FBP (FBP), and/or 5 mM ADP (ADP) was revealed by immunoblot assays using antibody 
against Y705 phosphorylated stat3 (IB:pY-stat3). Immunoblot analyses using antibody against 
stat3 (IB:Stat3) indicates the amounts of GST-stat3 used in each phosphorylation reaction. (D) 
Pyruvate kinase activity of the rPKM2 or R399E mutant (5 μg/ml) was analyzed by the method 
described by Christofk and co-workers. The pyruvate kinase activity was expressed as relative 
pyruvate kinase activity by define the activity in the rPKM2 as 100. (E) Phosphorylation of stat3 
in SW480 cells was examined by immunoblot analyses of the nuclear extracts (NE) using 
antibody against the Y705 phosphorylated stat3 (IB:pY-Stat3). PKM2 wild-type (HAPK) or the 
R399E (R399E) mutant was expressed in the cells by transient transfection. Immunoblots using 
anti-HA antibody (IB:HA) and anti-stat3 antibody (IB:Stat3) in the whole cell lysate (WCL) 
indicate the levels of stat3 and HA-PKM2/HA-R399E in the cells. Immunoblot of lamin A/C 
(IB:Lamin A/C) and β-actin (IB:β-actin) are loading controls. (F) Phosphorylation of GST-stat3 
by the HA-p68 and the HA-R399E mutant that were immunopurified from cell lysate of SW480 
178 
 
cells in the presence of 5 mM of PEP was revealed by immunoblot analyses using antibody 
against the Y705 phosphorylated stat3 (IB:pY-Stat3). The phosphorylation reactions were also 
carried out in the presence/absence of 5 mM of FBP (FBP), or 5 mM of ADP (ADP). The 
immunoblot of HA (IB:HA) indicates the amounts of HA-PKM2 or HA-R399E used in each 
reaction. IgG HC is the ponceau S stain of antibody heavy chain, representing the amounts of 
antibody used in immunopurification of the HA-PKM2 or the HA-R399E mutant from the 
extracts. (G) Expression of MEK5 mRNA in SW480 cells was analyzed by RT-PCR. HA-
PKM2(HAPK) or HA-R399E (R399E) was exogenously expressed in the cells. The results are 
presented as fold changes in PCR products before and 48 hours after HA-PKM2 or HA-R399E 
expression. (H) Cell proliferations of SW480 cells were measured using the cell proliferation kit. 
Cell proliferations were presented as fold changes in BrdU incorporation before and 48 hours 
after HA-PKM2 (HAPK) or HA-R399E (R399E) expression. The BrdU incorporation of the 
cells that were transfected with the empty vector (Vec) was defined as 1. (I) Interaction of 
GSTstat3 and R399E mutant in the presence of FBP (5 mM), PEP (5 mM), or various 
concentrations of ADP (10, 100, 1000 and 5000 μM) was analyzed by GST-pull-down using the 
glutathione beads. The co-precipitation of R399E with GST-stat3 was detected by immunoblot 
using the antibody against PKM2 (IB:PKM2). Immunoblots of precipitates using antibody 
against stat3 (IB: Stat3) indicate the amounts of GST-stat3 that was pulled-down by the 
glutathione beads. Error bars in (D), (G), and (H) are standard deviations of three independent 
measurements. Vec in (E), (F), (G), and (H) are the cells transfected with the empty vector. 
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Figure 5.6 The effects of PKM2 protein kinase activity on tumor growth 
PKM2 wild type (HAPK) or R399E mutant (R399E) was stably expressed in SW480 cells 
(IB:HA) and stat3 was phosphorylated in R399E mutant expressing cells (IB: pY‐stat3) (E). 
The derived cells were implanted to nude mice (six mice per group). The R399E tumors (R399E) 
grew substantially faster than that of PKM2 WT tumors (HAPK) in four weeks (A). Tumor 
growth was monitored by measuring tumor volumes every four days and the tumor volumes 
were calculated by formula Tumor volume = π/6 x (width) 2 x length (B). At end of four weeks 
growth, tumors were sliced out and weighted (C). Tissue sections were prepared from the 
harvested tumors and immune fluorescence stained with antibodies against Ki67 (Ab: Ki67, Red) 
and HA (Ab:HA, Green). The blue is DAPI stain of cell nucleus (D). In (A), (B), (C), (D), and 
(E), the Vec means the vector alone was expressed in the cells. The error bars in (B) are standard 
deviations from the measurements of six mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
181 
 
 
 
182 
 
Figure 5.7 Tyrosine phosphorylated p68 interacts with PKM2 
 (A) (Left panel) GelCode staining SDS-PAGE analyses of proteins pulled down from nuclear 
extracts of T98G cells by different peptides coupled to agarose beads. The peptides used are: the 
PepY593, the PhosPepY593, the D-PhosPepY593, and the PhosPepY567. The arrow indicates 
the protein band that was cut out and subjected to trypsin digestion followed by MALDI-tof/tof 
analyses. M is molecular weight markers. (Right panel) The amino acid sequence of PKM2. The 
bold and underlined sequence indicates the peptide fragments identified by MALDI-tof/tof. (B) 
Interaction of the peptides, the PepY593 and D-PhosphPepY593 with recombinant PKM2 
(rPKM2). The recombinant PKM2 pulled-downs (PD) by the peptides were examined by 
immunoblot using antibody against PKM2 (IB:PKM2). PD by rPKM2 is a control without 
peptide pull-down. Beads are the control pull-down using agarose beads alone. (C) 
Coimmunoprecipitations of exogenously expressed HA-p68s (WT and Y593F, Vec is vector 
alone) with endogenous PKM2 from nuclear extracts (NE) of T98G cells were examined by 
immunoblot with anti-HA (IP:PKM2, IB:HA). IBs of the nuclear extracts using anti-HA indicate 
the expression of HA-p68 (IB:HA). IBs of histone 2A (IB:H2A) are the loading controls. (D) 
Co-immunoprecipitation of p68 (IP:p68) with exogenously expressed HA-PKM2 in cellular 
extracts of T98G cells supplementary with various concentrations of FBP was examined by 
immunoblot using the anti-HA antibody (IB:HA). IgG HC is the ponceau S stain of antibody 
heavy chain, representing the amounts of antibody used in immunopurification of p68. (E) 
Coimmunoprecipitation of p68 with the exogenously expressed HA-PKM2 and mutants 
(indicated) in the cellular extracts prepared from T98G cells. In (upper panel), the antibody p68-
RGG was used as immunoprecipitation antibody (IP:p68). Co-immunoprecipitations of HA-
PKM2 and mutants with p68 were examined by immunoblot using antibody against PKM2. 
Immunoblot of p68 (IB:p68) indicated amounts of p68 that was immunoprecipitaed down. In 
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(lower panel), the anti-HA antibody was used as immunoprecipitation antibody (IP:HA). Co-
immunoprecipitations of p68 with HA-PKM2 and mutants were examined by immunoblot using 
antibody against p68 (IB:p68). IgG HC is the ponceau S stain of antibody heavy chain, 
representing the amounts of antibody used in immunoprecipitations. (F) Size exclusion 
chromatography fractionation of the wild-type rPKM2 in the presence of different peptides (3 
μM) D-phosPepY593 (upper panel), PepY593 (middle panel), and phosPepY567 (lower panel). 
The rPKM2 100 μl in 15 μM were loaded onto column. The chromatography fractions F10 – F18 
were collected using a FPLC at 300 μl per fraction. The collected fractions were immunoblotted 
using the antibody PabPKM2 (IB:PKM2). 
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Figure 5.8 Tyrosine phosphor-protein/peptide reciprocally regulates protein kinase and 
pyruvate kinase activity of PKM2 
 (A) Phosphorylation of GST-stat3 by the rPKM2 (10 μg/ml) and the R399E mutant (10 μg/ml) 
in the presence of different peptides (3 μM) D-phosPepY593, PepY593, and phosPepY567 
wasrevealed by immunoblot assays using antibody against Y705 phosphorylated stat3 (IB: pY-
stat3). (B) Phosphorylation of GST-stat3 by the rPKM2 (10 μg/ml) or the rPKM1 (10 μg/ml) in 
the presence of HA-p68 that was immunopurified from nuclear extracts of T98G cells and 5 mM 
of PEP was revealed by immunoblot assays using antibody against Y705 phosphorylated 
stat3(IB:pY-stat3). In some phosphorylation reactions, 5 mM of FBP (FBP) or 5 mM ADP (ADP) 
was added to the reaction. Immunoblots of stat3 (IB:Stat3), HA-p68 (IB:HA), and PKM2 
(IB:PKM2) indicate the amounts of GST-stat3, HA-p68, and the rPKM2 used in each 
phosphorylation reaction. (C) Pyruvate kinase activity of the rPKM2 (5 μg/ml) in the presence of 
different peptides (2 μM) D-phosPepY593, PepY593, phosPepY567, or buffer was analyzed by 
the method described by Christofk and co-workers. The pyruvate kinase activity of the rPKM2 
was expressed as relative pyruvate kinase activity by define the activity in the presence of Buffer 
as 100. The error bars represent the standard deviations of four measurements. (E) Interaction of 
GST-stat3, the bacterially expressed rPKM2, and the HA-p68 immunopurified from T98G cells 
was analyzed by GST-pull-down using the glutathione beads. The GST-stat3 (2 μg/ml), the 
rPKM2 (2 μg/ml), and the HA-p68 were incubated in 500 μl at room temperature. The GSTstat3 
was precipitated by the GST beads. Co-precipitations of the HA-p68 and the rPKM2 from the 
mixture were analyzed by immunoblot using antibodies against p68 (IB: p68) and PKM2 
(IB:PKM2). The strip blot using anti-phosphor-tyrosine indicates the tyrosine phosphorylation of 
the precipitated HA-p68. Immunoblot of stat3 (IB: Stat3) indicates the amounts of GST-stat3 that 
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were precipitated by GST beads. (E) Co-immunoprecipitations of PKM2 and stat3 with HA-p68 
in the cellular extracts of T98G cells. The exogenously expressed HA-p68 was 
immunoprecipitated using anti-HA antibody. The amounts of p68 precipitated from the extracts 
were examined by immunoblot using antibody against p68. The co-precipitation of PKM2 and 
stat3 were probed by immunblot using antibodies against PKM2 (IB:PKM2) and against stat3 
(IB:Stat3). IgG HC is the ponceau S stain of antibody heavy chain, representing the amounts of 
antibody used in immunoprecipitation of HA-p68 from the extracts.  
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Figure 5.9 Growth stimulation activates protein kinase activity of PKM2 
 (A) Size exclusion chromatography fractionation of cell lysate prepared from SW480 cells that 
were treated/untreated by 25 ng/ml EGF for 8 hours. The cell lysate (100 μl) were loaded onto 
the column. The chromatography fractions F9 – F20 were collected using a FPLC at 300 μl per 
fraction. The collected fractions were immunoblotted using the antibody against PKM2 (IB: 
PKM2). (B) The PKM2 levels in the nuclear extracts (NE) of SW480 cells that were treated with 
EGF (25ng/ml) at different time points (indicated) were examined by immunoblot of the nuclear 
extracts using antibody against PKM2 (IB: PKM2). Immunoblot analyses of PKM2 (IB: PKM2) 
in the whole cell lysate (WCL) indicate the cellular levels of PKM2. Immunoblot of β-actin 
(IB:β-actin) and lamin A/C (IB:Lamin A/C) were the loading controls. (C) Tyrosine 
phosphorylation of p68 in the in the nuclear extracts (NE) of SW480 cells that were treated with 
EGF (25 ng/ml) at different time points (indicated) were examined by immunoblot analyses of 
p68 that was immunoprecipitated (IP:68) from the extracts using the anti-phosphor-tyrosine 
antibody (IB:pY20). Immunoblot analyses of p68 (IB:p68) in the whole cell lysate (WCL) 
indicate the cellular levels of PKM2. Immunoblot of β-actin (IB:β-actin) was the loading control. 
(D) A hypothetic model that illustrates the functional role of PKM2 in gene transcription and the 
regulation of protein kinase and pyruvate kinase activities of PKM2. 
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Figure Supplement 5.1 
(A) Cell proliferations of ten cancer cell lines (indicated) were measured using a commercial cell 
proliferation kit. The proliferation rates are presented as fold changes of BrdU incorporation of 
the same cultured cells before and after 48 hours culturing by defining the initial BrdU 
incorporation as 1. (B) (Upper panel) Cellular levels of MEK5 and exogenously expressed HA-
PKM2 in WM266 and SW620 cells were analyzed by immunoblot using antibodies against 
MEK5 (IB:MEK5) and HA (IB:HA). MEK5 in the cells was knocked down by RNAi (PK). 
PKM2 was exogenously expressed in the cells using the adeno-viral expression kit. (Bottom 
Panel) Cell proliferations of WM266 and SW620 cells were measured using the cell 
proliferation kit. Proliferations of WM266 (1 – 4) or SW620 (5 – 8) cells were measured under 
following conditions: 1) and 5) Open bars, HA-PKM2 expression and no MEK5 knockdown; 2) 
and 6) Gray bars, HA-PKM2 was expressed and no MEK5 knockdown; 3) and 7) Black bars, no 
PKM2 expression and MEK5 knockdown; and 4) and 8) Striped bars, PKM2 expression and 
MEK5 knockdown. The proliferations are presented as fold changes of BrdU incorporation 
before and after indicated treatments. NT represents the cells treated with nontarget RNAi. Vec 
were the cells infected with virus that carry the empty vector. (C) Cellular MEK5 levels and 
phosphorylation of the protein in ten different cell lines (indicated at top) were examined by 
immunoblot of whole cell lysate using antibodies against MEK5 and phosphorylated MEK5. 
Immunoblots of β-actin (IB:β-actin) in (B) and (C) are loading controls. Error bars in (A) and (B) 
are standard deviations of three measurements. 
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Figure Supplement 5.2 
(A) & (B) Co-immunoprecipitations of endogenous PKM2 (A) and exogenous HA-PKM2 (B) 
with stat3 were analyzed by immunoprecipitation using antibody against stat3 (IP:α-stat3 in A) 
and anti-HA antibody (IP:HA in B) from nuclear extracts prepared from SW620 and SW480 
cells. The immunoprecipitates were analyzed by immunoblot using antibodies against stat3 
(IB:Stat3) or PKM2 (IB:PKM2). Ponceau S staining of IgG heave chain (IgG HC) in the 
immunoprecipitates is the loading control. Immunoprecipitation using rabbit IgG (IP:IgG) was 
the control immunoprecipitation. In (B), the immunoblot using anti-HA antibody was an 
additional loading control. (C) & (E), Expressions of MEK5 (IB:MEK5) in SW620/SW480 (C) 
and WM115/WM266 (E) cells were analyzed by immunoblot the whole cell lysate (WCL) 
prepared from the cells in which a stat3 dominant negative mutant (stat3-DN) and HA-PKM2 
(HAPK) were expressed (C, Upper) or PKM2 was knocked down (RNAi-PK) (C, Bottom). 
Immunoblot of HA-Stat3DN (IB:HA-stat3DN) and HA-PKM2 (IB:HAPK) indicated the 
exogenous expression levels. Immunoblot of PKM2 indicated the cellular levels of PKM2. The 
cellular levels of phosphorylated MEK5 were also examined by immunoblot using the antibody 
against phosphorylated MEK5 (IB:p-MEK5). (D) & (F) RT-PCR analyses of cellular MEK5 
mRNA levels in SW620/SW480 (D) and WM266/WM115 (F) cells in which a stat3 dominant 
negative mutant (DNST) and HA-PKM2 (HAPK) were expressed. The results are presented as 
fold changes in PCR products before and 48 hours after the dominant negative stat3 mutant and 
HA-PKM2 expression in the same cells. The level of PCR products from each cell line that was 
infected with virus that carry the empty vector (Vec) and no stat3 mutant expression was defined 
as 1. (G) Expressions of MEK5 (IB:MEK5) in SW620/WM266 cells (indicated) were analyzed 
by immunoblot the whole cell lysate (WCL) prepared from the cells in which HAPKM2 was 
exogenously expressed (HAPK) and that were treated with the stat3 inhibitor (Inhibitor). Cells 
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treated with DMSO (the same amounts as used in inhibitor treatments as solvent for dissolve the 
inhibitor) are the control treatments. (H) RT-PCR analyses of cellular MEK5 mRNA levels in 
SW620/WM266 cells. The results are presented as fold changes in PCR products before and 48 
hours after the dominant negative stat3 mutant and HA-PKM2 expression in the same cells. The 
level of PCR products from each cell line that was infected with virus that carry the empty vector 
(Vec) and no stat3 mutant expression was defined as 1. In (C), (E), and (G), immunoblot of β-
actin (IB:β-actin) is the loading control. Error bars in (D), (F), and (H) are standard deviations of 
three measurements. 
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Figure Supplement 5.3 
(A) & (B) Activation JAK2 (A) or c-Src (B) in SW620 cells in which HA-PKM2 was expressed 
(HAPK) was analyzed by immunoblot of cytoplasmic extracts (Cyto) using antibody against 
phosphorylated JAK2 (A, IB:p-JAK2) or antibody against phosphorylated c-Src (B, IB:p-c-Src). 
Vec means the cells were infected by virus carry the empty vector. Immunoblots of JAK2 
(IB;JAK2) in (A) and c-Src (IB:Src) in (B) are loading control. Immunoblot of β-actin is another 
loading control. The expression levels of HA-PKM2 were examined by immunoblot of HA-tag. 
(C) Phosphorylation of stat3 was examined by immunoblot analyses of nuclear extracts (NE) 
prepared from SW620 cells that were treated by JAK2 (AG490) inhibitor or solvent DMSO 
(DMSO) using the antibody against Y705 phosphorylated stat3 (IB:pY‐ stat3). Wild type 
(HAPK) or R399E mutant (R399E) was expressed in the cells. Vec represent the cells were 
transfected with empty vector. Immunoblot of lamina (IB:Lamin A/C) in nuclear extracts and 
immunoblot of stat3 (IB:stat3) and β‐actin (IB:β‐actin) in the whole cell lysate (WCL) are the 
loading controls. Immunoblot of HA indicates the exogenously expressed HAPK or R399E. 
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Figure Supplement 5.4 
(A) Chromatographic elution profile of the molecular weight calibration kit proteins (indicated) 
on the Superdex 200 10/300GL column. The x-axis is the elution volume. The y-axis is the 
absorbance of the elution at 280 nm. (B) The standard curve of elution of the molecular weight 
calibration kit proteins on the Superdex 200 10/300GL column. The elution volumes were 
plotted against LogMW. (C) Immunoblot analyses of PKM2 in the cytoplasmic (Cyto) and 
nuclear (NE) extracts of SW620 cells. The extracts (6 μl) were treated and loaded on an 8% non-
denaturing gel electrophoresis. The gel was subjected to immunoblot using the antibody 
PabPKM2 (IB:PKM2). The molecular weight markers, BSA (dimer) and Urease (trimer), were 
loaded on the same gel and were visualized by ponceau S staining (ponceau S stain). 
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Figure Supplement 5.5 
(A) Phosphorylation of GST-stat3 by the rPKM2 (10μg/ml), the rPKM1 (10 μg/ml), or the 
R399E mutant (10 μg/ml) in the presence of 32P-PEP (~0.002 μCi) and unlabeled PEP (5 mM). 
The reaction mixture were separated by 10 SDS-PAGE and subjected to autoradiograph. (B) 
Phosphorylation of GST-stat3 by a recombinant JAK2 (JAK2, 10 μg/ml) in the presence of 3 
mM ATP or the bacterially expressed R399E mutant (R399E, 10 μg/ml) in the presence of 5 mM 
PEP (PEP) was revealed by immunoblot assays using antibody against Y705 phosphorylated 
stat3 (IB:pY-stat3). Phosphorylation of recombinant stat5 (C) and BSA (D) by the recombinant 
R399E were analyzed by immunoblot using antibody against phosphorylated stat5 (IB:pY‐stat5 
in (C)) and antibody against phosphor‐tyrosine antibodies (IB: pY10 and IB:pY100). Ponceau 
stain of stat5 (stat5) and BSA (BSA) indicate the amounts recombinant stat5 and BSA used in 
the phosphorylation reactions. (E) Phosphorylation of GST-stat3 by the bacterially expressed 
R399E mutant (R399E, 10μg/ml) in the presence of different concentrations of PEP (indicated) 
was revealed by immunoblot assays using antibody against Y705 phosphorylated stat3 (IB:pY-
stat3). (F) Size exclusion chromatography fractionation of the wild-type HA-PKM2 (HAPK) or 
HA-R399E (R399E) that were immunopurified from SW480 cell lysate. The HA-PKM2 or HA-
R399E (100 μl in 0.4μg/μl) was loaded onto the column. The chromatography fractions F9 – F18 
were collected using a FPLC at 300 μl per fraction. The collected fractions were immunoblotted 
using the anti-HA antibody (IB:HA). Immunoblot analyses using antibody against stat3 (IB:Stat3) 
in (B) and (E) indicates the amounts of GST-stat3 used in each phosphorylation reaction. 
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Figure Supplement 5.6 
(A) Pull-down (PD) of p68 from nuclear extracts (NE) of T98G cells by recombinant PKM2 
(rPKM2) was examined by immunoblot using antibody p68-RGG (IB:p68-RGG). The tyrosine 
phosphorylation of p68 was indicated by strip-blot of the pulldown using antibody against 
phospho-tyrosine (IB:PY20). Beads is the control pull-down using agarose beads alone. (B) (Up 
panel) Co-immunoprecipitations of p68 with endogenous PKM2 from nuclear (NE) and 
cytoplasmic (Cyto) extracts of T98G cells were examined by immunoblot with antibody p68-
RGG (IP:PKM2, IB:p68-RGG). (Lower panel) Co-immunoprecipitations of p68 with 
exogenously expressed HA-PKM2 from nuclear (NE) and cytoplasmic (Cyto) extracts of T98G 
cells were examined by immunoblot with antibody p68-RGG (IP:HA, IB:p68-RGG). IBs of HA-
PKM2 indicate the immunoprecipitateded HA-PKM2 from the extracts. IBs of GAPDH 
(IB:GAPDH) and lamin A/C (IB:Lamin A/C) are the loading controls. 
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Figure Supplement 5.7 
(A) Trp fluorescence emission spectrum of the rPKM2 (4μM) with the titration of various 
different concentrations (indicated) of peptide D-PhosPepY593. Binding of the peptide to the 
rPKM2 was indicated by the decrease in fluorescence intensity at 334 nm. (B) Trp fluorescence 
emission intensity of the rPKM2 at 334 nm in the presence of various peptides (2 μM) D-
PhosPepY593 (red circles), PepY593 (blue crosses), PhosPepY567 (green diamonds), and D-
PhosPepY593 + 2 mM FBP (black squares). Y-axis is the flurescence intensity at 334 nm. X-axis 
is peptide concentrations. (C) The dissociation constant (Kd) of the rPKM2 with the peptides D-
PhosPepY593, PepY593, and PhosPepY567 were determined by the data fitting to langmuir 
equation (assume 1:1 binding). The Kds were determined based on data fitting on three 
independent measurements. (D) Pull-down of the rPKM2 by the HA-p68 immunopurified from 
T98G cellular extracts (PD:HA-p68) was analyzed by immunoblot using antibody against PKM2 
(IB:PKM2). The Pull-down experiments were performed in the presence of various 
concentrations of FBP (indicated in figure). IgG HC is the ponceau S stain of antibody heavy 
chain, representing the amounts of antibody used in immunopurification of HA-p68. IB:p68 
indicate amounts of HA-p68 used in the pull-down. 
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Figure Supplement 5.8 
(A) Phosphorylation of GST‐stat3 by the rPKM2 (10μg/ml) and the R399E mutant (10 μg/ml) 
in the presence of different peptides (3 μM) D‐phosPepY593, PepY593, and phosPepY567 was 
revealed by immunoblot assays using antibody against Y705 phosphorylated stat3 (IB:pY‐
stat3). (B) Phosphorylation of stat3 by immunopurified HA‐PKM2 from nuclear extracts 
(HAPK) of SW620 cells in the presence of ATP or PEP was analyzed by immunoblot using the 
antibody against the Y705 phosphorylated stat3 (IB:pY‐stat3). P68 was knocked down by 
duplex RNAi. Immunoblot of stat3 (IB:stat3) shows the amounts of stat3 that were 
immunoprecipitated from the nuclear extracts. Immunoblot of HA (IB:HA) indicate the 
expression levels of HA‐PKM2. Ponceau S stain of IgG heave chain (IgG:HC) indicate the 
amounts of antibody used in each PKM2 purification from nuclear extracts. (C) (Upper panels) 
Phosphorylation of nuclear stat3 was analyzed by immunoblot using antibody against Y705 
phosphorylated stat3 (IB:pY‐ stat3) in the nuclear extracts prepared from different cells. 
immunoblot of stat3 (IB:stat3) indicate the stat3 levels in the nuclear extracts. Immunoblot of 
lamin (IB:Lamin A/C) is a loading control. (Bottom panels) Phosphorylation of p68 in nuclear 
extracts was analyzed by immunoblot of the immunoprecipitated p68 (IP:p68) using the antibody 
pY10 (IB:pY10). Immunoblot of p68 (IB:p68) indicate the amounts of p68 that was 
immunoprecipited from nuclear extracts (IB:p68). Pansaus stain of IgG heave chain (HC) 
indicate the amount of antibody used in each immunoprecipitation reaction. (D) Quantization of 
phosphorylation levels of stat3 (Upper panel) and the immunoprecipitated p68 (Bottom panel) 
in nuclear extracts of different cells. The phosphorylation levels of stat3 and immunoprecipitated 
p68 were presented as relative phosphorylation levels (pY‐ stat3/stat3) and (pYp68/p68) 
respectively. The error bars in are standard deviations from four independent experiments. 
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CHAPTER 6 
 CONCLUSION AND DISCUSSION  
6.1 Shuttling and translocation of p68 in cell migration 
6.1.1 P68 is a nucleocytoplasmic shuttling protein and calmodulin binding regulated the 
nuclear exportation of p68 in migrating cells  
P68 RNA helicase (p68) is a well known DEAD box family of RNA helicase protein. 
P68 is found to be dominantly located in the nucleus. However, studies indicate the existence of 
p68 in the cytoplasm. In this study, we found that p68 is a nucleocytoplasmic shuttling protein 
(Wang, Gao et al. 2009). Two functional nuclear localization signals (NLSs) and two functional 
nuclear export signals (NESs) were demonstrated to mediate the nucleocytoplasmic shuttling 
activity of p68. We found that the shuttling of p68 was mediated by a typical RanGTPase 
dependent pathway. However, the detail regulation mechanism behind the shuttling of p68 is not 
fully understood. P68 is dominantly located inside the nucleus in most of the cancer cells. We 
reasoned that the nuclear localization of p68 may be due to its functional NLSs that target p68 
into the nucleus after the protein has been translated. The nuclear localized p68 might be arrested 
by forming complex with some nuclear proteins or trapping in a particular nuclear structure, 
which leads to the residence of p68 in the nucleus. However, how p68 is exported to the 
cytoplasm and what is the function of p68 in the cytoplasm becomes an important question as 
more and more studies detected the existence of cytosol p68. In the initial experiment, 
calmodulin was fused to the C-terminal of p68 to artificially form the interaction between p68 
and calmodulin. Interestingly, high levels of the fusion protein localized into the cytoplasm when 
the cells expressed this fusion protein. Most importantly, the cells easily gained the migration 
status. We further found that the interaction between p68 and calmodulin was increased in 
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migrating cells. Meanwhile, there was transient increase in the levels of p68 and calmodulin in 
the cytoplasm in migrating cells than in the resting cells. We reasoned that binding of calmodulin 
to the IQ motif of p68 might promote the export of p68 to the cytoplasm, as the mutation at the 
IQ motif of p68 abolished the binding with calmodulin and the mutant no longer localized in the 
cytoplasm under the migration stimuli.  
6.1.2 Working model for the cytosol translocation of p68 through binding with Ca
2+
- 
calmodulin 
       P68 is predominantly located in the nucleus even though p68 is a nucleocytoplasmic 
shuttling protein. Many proteins localize at specific regions because of their interaction with a 
specific cellular structure or proteins. We reasoned that p68 retained in the nucleus may be due 
to the interaction of p68 with RNA (or RNA complex) in the nucleus, as p68 co-
immunoprecipitates with RNAs at physiological salt concentration (Iggo and Lane 1989). 
Several evidences showed that C-terminal of p68 may be involved in the binding of p68 to RNA. 
C-terminal of p68 is found to bind with ssRNA in vitro. Meanwhile, phosphorylation of C-
terminal of p68 can abolish the interaction between p68 and RNA (Yang, Yang et al. 2004). 
Under the stimulation of PDGF, more p68 is phosphorylated at Y593 in the cells. The 
phosphorylated p68 may be released from the RNA complexes and exported to the cytosol. The 
cytosolic translocated phosphorylated p68 subsequently carry beta-catenin back to the nucleus in 
order to regulate the EMT related gene expression.  IQ motif exists in the C-terminal of p68. 
Interestingly, IQ motif of p68 is also believed to be involving in RNA binding. The IQ motif also 
harbors the site of PKC (serine/threonine kinase) phosphorylation of p68 (Buelt, Glidden et al. 
1994). It is known that p68 alone has no ATPase activity. The RNA dependent ATPase activity 
of p68 requires the interaction with RNA. Interestingly, RNA dependent ATPase activity of p68 
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is decreased when p68 is phosphorylated by PKC at the IQ motif. This might be due to that the 
serine/threonine phosphorylated p68 at the IQ motif has lower affinity (or no) for RNA than the 
non-phosphorylated p68. Meanwhile, the phosporylation rate of p68 by PKC can be dramatically 
increased when p68 is pretreated with RNase. The removal of bound RNA may expose the IQ 
motif, which leads to the increase of the phosphorylation by PKC. All these evidences strongly 
support the idea that the IQ motif is the key site in regulating the binding of p68 to RNA (or 
RNA complex), which may determine the localization of p68 in the cell. 
      Interestingly, we found that more p68 exists in the cytosol of migrating cells than in the 
resting cells. Correspondingly, there is more cytosolic p68 in the highly metastatic colon cancer 
cells than in low metastatic cancer cells. P72 is a homologous protein of p68. P72 has a high 
similar sequence at the helicase core domain (91.8%) with p68 and has a low similar sequence 
(54.5%) at the C-terminal, specifically lacking of IQ motif. Interestingly, p72 is found to be 
dominantly located in the nucleus in both metastatic and non-metastatic cancer cells. The nuclear 
location of p72 seems not due to the absence of NESs in p72, as p72 carries similar functional 
NESs (sequence alignment and analysis). This further supports the idea that nuclear export of 
p68 in migrating cells might be regulated at the IQ motif of p68. 
      We reasoned that p68 may interact with RNA complexes and retained inside the nucleus 
when there is neither calmodulin binding nor phosphorylation at the IQ motif. P68 may be 
released from the RNA complexes when calmodulin binds to p68. This leads to the export of 
p68/calmodulin to the cytoplasm. Overall, Ca
2+
-calmodulin dissociates the p68/RNA complex is 
very possible, as the addition of Ca
2+
-calmodulin to the mixture of ATPase assay can abolish the 
RNA-dependent ATPase activity of p68 (Buelt, Glidden et al. 1994). PKC is activated in 
migrating cells. The dissociation of p68 from RNA complex could be maintained if PKC 
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phosphorylates the serine/threonine residue(s) at the IQ motif of p68 in migrating cells. The 
phosphorylation by PKC may require the binding of calmodulin to the IQ motif of p68. 
     
 
Figure 6.1 Working model about p68 cytosol exportation under the binding of Ca
2+
-
calmodulin 
IQ motif locates at the C-terminal of p68. The binding of CaM at the IQ motif of p68 
may not affect the helicase core structure of p68, as the p68/CaM complex has the RNA 
dependent ATPase activity. C-terminal of p68 is very dynamic according to the structure 
prediction of p68. We reasoned that the binding of CaM at IQ motif may regulate the C-terminal 
structure of p68. This may lead to the change of the binding affinity of C-terminal of p68 to 
RNA or other nucleur structure. Meanwhile, CaM binding at the C-terminal of p68 may expose 
the NESs of p68. The exposure of NESs of p68 may lead to the exportation of p68 to the 
cytoplasm. 
6.1.3 Nucleocytoplasmic shuttling p68 facilitated the translocation of its binding proteins 
Nuclear pore complex (NPC) is considered as the place to allow the molecules to get in 
or go out of the nucleus. It was reported that molecules smaller than 45-60 kDa can get through 
NPC by passive diffusion. The larger molecules or protein complexes require receptors to 
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mediate the transportation across NPC by carrying NES/NLS (Allen, Cronshaw et al. 2000). The 
large proteins can get through the NPC without their own NES/NLS. Their translocation depends 
on the association with other proteins which have NES/NLS. The permeability of NPC can be 
regulated. The passive diffusion of molecules larger than 10kDa but smaller than 45kDa can be 
prevented when the Ca
2+
 stores, such as endoplasmic reticulum (ER) or nuclear store, are 
emptied (Stehno-Bittel, Perez-Terzic et al. 1995; Perez-Terzic, Gacy et al. 1999). Therefore, the 
translocation of the molecules between 10kDa and 45kDa may still need to associate with other 
NES/NLS carrying proteins to get through the NPC. 
6.1.3.1 P68 shuttled calmodulin out of nucleus and functions in cell migration 
Calmodulin is a calcium sensor protein that exists as a monomer of 16.8 kDa. Calmodulin 
can regulate processes both in the cytoplasm and in the nucleus by transducing a Ca
2+
 signal into 
a cellular response. This biological process includes changes in cytoskeletal structure and gene 
expression. However, how the calmodulin move into or out from the nucleus is still controversial. 
Even though the molecular size of calmodulin is less than 45 kDa; the simple diffusion of 
calmodulin in/out of the nucleus through the NPC is unlikely. This is because most of the 
calmodulin is always associated with other protein in a Ca
2+
 dependent/independent manner. The 
binding of calmodulin to other proteins will make the molecule size too big to pass through NPC. 
There are less than 5% of the total calmodulin free in smooth muscle cells at resting status 
(Luby-Phelps, Hori et al. 1995). The facilitated transportation of Calmodulin is an effective way 
to translocate calmodulin to the nucleus as the facilitated transport of Ca
2+
/calmodulin into the 
nucleus was about 25-fold more rapid than passive diffusion (Thorogate and Torok 2004). 
Therefore, the facilitated transportation of calmodulin across the NPC is very important in 
mediating its cellular functions. 
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In this study, we found that p68 interacted with calmodulin in migrating cells. Both p68 
and calmodulin were found to be accumulated in the cytosol of migrating cells. The cytosolic 
localized p68 as well as p68-calmodulin fusion protein depend on the NES(s) of p68. Since 
calmodulin itself has no NES, we concluded that the cytosolic translocation of p68 together with 
calmodulin depends on the shuttling function of p68. Interestingly, we observed that calmodulin 
started to translocate and accumulate in the cytoplasm at one hour post migration stimulation. 
Calmodulin is known to be redistributed from cytosol to the nucleus in response to a rise of 
cellular Ca
2+
 (Luby-Phelps, Hori et al. 1995). When the intracellular Ca
2+
 is increased, the 
nuclear translocation of calmodulin is initiated at around 40 seconds (Thorogate and Torok 2004). 
The nuclear translocation of calmodulin can be completed in 260-300 seconds (Craske, Takeo et 
al. 1999; Teruel, Chen et al. 2000). We reasoned that when the cell received the stimuli to 
migrate, the cytoplasmic Ca
2+
 was upregulated and calmodulin was accumulated in the nucleus 
initially. Ca
2+
/calmodulin is shown to inhibit several nuclear events, such as transcription by 
direct interaction with the transcription factor (Corneliussen, Holm et al. 1994). We reasoned that 
the nuclear translocation of calmodulin might inhibit the binding of p68 to RNA, and might also 
inhibit the function of p68 as a transcription cofactor. Therefore p68/calmodulin was able to be 
relocated to the cytoplasm. This process allowed the cell to enter into the process of migration.  
The calcium oscillation in the cell can lead to the binding switch of calmodulin to 
different proteins which are Ca
2+
 dependent or independent.  The Ca
2+
 oscillation may also lead 
to the translocation of the calmodulin between the cytoplasm and the nucleus. This is important 
for a number of cellular functions. However, most of the studies have been focused on 
understanding the mechanism governing the nuclear translocation of calmodulin. How does 
calmodulin move back to the cytoplasm is not clear. Here, we provided a model to explain how 
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calmodulin is exported from the nucleus by interacting with nuclear protein p68 under the 
stimulation of cell migration. Since the interaction between p68 and calmodulin is Ca
2+
 
dependent, we reasoned that the cytoplasmic transportation of calmodulin by p68 depends on the 
nuclear level of Ca
2+
. Our preliminary data showed that the distribution pattern of p68/593F- 
calmodulin fusion proteins was similar to p68/WT-calmodulin fusion proteins. We speculated 
that Ca
2+
-calmodulin could be exported by both WT and Y593 phosphorylated p68 to the 
cytoplasm.  
6.1.3.2 P68 shuttled PKM2 and beta-catenin to the nucleus 
PKM2 plays important roles in tumor progression. Most of the studies on PKM2 are 
focused on the cytosolic pyruvate kinase function. Interestingly, PKM2 is found to exist in the 
nucleus. How does PKM2 translocalize into the nucleus, and what is the function of PKM2 in the 
nucleus are not known. PKM2 has a function in regulation of the transcription of OCT-4 proteins. 
Our lab found that PKM2 could regulate the activity of the transcription factor Stat3. Therefore, 
PKM2 may function as a transcription cofactor. Previous studies showed that PKM2 can interact 
with tyrosine phosphorylated peptide. In the present study, we found that double tyrosine 
phosphorylated p68 can bind to PKM2.  No classical NLSs are found in PKM2 by sequence 
analysis. Interestingly, we found that PKM2 could accumulate in the nucleus by binding to 
double phosphorylated p68 but not to the 593F mutant of p68 (a mutant no longer be double 
phosphorylated at Y593 and Y595). We reasoned that PKM2/p68 complex could translocate to 
the nucleus due to the nucleocytoplasmic shuttling activity of p68. Previous study from our 
laboratory (Yang, Lin et al. 2006) showed that Y593 phosphorylated p68 could be exported to 
the cytoplasm and interact with beta-catenin by replacing axin. Beta-catenin could be finally 
transported to the nucleus by p68. The nuclear beta-catenin then functioned as a transcription 
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factor. We later demonstrated that p68 did shuttle between the cytoplasm and the nucleus (Wang, 
Gao et al. 2009). We found that overexpression of Y593E did increase the nuclear beta-catenin. 
The Y593E mutant may mimick the Y593 phosphorylated p68. We further found that 593E and 
593/595E shuttle between the cytoplasm and the nucleus by the heterokaryon assay. All these 
information indicated that shuttling p68 can carry different transcription factors (co-factors) into 
the nucleus to regulate the specific gene transcriptions. And the transportation of different 
transcription factor (co-factors) to the nucleus seems to depend on the post-translational 
modification of p68.  
6.2 P68/calmodulin functioned as a microtubule motor in migrating cells 
      In the present study, we found that the interaction between p68 and calmodulin increased 
in migrating cells. The interaction between p68 and calmodulin was found to be required for the 
cell migration as disruption of the interaction could inhibit the cell migration as well as cancer 
cell metastasis. Interestingly, high levels of p68 and calmodulin were found in the cytosol of 
migrating cells than in the resting cells. The cytosolic location of p68 was found to depend on the 
binding to calmodulin.  
6.2.1 P68/calmodulin functioned as a motor in migrating cells  
We presented evidence to show that p68/calmodulin functioned as a microtubule motor in 
migrating cells.  We found that p68/calmodulin that was purified from the migrating cells 
interacted with microtubule directly. The p68/calmodulin complex had microtubule dependent 
ATPase activity. When we added the microtubule onto the p68/calmodulin complex, we 
observed that microtubule moved on the protein complex in the presence of ATP in the 
microtubule gliding assay. We further demonstrated that p68 moved on the microtubule in the 
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living migrating cells. All this results supported the notion that p68/calmodulin functioned as a 
microtubule motor in migrating cells. 
A conventional microtubule motor, such as kinesin I, usually has two copies of heavy 
chains and light chains. P68 can exist as a homodimer (Ogilvie, Wilson et al. 2003). Calmodulin 
itself can dimerize through a domain that is external to its Ca
2+
 dependent interaction with the 
target proteins (Lafitte, Heck et al. 1999). We reasoned that p68/calmodulin might dimerize to 
form one unit of microtubule motor. The movement of p68 along the microtubule was observed 
by the real time imaging of the fluorescently labeled p68 and microtubule. Interestingly, the 
movement of p68 along the microtubule was in a discontinued way in the living cells. Two 
possible reasons may explain this phenomenon. First, other protein(s) may interact with the 
p68/calmodulin motor complex to regulate the moving complex along the microtubule in the 
living cells. The back and forth movement of a motor on the microtubule are common 
phenomena observed in other microtubule motors (Vale, Malik et al. 1992). Second, the 
formation of p68/calmodulin complex depended on the presence of Ca
2+
. The oscillation of Ca
2+
 
in the cytosol might affect the stability of p68/calmodulin complex, and might affect the 
interaction of this protein complex with microtubules, as p68 alone could not bind to the 
microtubule. 
      During cell migration, the cell is polarized by relocalizing the microtubule-organizing 
center and Golgi in front of the nucleus and to the leading edge. The orientation of MTOC may 
contribute to the polarized migration, as the microtubule should grow into the leading edge. The 
forward protrusion is initiated/maintained, as the microtubule mediated the delivery of vesicles 
and protein complex to the leading edge (Rodriguez, Schaefer et al. 2003). P68 and calmodulin 
formed a complex in migrating cells. The cytoplasmic p68/calmodulin was identified to play 
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functions as a microtubule associated motor. Therefore, p68/calmodulin may not determine the 
polarization of the cell. Rather, this protein complex may play a role in initiating/maintaining the 
protrusion during cell movement. 
6.2.2 The leading edge transportation of calmodulin by motor unit of p68/calmodulin  
Calmodulin has important function in cell motility. The functions of calmodulin in cell 
motility are known to target other proteins and then regulate the functions of the target proteins. 
Interestingly, a lot of proteins located near cytoplasmic membrane (edge located) are known to 
play roles in cell migration, and they are regulated by calmodulin. We found that calmodulin 
accumulated at the leading edge in migrating cells. How calmodulin was accumulated to the 
leading edge was not known. As we know, most of calmodulin is bound to other proteins in Ca
2+
 
dependent or independent manner. Only 5% of the total calmodulins are free in the cells at 
resting intracellular Ca
2+
 (Luby-Phelps, Hori et al. 1995), which makes the diffusion of 
calmodulin in the cytoplasm less likely. The facilitated transportation of calmodulin to the edge 
(including leading edge) seems more effective than the diffusion manner. We observed that 
p68/calmodulin functioned as a motor and p68 moved towards the leading edge. We speculated 
that the movement of p68/calmodulin towards plus end of microtubule could lead to the 
translocation of p68 with its associated calmodulin to the leading edge.   
6.2.3 The putative signaling pathway in regulating the interaction between p68 and 
calmodulin  
Previous study shows that the interaction between calmodulin and neuromodulin (at the 
IQ domain) decrease the phosphorylation by PKC, while the phosphorylation of neuromodulin 
conversely prevents the interaction between calmodulin and neuromodulin (Liu and Storm 1990). 
P68 possesses a region that has a sequence similar to neuromodulin, which contains the 
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conserved protein kinase C phophorylation site and calmodulin binding site, IQ motif. The 
phosphorylation of p68 by PKC has been demonstrated by an in vitro assay. The interaction 
between p68 and calmodulin has also been documented (Buelt, Glidden et al. 1994). The 
interaction between calmodulin and p68 decreases the phosphorylation of p68 by PKC. P68 is 
very likely phosphorylated by PKC in the migrating cells. However, the effect of 
phosphorylation of p68 by PKC on the interaction between calmodulin and p68 is not clear. We 
observed that the p68/calmodulin interaction was strengthened in migrating cells, and there were 
quite high levels of p68 and calmodulin at the leading edge of migrating cells. The translocation 
of p68/calmodulin to the leading edge depended on the p68/calmodulin interaction and ATPase 
activity of p68, as IQ-calmodulin and LGLD-calmodulin fusion proteins no longer accumulated 
at the leading edge. We hypothesized that PKC phosphorylation may lead to the strengthened 
interaction between p68 and calmodulin. Under this hypothesis, when [Ca
2+
] is increased, 
calmodulin binds to p68 and leads to the p68/calmodulin cytosol translocation; when [Ca
2+
] is 
decreased, the dissociation of calmodulin from p68 may lead to the PKC phosphorylation at the 
IQ motif of p68 in the cytosol. The phosphorylated p68 will then bind to calmodulin in a Ca
2+
 
independent way. The p68/calmodulin complex could function as a motor in migrating cells. 
SW480 cells could be induced into migration status under the treatment of EGF. It is 
known that EGFR activation promotes cell motility through specific intracellular signaling 
pathways. The activation of PLCγ-1, and the subsequent hydrolysis of phosphor-inositide 
bisphosphate is a required signaling pathway (Chen, Xie et al. 1994). Activation of protein 
kinase C and the increase of cytoplasmic calcium due to the generation of inositol triphosphate 
and diacylglycerol are important in modulating the process of cell motility. In our study, 
upregulated cytoplasmic calcium may induce the calmodulin nuclear translocation initially. Ca
2+
-
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calmoduin binding might promote the release of p68 from the RNA complexes. The 
p68/calmodulin would then be exported from the nucleus and function as a motor in migrating 
cells. The model of EGF-mediated cell motility can be divided into at least two divergent 
pathways. One is cytoskeletal reorganization, and the other is to destabilize cell-substratum 
interactions (the loss of focal adhesions leads to the reduction of the cell adhesiveness to 
substratum) (Xie, Pallero et al. 1998). Currently, we do not know whether p68/calmodulin has a 
function in the stabilization of the microtubule. P68/calmodulin may play a role in the cell-cell 
attachment, or cell-substratum interaction, as p68 is known to interact with beta-catenin. We 
further observed that p68 could interact with GrB2. GrB2 can bind to EGFR. EGF can stimulate 
the cell migration. The leading edge translocation of p68 may be involved in the feed back on 
signaling pathway by binding to GrB2. In general, growth factor-induced cell motility requires 
three coordinated processes: lamellipodial extension, establishment of cell-substratum adhesions 
at the leading edge, and detachment of the substratum at the rear side (Xie, Pallero et al. 1998). 
We observed translocation of p68/calmodulin to the leading edge in present study. Whether the 
p68/calmodulin complex or single protein plays a role in the lamellipodial extension or 
establishment of cell-substratum adhesions at the leading edge is unknown. Further study is 
required to identify the detail function of p68 or p68/calmodulin at the leading edge. 
Interestingly, other migration-inducing growth factors, such as PDGF, also utilize 
signaling pathway similar to that of EGF (Bornfeldt, Raines et al. 1994). This might provide the 
explanation for why the cytosolic export of p68 occurs in cells that are treated by EGF or PDGF. 
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Figure 6.2 Putative signaling pathway in the regulation of the interaction between p68 and 
calmodulin 
 We found that the interaction between p68 and CaM was also increased in migrating 4T1 
cells (mouse breast cancer cell). The metastasis capability of 4T1 cells to the lung and liver was 
decreased under the treatment of IQ peptide (data not shown). This supports the idea about that 
the interaction between p68 and CaM may be critical in other cancer cell lines too. We are not 
sure whether the intracellular Ca2+ level is the only regulation factor controls the binding of p68 
and CaM. And the function of p68/CaM in cell migration may specifically apply to some cancer 
cells as different signaling pathway may be involved in different cell lines. 
On the other hand, the expression levels of p68 and CaM are different in different cell 
line as we screened. This may indicate that the significance of the interaction between p68 and 
CaM in cell migration might be different in different cell lines. In normal colon tissue, the RNA 
level of p68 is extremely low [Am J Transl Res. 2010; 2(3): 223–234. ]. We reasoned that the 
interaction between p68 and CaM may not function in the process of cell migration in normal 
colon cells. 
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6.2.4 Other putative cytoplasmic function of p68 
As we proposed previously, transiently cytosolic localized p68 can transport the cytosolic 
proteins, including beta-catenin and PKM2, into the nucleus. We observed that the cytosolic p68 
together with calmodulin acted as microtubule dependent motor to facilitate cell migration. We 
concluded that the leading edge translocation of calmodulin was facilitated by the action of 
p68/calmodulin motor. Whether other cargos or proteins can be transported by the 
p68/calmodulin motor actions is not known. Interestingly, we also found p68 interacted with 
Grb2 other than calmodulin translocation, which indicated that p68 may have functions at the 
leading edge of the migrating cells.  
6.3 Colon tissue array and mouse xenograft model for cancer metastasis 
6.3.1 Colon tissue array 
In the tissue array analyses, we found that the cytoplasmic levels of p68 in the colorectal 
cancer cells were higher than in the cells of normal tissues. This observation is consistent with 
the Sook Shin et al’s observation that p68 RNA helicase overexpression level is higher in 
adenocarcinomas.  P68 has an important function in organ differentiation during development. 
P68 is overexpressed in the differentiated adipocyte and skeletal muscle cells (Fuller-Pace and 
Ali 2008). Interestingly, we also detected higher p68 levels in highly differentiated (grade 1) 
colon cancer tissue than in the poorly differentiated tissue (grade 3). The cancer cells in the 
poorly differentiated tumor tissue have much stronger metastatic capability than the cells in the 
high differentiated tumor tissue. We concluded that the migration capability was not directly 
linked to the cellular level of p68 in the cancer cells. The cytoplasmic level of p68 can be 
affected by the total cellular level of p68 in the cells. We reasoned that the ratio of p68 between 
the cytoplasm and the nucleus might be critical in migrating cells. In other word, higher ratio of 
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p68 between the cytoplasm and the nucleus may indicate higher migration capability. It is 
possible that the serine/threonine phosphorylated p68 in the cytoplasm may be the portion of p68 
that plays a role in cell migration, as the serine/threonine phosphorylated p68 may form the 
stable p68/calmodulin motor complex and function in cell migration. Simply analysis of the 
cytoplasmic level of p68 in the colon cancer tissue may not reflect the metastasis status. One 
may need to analyze the ratio between cytoplasmic and nuclear p68 in the tissue. How the 
serine/threonine phosphorylated p68 functions in the migrating cells is an open question. 
In order to find out whether there is a pattern of cytoplasmic level of p68 in different 
tumor tissues, we analyzed the cytoplasmic p68 in tumors at different stages but in the similar 
differentiation level (same grade). Interestingly, we found that there were more cytoplasmic p68 
in higher stages of the tumor than that in the lower stage of the tumor.  The cancer cells in higher 
stage tumor have higher capability of cell migration. This observation supported the notion that 
cancer cells with higher migration capability have higher levels of p68 in the cytoplasm.  
We also found that there was high level of p68 in the cytoplasm of the tumor cells 
compared to that in the surrounding normal cells. In the subcutaneously implanted tumor, we 
also found there was a high level of p68 in the cytoplasm of the tumor cells. This phenomenon 
was not observed in the in vitro cultured colon cancer cells, such as SW480, HT29 and SW620 
cells. It is known that most of the cancer cells within the tumor tissue are under the hypoxia 
condition (normally below 3%-5% O2), while the cultured cells under normal culture condition 
are under normoxia conditions. We speculated that the colon cancer cells under hypoxia 
conditions have higher migration capability than the cells under normoxia condition have. P68 
was observed to be dominantly localized in the nucleus (primary data from Dr. Shiyong Sun) in 
the lung cancer tissue. This observation provided further support for the idea that hypoxia 
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conditions might induce the cytoplasmic translocation of p68. The hypoxia condition may not 
exist in the lung cancer tissue as the lung tissue is provided with high concentration of O2.  
Cytoplasmic translocation of p68 might depend on tissue environments. 
6.3.2 Mouse xenograft model for cancer metastasis 
6.3.2.1 The subcutaneous implantation to study the colon cancer metastasis to spleen is a suitable 
system. 
Many genetic mouse models of benign adenoma have been established. However, very 
few models of colon cancer, excluding the locally invasive models, have been developed. Unlike 
in humans, there are no genetic mouse models in which cancer can spontaneously form tumors in 
the intestines and become invasive and metastasize to the other organs. Since mortality of most 
of the colon cancer is due to cancer metastasis, it is very important to study the colon cancer 
metastasis. The transplantation (xenograft) models are therefore becoming the primary model 
system to study the colon cancer metastasis currently (Taketo and Edelmann 2009). Study of the 
colon cancer metastasis using model systems of the colon cancer includes intrarectal 
implantation of the colon cancer cells (Tsutsumi, Kuwano et al. 2001), orthotopic implantation of 
the tumor tissue (Sun, Sasson et al. 1999) or tumor cells (Cespedes, Espina et al. 2007), and 
subcutaneously implantation of tumor cells. In this study, we employed the model system of 
subcutaneous implantation of the colon cancer cells to study metastasis. This procedure is very 
simple. Even though the distant organ metastasis was not directly observed (not macrometastasis) 
in this xenograft model, trace amounts of the tumor cells that metastasized to spleen can be 
detected by RT-PCR (micrometastasis). The purpose of this study is to elucidate the function of 
p68/calmodulin complex in the cancer cell migration.  The generation of the macrometastasis 
from micrometastasis at the distant organ involves multiple process, including cell proliferation, 
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cell apoptosis, dormancy, and angiogenesis (Steeg 2006). The formation of the micrometastasis 
in spleen by subcutaneously xenograft is an approximate model system for our study.  
 6.3.2.2 Microscopic spleen metastasis was detected in spleen 
Tumor metastasis involves several processes which allow the tumor cells to move from 
the primary site to a distant organ. Tumor cells need to invade the surrounding tissue at the 
primary site, get into the lymph stream or the bloodstream, survive and arrest in the blood 
circulation, extravasate into a new tissue, and grow at the new place. Whether a tumor can 
metastasize to a distant organ or not depends on all these processes. When tumor cells 
successfully land in a distant organ, the formation of a macrometastasis tumor (observable) from 
a micrometastasis tumor at the new site depends on many conditions, including proliferation, 
apoptosis, and dormant situation of the tumor cells at the new sites. The primary tumor 
(implanted) may release some systemic suppressor factor(s) to prevent the growth of 
micrometastasis (Demicheli, Retsky et al. 2008). The angiogenesis at the new site provides the 
nutrition to the tumor cells and is also very important for the growth of the tumor (Steeg 2006). 
According to the study in model of melanoma metastasis, the survival rate of the tumor cells in 
the blood circulation is high (80%). However, the rate for formation of micrometastasis is low (1 
in 40 cells); and the rate for formation of macrometastasis from micrometastasis is even lower (1 
in 100 micrometastasis in 10 days) (Luzzi, MacDonald et al. 1998). 
Although very few colon cancer cells metastasize to the spleen as well as other organs 
(such as liver and lung) by subcutaneous injection, the micrometastatic tumors in distant organs 
are likely to exist when the highly metastatic cancer cells are subcutaneously implanted. The 
technique of RT-PCR can detect the trace amount of the tumor cells. The trace amount of tumor 
cells metastasizing to the distant organ (spleen) is clinically important. As the tumor cells had 
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succeeded to metastasize to the distant organ, it may colonize to form a macrometastasis tumor 
eventually. Whether the metastasized tumor cells can grow to a big tumor in distant organs 
depends on many conditions. The metastasized tumor cells at distant organs may not grow to 
form big tumor in a short time. Those cells may get into the dormant condition when it reaches 
the distant organ site. The regular survival rate of the tumor cells through the blood circulation is 
around 1/100 (orthotopic tumor). The survival rate of the metastatic cells by subcutaneous 
injection would be much less, as the nearby lymph nodes are not available. Also, the metastasis 
may take longer time to occur, as it requires the generation of blood vessels (angiogenesis) near 
by or into the tumor before the metastasis can take place. 
         The tumor can form when SW620 cells are directly injected into the spleen (Zhang, 
Halder et al. 2010). The metastatic SW620 did not grow to a clinical detectable size tumor in 
studies in our and other laboratory. This might be due to the following reasons. First, the time for 
the tumor growth at the metastatic site (spleen) was not long enough. Second, the primary tumor 
at the SC site might secret some inhibitory factors that affect the metastatic tumors. Third, the 
spleen metastatic tumor cells might have lost the growth capability during the metastastic 
selection. 
   Spleen is a large lymphoid organs, it has functions similar to lymph nodes. Spleen filters 
blood stream and engulfs dead cells and foreign particles. Therefore, the detection of SW620 
cells in the spleen may be due to the simple engulfment of the cells by the spleen. The human 
SW620 cells might be regarded as foreign particles by the spleen, or these cells were already 
dead when the cells reached the spleen. One thing that is certain is that SW620 cells did migrate 
through the primary subcutaneous boundary and reached the blood circulation.  
224 
 
      When the cancer cells colonize at the distant organ, they may further disseminate to the 
other organ as the primary site for second metastasis (Hanahan and Weinberg 2011). If we 
consider the subcutaneously implanted colon tumor as the metastatic tumor, the cancer cells 
likely disseminate back to the colon. Therefore, examining the metastasis of the subcutaneously 
implanted colon cancer cells at the colon site would also be a useful test. Liver and Lung are the 
main metastastis organs for the colon cancer. Therefore, examination of the metastasis trace (RT-
PCR) in the liver and lung could be additional tests in our future study. 
6.3.2.3 About the structure of SW620 generated tumor 
We found that SW620 tumor grew fast; however, the tumor was poorly glandularly 
differentiated. The possible reason is that SW620 is derived from a metastatic tumor (isolated 
from lymphometic metastatic site. Broderss’ grade IV). Highly metastatic tumors usually are less 
well differentiated than the primary tumors do. The parental tumor for SW620 has no glandular 
differentiation. SW620 produces very low differentiated glandular structure when the cells are 
injected into the spleen (Hewitt, McMarlin et al. 2000). Therefore, it was reasonable to see the 
poor glandular differentiation structure with the SW620 xenograft tumor. 
Most of the metastatic tumors invade and migrate through the blood vessel to metastasize 
to the distant organs. We expected that there would be more migrating cells in the blood vessels 
site, which means that the area with high density of blood vessels would have more migrating 
cells. Interestingly, microvessels are dense in the periphery area of the SC tumors and less dense 
in the middle area. Therefore, we compared the cytoplasmic level of p68 between those two 
typical regions. We observed that there were more p68 in the cytolpasm in the periphery area 
than that in the middle area, which supported our notion about the migrating cells had more 
cytoplasmic p68 than that in the resting cells.  
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Previous study demonstrated an infiltrative pattern of invasion in the periphery area of 
the implanted SW620 tumor (Hewitt, McMarlin et al. 2000). We also observed an infiltrative 
pattern of SW620 cells relative to the mouse stromal cells (nuclei staining, data not shown). 
SW620 tumor was found firmly attached to the thoracic wall due to the tumor invasion 
underlying skeletal muscle, which is consistent with the previous study (Hewitt, McMarlin et al. 
2000).  
6.3.2.4  IQ peptide inhibited the cytosolic translocation of p68 and tumor growth 
There was high level of p68 in the cytosol of cells in the periphery area. The IQ peptide 
could compete to bind to calmodulin to disrupt the interaction between p68 and calmodulin. We 
found that the amount of cytosolic p68 at the periphery area of the tumor was decreased when 
the mice were treated with IQ peptide. This phenomenon was not observed in the mice which 
were treated with a control peptide. This result supported our speculation that disruption of the 
interaction between p68 and calmodulin could inhibit the cytoplasmic export of p68. 
Interestingly, a calmodulin binding peptide M13 (amino acid residues are corresponding to the 
smMLCK to prevent Ca
2+
-calmodulin binding) can prevent calmodulin nuclear translocation 
(Mermelstein, Deisseroth et al. 2001). This study indicates that the nucleus translocation of 
calmodulin requires its interaction with smMLCK. We were not able to exclude the possibility 
that the cytoplasmic accumulation of calmodulin was due to that the IQ peptide affecting the 
calmodulin nuclear translocation. It is possible to resolve the issue by measuring the nuclear 
levels of calmodulin under the treatment of IQ peptide in the future study. Further more, we can 
use the NLS-tagged IQ peptide to test what would happen when the interaction between p68 and 
calmodulin is specifically disrrupted in the nucleus. 
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We demonstrated that IQ peptide could inhibit the spleen metastasis of the SW620 
xenograft tumors. We observed that the growth of the SW620 tumor was affected by the 
treatment of IQ peptide. There were several explanations. First, the interaction between p68 and 
calmodulin might have a function in the cell proliferation in vivo, even though our study showed 
that the proliferation of SW620 cells was not affected by the IQ peptide in vitro. Second, the IQ 
peptide might function as a calmodulin antagonist, as calmodulin antagonist is known to inhibit 
the proliferation of the cells (Rasmussen, Lu et al. 1992). However, this is less likely. The 
binding of calmodulin to other proteins (result) were not affected in the presence of IQ peptide. 
Third, the IQ peptide could disrupt the interaction between p68 and calmodulin in mice stromal 
cells (including the endothelial cells), which could affect the migration of stromal cells. As a 
consequence, the tumor growth would be inhibited. The sequence alignment showed that the 
sequence of calmodulin is identical in human and in mouse. The IQ motif is identical for p68 
from mouse and human. Thus, the IQ peptide may affect the migration of the endothelial cells to 
form the new blood vessel to provide the nutrients for the growth of the tumor.  This is very 
likely as knockout of p68 in mice causes the malformation of blood vessels (Fukuda, Yamagata 
et al. 2007).  
Colon cancer metastasis is the major cause that leads to the death of the cancer patient. 
The FDA approved drugs for treatment of colon cancer and metastasis have strong side effects. 
The IQ peptide derived from the p68 IQ motif can inhibit the cancer metastasis. However, the 
effect on metastasis inhibition was not so dramatic when compared to that in the cells in which 
IQ peptide fusion protein is (GFP-IQ) stably expressed. We reasoned that the circulation time of 
a peptide is short, and the peptide is unstable in circulation. Designing a new compound to 
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disrupt the interaction between p68 and calmodulin could be used to prevent the cancer 
metastasis in future. 
6.4  Cell proliferation contributed by shuttling function of phosphorylated p68  
The expression level of p68 is known to be correlated with the growth of cells. 
Interestingly, our laboratory observed that p68 was highly phosphorylated at Y593 in highly 
proliferating cancer cells.  The phosphorylation of p68 at Y595 was also observed. The 
phosphorylation of Y595 depended on the phosphorylation of Y593. All these observations 
supported the notion that Y593-Y595 double phosphorylated p68 might have a function in cell 
proliferation. The phosphor Y593-Y595 peptide was synthesized. It is found that the peptide 
binds PKM2. P68 was identified to be a nucleocytoplasmic shuttling protein. The shuttling of 
p68 did not depend on the phosphorylation, as both the Y593E and Y593F mutants shuttled 
between the cytoplasm and the nucleus. We speculated that PKM2 could be transported to the 
nucleus by shuttling activity of the Y593-Y595 phosphorylated p68. The Y593F mutant can no 
longer be phosphorylated. The mutant was not able to bind PKM2. Correspondingly, we 
observed that PKM2 accumulated in the nucleus to a less degree when Y593 of p68 was mutated 
to Y593F.  
Nuclear PKM2 play a role in cell proliferation (Hoshino, Hirst et al. 2007).  It is 
speculated that nuclear PKM2 may participate in the phosphorylation of Histone 1. In our study, 
we observed that nuclear PKM2 functions as a transcription co-activator. Nuclear PKM2 could 
phosphorylate Stat3 and regulate the expression of its target genes, including MEK5. Since 
nuclear PKM2 can act as a protein kinase, other transcription factors or cofactors may also be 
targets of PKM2 in the nucleus. 
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6.5  Phosphorylated p68 may promote the dimer transformation of PKM2 and regulate the 
metabolism in the cancer cells.  
Y593-Y595 phosphorylated p68 interacted with PKM2 (in submission). Interestingly, 
phosphor-p68 bound to PKM2 but not PKM1. The segment with different sequence between 
PKM2 and PKM1 is located at the interface of two dimeric subunits. There are 23 amino acids 
difference at the carboxy terminus (a.a. 378-434) between PKM2 and PKM1. The binding of p68 
to the interface of two dimeric subunit of PKM2 might promote the dimerization of PKM2. This 
is very likely, as dimerization of PKM2 in tumor cells can be induced by direct interaction of 
PKM2 with other oncoproteins, including pp60v-src, HPV-16 E7, and A-Raf. Dimeric PKM2 are 
known to have less glycolytic activity, as the dimeric PKM2 has low affinity for PEP and 
dimeric PKM2 is almost inactive at physiological PEP concentration. Therefore, the binding of 
p68 to PKM2 might down-regulate the pyruvate kinase activity, upregulate the glucose 
transporters, and increase glucose import, which eventually facilitates the metabolic switch to 
glycolysis in cancer cells. On the other hand, the reliance on glycolysis can be further 
accentuated under the hypoxic condition. We also observed that there were more p68 in the 
cytoplasm under hypoxic condition (implanted tumor tissue verse to the cultured SW620 cells). 
Further studies will be performed to test whether p68 is more serine/threonine phosphorylated 
under the hypoxia condition, and how phosphorylation of p68 functions in the cancer metabolism. 
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APPENDICES 
A. THE RECOMBINANT β SUBUNIT OF C-PHYCOCYANIN INHIBITS CELL 
PROLIFERATION AND INDUCES APOPTOSIS 
A.1 Abstract 
C-Phycocyanin (C-PC) from blue-green algae has been reported to have various 
pharmacological characteristics, including anti-inflammatory and anti-tumor activities. In this 
study, we expressed the β-subunit of C-PC (ref to as C-PC/β) in E. coli. We found that the 
recombinant C-PC/β has anticancer properties. Under the treatment of 5 μM of the recombinant 
C-PC/β, four different cancer cell lines accrued high proliferation inhibition and apoptotic 
induction. Substantially lower response occurred in non-cancer cells. We investigated the 
mechanism by which C-PC/β inhibits cancer cell proliferation and induces apoptosis. We found 
that the C-PC/β interacts with membrane-associated β-tubulin and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Under the treatment of the C-PC/β, depolymerization of microtubules 
and actin-filaments were observed. The cells underwent apoptosis with an increase in caspase-3, 
caspase-8 activities. Cell cycle was arrested at the G0/G1 phase under the treatment of C-PC/β. 
In addition, the nuclear level of GAPDH decreased significantly. Decrease in nuclear level of 
GAPDH prevents cell cycle from entering into the S phase. Inhibition of cancer cell proliferation 
and induction of apoptosis may potentate the C-PC/β as a promising cancer prevention or therapy 
agent. 
A.2 Introduction 
C-Phycocyanin (C-PC) is a photoharvesting pigment that provides the intense blue color 
in blue-green algae. Due to its deep and intense color, C-PC is widely used as natural dye for 
various purposes [1]. C-PC is a non-toxic biliprotein consisting of α- and β- subunits. It exists as 
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a monomer, trimer, or hexamer aggregation in native conditions [2]. The α and β subunits of C-
PC do not share any significant sequence homology. Expression separately in bacterial E. coli 
Reveals that the α subunit of C-PC is easily self-aggregated during expression and purification at 
physiological conditions, indicating that interactions between the α subunits may contribute to 
the force for the C-PC trimeric aggregation. On the other hand, the C-PC/β can be expressed and 
purified as soluble recombinant protein in E. coli (unpublished observation). C-PC has recently 
been reported to have many pharmacological characteristics. Its properties of anti-inflammatory 
[3, 4], anti-oxidant [4], and radical scavenging [5] are well documented. Recently, C-PC was 
demonstrated to have anti-tumor activity [6, 7]. It was demonstrated that C-PC inhibits 
cyclooxygenenase-2 [8]. It was shown that C-PC induces apoptosis by promoting the changes in 
the Bcl-2/Bax ratio and releases of cytochrome c into the cytosol. Furthermore, treatment of a 
leukemia cell line with C-PC enhanced the cleavage of poly (ADP) ribose polymerase (PRAP), 
which contributes an important mechanism for apoptosis [7]. The activity of C-PC in induction 
of cancer cell apoptosis and relative low-toxicity toward non-cancer cells makes it a very good 
candidate as a cancer chemoprevention agent. However, the molecular mechanism underlying 
the anti-tumor and anti-cancer activities of C-PC is not well understood. In the present study, 
evidence that the recombinant C-PC/β is an inhibitor for cell proliferation and an inducer for 
cancer cell apoptosis is presented. The C-PC/β inhibits cell proliferation and promotes cancer 
cell apoptosis by depolymerizing the microtubule/microfilaments, arresting the cell cycle at 
G0/G1 phase, and activating caspases -3 and -8. Our studies demonstrated a new insight into 
molecular mechanism by which C-PC has anti-tumor activity. More importantly, our studies 
demonstrated that the C-PC/β alone has anti-tumor activity. The action of β-subunit may be 
different from that of the whole C-PC protein. 
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A.3 Materials and methods 
A.3.1 Cell lines and culture 
Cell line 686LN was derived from a squamous cell carcinoma of the head and neck 
patient’s metastatic tumor. Cell line 686LN-M4C1 is a high metastatic derivative of 686LN. 
Both 686LN and 686LN-M4C1 are gifts from Dr. George Z. Chen, at Emory University. All 
other cell lines were purchased from ATCC and grown by following the vendor’s instructions. 
K562 is a chronic myelogenous leukemia cell line. HT-29 is a colorectal adenocarcinoma cell 
line. C5/MJ is a cell line derived from normal T lymphocytes. RPMI 1788 is a cell line derived 
from normal B lymphocytes and immortalized by EBNA. 
A.3.2 Plasmid construction 
The published gene sequence of the C-PC/β was obtained from www.Pubmed.com 
(Accession No. X05239). Living alga, Anabaena PCC 7120 (UTEX) was obtained from the 
culture collection of algae at the University of Texas at Austin. The Anabaena pellet was 
centrifuged and collected when the alga reached the exponential growth phase in BG11 medium. 
The alga was pelleted in preparation for PCR. Primers used to amplify the C-PC/β were: 5’-
GGGGATCCATGACATTAGACGTATTTA-3’ and 5’-GGGAATTCTTTAACCAACAGCAG 
CAGCAG-3’. The DNA code C-PC/β was obtained via whole cell PCR [9] and was cloned into 
BamHI and EcoRI sites of pGEX-2T (pGEX-2T-β). The C-PC/β expressed consists of the C-
PC/β fused at the C terminus to a GST sequence. The constructed plasmid was verified via DNA 
auto-sequencing. 
A.3.3 Expression, purification, concentration and refolding of the recombinant C-PC/β  
The procedure for expression of the recombinant C-PC/β is similar to that was described 
in our previous report [10]. Briefly, the constructed plasmid, pGEX-2T-β, was transformed into 
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E.coli BL-21 codonplus®, and the expression of the recombinant protein was induced by 0.1 
mM IPTG for 4.5 hours. Bacteria were harvested and underwent a freeze-thaw cycle followed by 
sonication disruption in lysis buffer (1% N-lauroyl sarcosine, 1mM EDTA, 500uM PMSF, 
10mM DTT in PBS, pH 7.3, pre-cooled to 4 oC). The GST-fusion protein (GST: C-PC/β) was 
purified over a glutathione-agarose column (Sigma). The C-PC/β was cleaved overnight by 
thrombin. The recombinant proteins (GST:C-PC/β, C-PC/β, and GST) were further purified over 
a Sephadex 200 gel-filtration column. The obtained recombinant proteins were dialyzed and 
refolded according to the method recommended by the protein refolding kit (Novagen). Finally, 
the expressed and purified GST:C-PC/β was analyzed by MALDI mass spectrometry. 
A.3.4 Proliferation of cancer cells and non-cancer cells 
Cell proliferation was determined using an MTT assay [11]. Cells were seeded into a 96-
well plate (2×104/ well) with appropriate fresh medium (with 10% FCS). The cultured cells were 
first treated with indicated concentrations of recombinant GST:C-PC/β, GST alone, or PBS 
buffer only (PBS buffered, pH 7.3) for 48 hours. After treatment, MTT assays were performed 
using a commercially available MTT kit (Roche). The absorbance was determined on a multi-
well plate reader (PerkinElmer precisely 1420 multilabel counting). The value was determined 
by averaging triplicate sample measurements. 
A.3.5 Immunofluorescent confocal microscopy 
The cells were seeded on chambered microslides (Molecular Probes) and treated as 
indicated. The cells were washed, fixed, and permeabilized with 4% formaldehyde and 0.1% 
Triton X-100 in 1× PBS. The cells were then blocked with Image-iT™ FX signal enhancer 
(Molecular Probes), and subsequently incubated with appropriate antibodies for 1 hour. After 
extensive wash, the samples were incubated with Alexa Fluor 488 (Molecular Probes) (1:1000) 
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to stain primary antibodies. Microslides were washed and mounted in ProLong® Gold antifade 
reagent with DAPI (Molecular Probes) and viewed using a Zeiss LSM510 Confocal Microscope. 
A.3.6 Apoptosis, caspases activities, and cell cycle analyses 
Cells were inoculated into a 12-well plate (2×105/well) with appropriate fresh medium 
and treated as indicated in figures. Apoptosis of cells were analyzed by Cell Death Detection 
ELISAPLUS kit (Roche). Cell apoptosis was expressed as enrichment of mono- and 
oligonucleosomes released into the cytoplasm. The specific enrichment of mono- and 
oligonucleosomes released into the cytoplasm was calculated using the formula: enrichment 
factor = absorbance of the sample (treated) / absorbance of the corresponding negative control 
(non-treated). For the caspase assays, cells were collected after treatment for 24 hours. 1×RIPA 
buffer with protease inhibitors was used to prepare whole cell lysates. 50μg of the protein was 
used in the immunoblotting. Caspase activities were detected by immunoblots using appropriate 
antibodies: monoclonal antibodies, anti-caspase 3 (Cell Signalling), anti-caspase 8 (Cell 
Signalling), and polyclonal antibody of anti-cleaved-caspase 3 (Cell Signalling). For cell cycle 
analyses, the cells were harvested and washed in PBS. The cells were then fixed with 1% 
paraformaldehyde and stored in 70% ethanol at -20 oC. Cells were stained with 0.5 ml PI/RNase 
staining buffer (BD Bioscience) for 15 minutes at 37 ºC and analyzed by fluorescence-activated 
cell sorting (FACS) Becton Dickinson. 
A.3.7 GST pull-down and co-immunoprecipitation 
The GST tagged C-PC/β was pre-bound to the glutathione-agarose beads. The GST 
moiety and the column were used as controls. The beads were incubated with the membrane 
protein extracts made from 686LN-M4C1 cells in PBS buffer with 0.5% NP-40 overnight at 4 
oC. The agarose beads were washed 5 times with PBS buffer containing 0.5% NP-40. The GST 
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pull-down proteins were separated by SDS-PAGE. The gels were stained with the gelcode® blue 
stain reagent (Pierce). The identified protein bands (pulled-down by the C-PC/β) were sliced out. 
The gels slices were treated with the ProteoProfileTM Trypsin In-Gel Digest kit (Sigma). The 
digested samples were analyzed by TOF/TOF-MS. The pull-down proteins were further analyzed 
by immunoblot using antibodies against β-tubulin (Sigma) and GAPDH (Chemicon). The 
interactions of C-PC/β with β-tubulin and GAPDH were also shown by co-immunoprecipitates 
using polyclonal antibody against GAPDH (abcam) or polyclonal antibody against β-tubulin 
(abcam), followed by immunoblot using antibodies against β-tubulin (Sigma), GST 
(CALBiochem) and GAPDH (Chemicon). 
A.3.8 Soluble and assembled tubulin / actin 
Soluble (depolymerized) tubulin/actin and assembled (polymerized) were analyzed by the 
same experimental procedure described previously [12]. Briefly, 686LN-M4C1 cells were 
treated as indicated in figures for 24 hours. After treatments, cells were washed with PBS 
containing 0.5 μg/ml Paclitaxel (Sigma), and lysed with 100 μL of lysis buffer (20mM Tris-HCl, 
0.5% NP-40, 1mM MgCl2, 2mM EGTA, and 0.5 μg/ml Paclitaxel). Then the samples were 
vortexed and centrifuged at 12,000×g for 10 min at 4 oC. Supernatants containing depolymerized 
tubulin/actin were separated from pellets containing polymerized tubulin/actin. The pellets were 
resuspended in 100 μl lysis buffer without paclitaxel. 14% SDS-PAGE gels were used to 
separate proteins. The relative quantity of depolymerized tubulin/actin and polymerized 
tubulin/actin were analyzed by immunoblot using antibodies against β-tubulin (Sigma) and actin 
(Santa cruz biotechnology). 
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A.3.9 Subcellular localization of GAPDH 
686LN-M4C1 cells were grown and treated as indicated in figures. The cells were 
washed with pre-cooled PBS and the Nuclear Extraction kit was used to preparation of nuclear 
extracts. 115 μg of the nuclear proteins were used for the immunobloting to detect the level of 
nuclear GAPDH. Meanwhile, 50 μg of the whole cell lysate proteins were used to measure the 
expression level of GAPDH. A 14% SDS-PAGE gel was utilized to separate the proteins and 
immunoblots were probed using monoclonal antibodies against GAPDH (Chemicon) and 
monoclonal antibody against β-tubulin (Sigma). 
A.4 Results 
A.4.1 Expression and purification of recombinant C-PC/β in E. coli 
Anabaena PCC 7120 is among the most primitive life forms on earth. Its cellular 
structure is a simple prokaryote. We carried out whole cell PCR and obtained a DNA fragment 
that coded for C-PC/β. Sequencing results confirm the identity of the DNA (by comparing to the 
C-PC/β in databases). The DNA fragment was cloned into the expression vector pGEX-2T and 
the C-PC/β was subsequently expressed in E. coli BL-21 as a GST-fusion protein. High 
expression level of C-PC/β was observed (Fig.A.1A). After purification over a glutathione-
agarose beads column and a Sephadex 200 gel-filtration column, high purity and concentration 
of the recombinant proteins were obtained. The concentration of the C-PC/β protein was 
estimated to be 0.9 mg/ml. Molecular weight of obtained recombinant proteins was determined 
by MALDI-TOF mass spectrometry (Fig.A.1B). The mass spectrometry results indicated that the 
obtained GST:C-PC/β had a MW of 45.4 kDa. This molecular weights was consistent with the 
corresponding calculated MWs. We also attempted to express and purify the α subunit of C-PC. 
However, the α subunit of C-PC rapidly aggregates in bacterial inclusion body. We purified the 
252 
 
insoluble α subunit of C-PC under denaturing condition and refolded the protein subsequently. 
Nevertheless, the refolded α subunit re-aggregated shortly after elution (data not shown). 
A.4.2 The C-PC/β inhibited cell proliferation 
C-PC was reported to inhibit cell proliferation in a number of cancer cell lines [6] [7]. To 
test whether the recombinant C-PC/β also inhibits cell growth, we carried out MTT assays with a 
number of cancer cell lines and two normal cell lines. Growth of all cancer cells was largely 
inhibited by treatment with C-PC/β (Fig.A.2A). The greatest inhibitory effect on cell 
proliferation occurred to 686LN-M4C1 cells (inhibitory ratio was 60.4%, Fig.A.2A). On the 
other hand, the C-PC/β had a minor inhibitory effect on growth of non-cancer cells (inhibitory 
ratios of C5/MJ and RPMI 1788 cells were 29.7% and 25.2% respectively, Fig.A.2A). As a 
control, GST alone had no significant effects on the growth of any of the cell lines tested. The 
results suggested that the recombinant C-PC/β inhibits cell growth. We noticed that the 
morphology of the cancer cells changed when the cells were treated with the C-PC/β. 686LN-
M4C1 cells became non-transparent and distorted (Fig.A.2B). Other cancer cell lines also 
changed significantly upon the treatment with C-PC/β. The majority of K562 cells changed from 
a round to a spindle-like morphology. HT29 cells grew sparsely. The 686LN cells became 
clustered and distorted. In contrast, no significant changes in the morphology of non-cancer cells 
were observed under the same treatments (Fig.A.2B). 
A.4.3 Recombinant C-PC/β induces apoptosis and cell cycle arrest 
We speculated that both cell growth inhibition and cell morphology changes were due to 
induction of apoptosis by the C-PC/β treatment. To test the speculation, we examined apoptosis 
with cancer and non-cancer cells using a commercially available apoptosis kit (detection of 
mono- and oligonucleosomes in the cytoplasm). Our experiments demonstrated that apoptosis 
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was induced in three cancer cell lines upon the C-PC/β treatment (Fig.A.3A) with the metastatic 
head and neck cancer cells, 686LN-M4C1, exhibiting the highest level of apoptotic induction. As 
a control, GST alone did not induce apoptosis in any of the cells tested (Fig.A.3A). No clear 
apoptosis was observed with non-cancer cells under the treatment with C-PC/β (Fig.A.3Α). 
Activation of different caspases is often associated with cell apoptosis. Thus, we examined the 
caspase activity that may be activated by the C-PC/β treatment. Since, the metastatic head and 
neck cancer cells, 686LN-M4C1, suffered the highest degree of growth inhibition and apoptosis, 
we chose this cell line as our test system for probing caspase activity. Under the treatment of the 
C-PC/β, both caspases 8 and 3 were activated as revealed by the cleavage of pre-caspase 8 and 
pre-caspase 3 (Fig.A.3B, Left panel). These results suggested that the C-PC/β triggered 686LN-
M4C1 cell apoptosis by activation of extrinsic cell death pathway. We also analyzed the cell 
cycle progression of 686LN-M4C1 cells under the C-PC/β treatment using FACS. The cell cycle 
profiles were monitored 24 hours after C-PC/β treatment. An accumulation of cells with 2N 
DNA contents and a decrease in cells with 4N DNA contents was evident by comparing to those 
of untreated cells (Fig.A.3B, Right panel). This result indicated that 686LN-M4C1 cells were 
mainly accumulated in the phase of G0/G1 after the cells were treated with the C-PC/β. In 
addition, an increase in cells with a sub-G1 DNA content was clearly observed, which is a 
characteristic of cells undergoing apoptosis (Fig.A.3B, Right panel) [13]. This observation 
provides an additional support for our conclusion that C-PC/β treatment induces apoptosis. 
A.4.4 Recombinant C-PC/β was accumulated on the plasma membrane 
The preceding experiments suggested that C-PC/β treatment inhibited cancer cell 
proliferation and induced apoptosis. C-PC/β treatment activated caspase and led cell cycle arrest. 
To understand the molecular basis for the apoptotic induction and cell cycle arrest, we examined 
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localization of the recombinant C-PC/β in cells after the treatment. We employed 
Immunofluorescent staining to detect the GST:C-PC/β in 686LN-M4C1 cells using antibody 
against GST. The recombinant GST:C-PC/β was mainly stained on the cell plasma-membrane 
(Fig.A.3C). While the membrane staining pattern was not observed with non-cancer cells (data 
not shown). Interestingly, the accumulation of membrane C-PC/β correlated with the degree of 
cell apoptosis (Compare Fig.A.3A to Fig.A.3C). This observation suggested a potential role of 
plasma-membrane C-PC/β in cell apoptosis. 
A.4.5 C-PC/β interacted with β -tubulin in the cell membrane promoting depolymerization of 
microtubules 
Since the recombinant C-PC/β was mainly accumulated on the cancer cell membrane, we 
attempted to probe the protein or protein complex that interacted with C-PC/β in the plasma 
membrane. To this end, we carried out a GST-pull down experiment with membrane extracts 
made from 686LN-M4C1 cells using GST:C-PC/β. We found that a 55 kDa and a 36 kDa protein 
bands were among the proteins that specifically associated with GST:C-PC/β (Fig.A.4A).  
MALDI-(ms/ms) analyses (Fig.A.4B) and immunoblot results (Fig.A.4C) showed that the 55 
kDa band was β-tubulin (gi|57209813, NCBI) and 36 kDa band was Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (gi|31654, NCBI). The interactions of C-PC/β with β-
tubulin and GAPDH were further confirmed by co-immunoprecipitation experiments using 
antibodies against β-tubulin and GAPDH with the cell extracts made from C-PC/β treated 
686LN-M4C1 cells. It was clear that GST:C-PC/β co-immunoprecipitated with β-tubulin and 
GAPDH separately (Fig.A.4D). 
C-PC/β interacted with β-tubulin. We asked whether microtubules were affected by this 
interaction. We examined the ratio of depolymerized/polymerized tubulin in 686LN-M4C1 cells 
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by immunoblotting under C-PC/β treatment. The ratio of depolymerized/polymerized tubulin 
was approximately 0.949 for C-PC/β treated cells, and was 0.371 for PBS treated cells (Fig.A.5A, 
right panel). This data suggest that the microtubules were depolymerized under the treatment of 
the β subunit protein of C-PC. Interestingly, we found that the microfilaments were also 
depolymerized under the treatment of the C-PC/β. The ratio of depolymerized/polymerized actin 
was approximately 0.721 for the C-PC/β protein treated cells and was 0.211 for PBS treated cells 
(Fig.A.5A, right panel). Thus, our results demonstrated that C-PC/β interacted with β-tubulin in 
the cell membrane promoting depolymerization of cytoskeleton, microtubules and 
microfilaments. 
A.4.6 C-PC/β interacted with GAPDH and promoted GAPDH redistribution 
Interaction of C-PC/β with GAPDH is intriguing. Biological functions of GAPDH are 
dependent upon the subcellular localization [14]. The nuclear form of GAPDH has been 
suggested to be a key transcriptional coactivator necessary for entry into S phase [15] [16]. We 
have observed the effects of C-PC/β on cell cycle progression. The cells were arrested in the 
G0/G1 phase under the treatment of the C-PC/β. We reasoned that C-PC/β treatment might have 
effects on GAPDH cellular localization. To this end, we examined the level of GAPDH in the 
cell nucleus and cytoplasm by immunoblotting the GAPDH in the nuclear and whole cell lysate 
made from cells before and after C-PC/β treatment. It was clear that the level of nuclear GAPDH 
was greatly decreased after the incubation with the C-PC/β protein for 24 hours (Fig.A.5B). 
Interestingly, more GAPDH was expressed under the treatment of the C-PC/β (Fig.A.5B). This 
might be the result of feedback from decrease in nuclear form of GAPDH. The effects of C-PC/β 
treatment on the distribution of GAPDH were likely specific, since no changes in the distribution 
of β-tubulin and Histone H2A were observed (Fig.A.5C). 
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A.5 Discussion 
In present study, we demonstrated that the recombinant C-PC/β inhibited cell 
proliferation and induced apoptosis. We believe that the C-PC/β inhibits cell proliferation and 
promotes apoptosis by promoting cytoskeleton depolymerization and activating the caspase 
activities that are associated with extrinsic cell death pathway. Interestingly, the C-PC/β causes 
cells to arrest at G0/G1 phase of cell cycle. Our data showed that C-PC/β treatment led to the 
export of GAPDH from the nucleus. It is conceivable that GAPDH nuclear exporting stimulated 
by C-PC/β treatment causes the cell cycle arrest, which subsequently inhibits cell proliferation. 
The ability of recombinant C-PC/β to preferentially inhibit cancer cell growth and induce cancer 
cell apoptosis is very important. This property may indicate a potential application of C-PC/β as 
a cancer prevention and/or treatment agent. Especially, we observed in our studies that C-PC/β 
exhibited the greatest effects on metastatic cancer cells compared to non-metastatic cancer cells. 
Thus, it is tempting to speculate and explore the potentials of using C-PC/β as an agent for 
preventing tumor metastasis. The mechanism by which C-PC/β co-precipitated with GAPDH in 
the GST-pull down is not clear. Previous reports show that β-tubulin is targeted to the membrane 
through association with GAPDH [17] [18] [19]. We suspected that the C-PC/β interacted with 
β-tubulin. GAPDH was co-precipitated due to association with β-tubulin. Actin filaments were 
reported to be associated with GAPDH under unbeneficial (Stress) environments [20]. We 
reasoned the depolymerization of actin might result from the association with GAPDH under the 
apoptotic induction by C-PC/β. Depolymerization of cytoskeleton, microtubules and 
microfilaments, also provides a good explanation for the observed cell morphology changes 
under the C-PC/β treatments. How the C-PC/β promotes reduction of nuclear GAPDH level is an 
open question. Our current speculation is, under the treatment of the C-PC/β proteins, GAPDH is 
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indirectly targeted by the C-PC/β and recruited to the plasma membrane. This may not only 
prevent the GAPDH nuclear translocation but also promote nuclear export of GAPDH. If the 
amount of the GAPDH in the nucleus is lowered to a certain level, it then prevent cells from 
entering into S phase [15]. Lower level of nuclear GAPDH will in turn activate the expression of 
GAPDH. It is intriguing that C-PC/β treatment activates caspase-3 and -8, which subsequently 
triggers cell apoptosis. It was reported that the biliprotein α/β:C-PC purified from blue-green 
algae also induces cell apoptosis [6] [8] [7]. However, the mechanism by which the α/β:C-PC 
triggers apoptosis seems different from the mechanism by which C-PC/β induces apoptosis. In 
addition, the α/β:C-PC enter cytoplasm of cancer cells [7], the recombinant C-PC/β was mainly 
accumulated on the plasma membrane. Under the C-PC/β treatment, cytoplasm GAPDH might 
be associated with actin and trigger the depolymerization of the actin. It is suggested that 
GAPDH is associated with apoptosis [21, 22]. No evidence demonstrates that α/β:C-PC has any 
effects on cytoplasm or nuclear GAPDH. In this regard, our studies seem to suggest that the 
recombinant β subunits of C-PC may be a more effective in inhibition of cell proliferation and 
apoptosis induction than α/β:C-PC does. 
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Figure A.1 (A) Expression of recombinant GST:C-PC/β expressed in E. coli BL 21. Bacterial 
cell lysates was analyzed by 10% SDS-PAGE, before IPTG induction (N), after IPTG inducing 
(I), and after purification (P). (B) Purified recombinant GST:C-PC/β was analyzed by mass 
spectrometry. 
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Figure A.2 (A) MTT assays of cell proliferation of different cell lines (indicated) upon 
treatments of different agents (indicated). The cell proliferations were expressed as percentage of 
growth and were calculated in comparison to PBS treated cells. Values were calculated as mean 
± S.D. of triplicate measurements (P<0.05). (B) Morphologies of different cell lines (indicated) 
upon the treatments of 5 μM of GST:C-PC/β or other agents (indicated). 
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Figure A.3 (A) Apoptosis of different cell lines (indicated) upon the treatment via different 
agents (indicated). The apoptosis was expressed as the enrichment of mono- and 
oligonucleosomes released into the cytoplasm. (B, left panel) Immunoblot analyses of cellular 
caspase -3 and -8 (Cas3 or Cas8) in cell extracts made from 686LN-M4C1 cells that were treated 
with C-PC/β or PBS using antibodies against Cas3 or 8. The arrows indicate the cleavage 
products of caspases (Cle-Cas8, or Cle-Cas3). (B, right panel) FACS analyses of cell cycle for 
686LN-M4C1 cells upon the treatment of PBS (shaded) or C-PC/β (dotted line). Cells were 
analyzed for DNA content by PI staining (FL2-A) and flow cytometry. (C) Immunofluorescence 
staining of GST:C-PC/β in different cell lines (indicated) upon 5 μM GST:C-PC/β treatment 
using antibody against GST. The green signal represents staining of GST:C-PC/β. 
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Figure A.4 (A) SDS-PAGE analyses of the GST:C-PC/β pull-downs from the membrane 
extracts made from 686LN-M4C1 cells. The GST moiety, the column (Col.), and the membrane 
extracts (ME) were used as controls. Arrows indicate the protein bands that associate with C-
PC/β. (B) MALDI/TOF/TOF-MS analyses of the C-PC/β association proteins. Bold characters 
indicate the sequences identified by mass-spectroscopy. (C) Immunoblot analyses of the GST:C-
PC/β pull-downs by immunoblot using antibodies against β−tubulin (IB:β-tub) and against 
GAPDH (IB:GAPDH). (D) Co-immunoprecipitation of GST:C-PC/β by the antibodies (IP:Ab) 
against β-tubulin (β-tub) and GAPDH (GAPDH) was analyzed by immunoblot the co-
precipitates using appropriate antibodies (indicated). IP by mouse IgG was a control for the co-
immunoprecipitation. 
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Figure A.5 (A) Immunoblot analyses of soluble (S) tubulin and actin and insoluble (P, 
precipitates) tubulin and actin in the soluble and insoluble extracts made from the PBS or C-PC/β 
treated 686LN-M4C1 cells (left panel). Right panel is the quantification of the immunoblotting 
results expressed as the ratio of soluble/insoluble tubulin (filled bars) and actin (open bars). (B) 
Immunublot analyses of cellular (lysate) and nuclear (NE) levels of GAPDH in PBS or C-PC/β 
treated 686LN-M4C1 cells. IBs of β−tubulin (β-tub) was a loading control. Right panel is the 
quantification of the immunoblotting of GAPDH. The quantification was expressed as relative 
GAPDH levels in nuclear extracts or in total cell lysate by defining the GAPDH levels in nuclear 
extracts or in total cell lysate made from PBS treated cells as 1% (open bars). (C) Immunoblot 
analyses of cytoplasmic (CE) and nuclear (NE) levels of β−tubulin and Histone H2A in PBS or 
C-PC/β treated 686LN-M4C1 cells. 
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B. P68 IS A POTENTIAL SUBSTRATE OF CASPASE 3 
B.1 Materials and methods 
B.1.1 Apoptosis induction of SW480 cells by Oxiplantin 
10uM of Oxiplantin was added into the culture medium. Cells were cultured for 
additional 24 hours. Cells were then collected and the whole cell lysate was obtained. The anti-
cleaved-Capase 3 antibodies were used to examine whether Caspase 3 was activated. Antibodies 
recognizing N-terminal or C-terminal (RGG) of p68 were used to examine whether p68 was 
cleaved by the activated Caspase 3. The inhibitor for Caspase 3 (DEAD-CHO) was used to block 
the activity of Caspase 3. The recombinant Caspase 3 (active) was used to cleave the target 
proteins under in vitro situation. 
B.1.2 Plasmids construction and truncates of p68 expression  
 The DNA sequences encoding four truncates of p68 were constructed into the pHM6 
vector at the HindIII and NotI digestion sites respectively. The primers for F1 truncate were 5’-
GGGAAGCTTATATTCGAGTGACCGAGACCG-3’ and 5’-GGGCGGCCGCTTAGTCTGCT 
TCATCAAGGACAAGG-3’. The primers for F2 truncate were 5’-GGGAAGCTTAAGAATGC 
TTGATATGGGCTTTG-3’ and 5’-GGGCGGCCGCTTAATCTTCCACATCTAGCCCTCT-3’. 
The primers for F3 truncate were 5’-GGGAAGCTTAGTGAAATTTGTCATCAATTATGAC-
3’and 5’-GGGCGGCCGCTTAGTCCCGACGGTCATCCTTC-3’. The primers for F4 truncate 
were 5’-GGGAAGCTTACGATACTCTGCGGGCAAAAGG-3’ and 5’-GGGCGGCCGCTTAT 
TGGGAATATCCTGTTGGCATT-3’. The sequences were then cloned into virus vector. 
SW480 cells were expressed with four different truncated proteins respectively. The activation of 
Caspase 3 was examined in SW480 cells two days post-transfection. 
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B.2 Results 
B.2.1 Three putative cleavage sites of p68 by Caspase 3 
 There are three putative cleavage sites in p68 based on the sequence analysis (Fig.B.1.A). 
All putative cleavage sites in p68 are exposed for Caspase 3 according to the location of the 
cleavage sites in the predicted helicase core structure (Fig.B.1.B). 
B.2.2 P68 can be cleaved by Caspase 3 
 Four truncates of p68 were detected by running western-blot when SW480 cells were 
induced into apoptosis. And the molecular weight of the protein bands match to the predicted 
truncates (Fig.B.2.A and B): F1 (~25kDa), F2+F3+F4 (~43kDa), F3+F4 (~22.8kDa), and F4 
(~13kDa). Caspase 3 was activated when the cells were induced into apoptosis as we expected. 
Interestingly, the cleaved truncates of p68 (protein bands) were no longer observed by running 
western blot (Fig.B.2.B) when the cells were treated with the Caspase 3 inhibitor DEVD-CHO. 
The truncates of p68 were observed again on the western blot when the same cell lysates were 
incubated with active Caspase 3. This supports the idea about that p68 can be specifically 
cleaved by the active Caspase 3. The recombinant p68 was cleaved by the active Capase 3 in 
vitro further confirmed that p68 is the substrate of active Caspase 3 (Fig.B.2.C). However, only 
two fragments (~55kDa and 43kDa) of p68 were observed in SDS gel according to the result of 
in vitro cleavage assay. 
B.2.3 Expression of F4 truncate of p68 activates Caspase 3 in cells 
 The plasmids encoding F1, F2, F3, and F4 were successfully cloned into the pHM6 
vector (Fig.B.3.A). The plasmids were then cloned into the virus vectors respectively and the 
truncates of p68 were successfully expressed in SW480 cells (Fig.B.3.B). Interestingly, Caspase 
3 was activated under the expression of those four truncates at different levels (Fig.B.3C). 
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Caspase 3 was activated most when the cells were expressed with F4 truncate. This result 
indicates that the cleavage product of p68 by Caspase 3 has a positive feedback function in cell 
apoptosis. 
 
Figure B.8 Three putative cleavage sites of p68 by active Caspase 3 
A)  Diagram of the putative cleavage sites of p68 by Caspase 3. B) The location of predicted 
cleavage sites on the helicase core structure of p68. 
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Figure B. 2 P68 was cleaved by the activated Caspase 3 
A)  Oxiplantin induced cell apoptosis and Caspase 3 was activated. Three truncates of p68 were 
detected by two different antibodies which recognize N-terminal and C-temrinal of p68 
respectively. B) The cleavage of p68 under the treatment of Oxiplantin was prevented when the 
cells were incubated with the DEAD-CHO, a Caspase 3 inhibitor. P68 was cleaved again when 
the cell lysate was added with the active Caspase 3. C) The protein fragments of recombinant 
p68 were generated under in vitro Caspase 3 cleavage assay.  IB of p68 was used to identify that 
recombinant p68 was successfully pulled down by the Ti-NED beads. The blue boxes indicate 
the putative combination of the protein fragments of p68. 
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Figure B.3 Caspase 3 was activated upon the expression of truncates of p68 
A)  F1, F2, F3 and F4 truncates of p68 encoding plasmids was successfully constructed. The 
plasmids were confirmed by digestion with HindIII and NotI. B) The expression of four 
truncates of p68 (expressing eGFP) in SW480 cells were confirmed by fluorescent images of 
cells as indicated. C) Western blot showed that Caspase 3 was activated by overexpression of the 
four different truncates of p68 in cells. 
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C. P68/CAM MAY HAVE A FUNCTION IN PC-12 DIFFERENTIATION 
C.1 Material and method 
 PC-12 cells were gifted by Dr. Keqiang Ye in Emory University. RPMI1640 medium 
contains 10% FBS and5% Horse Serum was used to culture PC-12 cells for 3 days. On the fourth 
day, the cells were seeded with low density (~10%) in plates which had been coated with poly-L-
lysine. The medium was replaced with RPMI1640 medium contains 2% FBS and 100 ng/ml 
NGF (CalBiochem, cat. 480352). The medium was changed everyday for 4-5 days till the cells 
were well differentiated. The cells were fixed on the different day as indicated in the figure. The 
fixed cells were penetrated by the Triton-100 as we did previously. And anti-p68 antibodies and 
anti-calmodulin antibodies were used to show the locations of p68 and calmodulin in the 
differentiated cells.  
C.2 Result 
C.2.1 P68 and calmodulin colocalized at the leading edge of the dendrites in PC-12 cells 
 PC-12 cells were successfully differentiated (Fig.C.1). Interestingly, p68 was found to be 
accumulated at the leading edge of the dendrites during differentiation. Calmodulin was found to 
colocalize with p68 at the leading edge of the dendrites. The results indicated that p68 together 
with calmodulin may have function in the formation of the dendrites which plays important roles 
during the differentiation of PC-12 as well as other neuron cells. 
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Figure C.1 P68 and calmodulin colocalized at the leading edge of the dendrites in PC-12 
cells 
Day 0 indicates the day the cells were seeded into the chamber but without the treatment of NGF. 
Day 2 indicates the cells were treated with NGF for two days. So do the day 3 and the day 5. In 
the images, red presents for p68, and green presents for calmodulin. Yellow indicates the 
colocalization of p68 and CaM (Red and green). Blue shows the nuclei of PC-12 cells. 
 
